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Abstract 
In equine medicine there is a need to identify osteoarthritis at an early stage in order to 
improve the effectiveness of therapy. Therapies require accurate assessment necessitating 
well run clinical trials. For both these purposes it is necessary to use valid and reliable 
measures of the disease process. A pilot clinical study was conducted which allowed the 
requirements for a good clinical trial to be assessed, and evaluated the use of lameness 
scoring, owner questionhaires, radiography, scintigraphy and biochemical markers in the 
measurement of the disease, while investigating the effect of calcium pentosan 
polysulphate in cases of osteoarthritis in horses. In order to establish good guidelines for 
trial protocols the hypothesis that "joints are biologically differenf 'was explored. 
The assessment of functional outcome by lameness scoring and questionnaires, and the 
use of a radiographic scoring system were found to be reliable measurement tools. 
Scintigraphy was helpful diagnostically but requires further investigation to be useful in 
assessment of disease change. Keratan sulphate (5D4) and bone specific alkaline 
phosphatase were found to correlate well with degree of articular cartilage damage. Cross 
sectional differences between osteoarthritic and contralateral joints were found in synovial 
fluid levels of hyaluronan, keratan sulphate, total glycosaminoglycans and bone specific 
alkaline phosphatase, but these markers were not useful in assessing temporal changes 
during the trial. Marked differences were identified in concentration of the above 
synovial fluid markers between normal equine metacarpophalangeal, proximal 
interphalangeal, and distal interphalangeal joints, and normal ranges were established . 
Articular cartilage from these same joints was found to respond differently when 
challenged by interleukin -I in vitro. 
The results of this study indicate that equine clinical trials should be joint specific, and 
verify that lameness scoring is a valid measure of functional change, and radiography 
scoring is a reliable measure of structural outcome. 
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Where there is much desire to learn, there of necessity will be much arguing, much 
writing, many opinions; for opinion in good men is but knowledge in the making. 
John Milton 1608 - 1674 
Ostegarthritis -a definitiOn? 
The search for a generally accepted definition of osteoarthritis (OA) has occupied 
rheurnatologists for many years. 
In horses the condition that we now consider to be OA, was originally believed to be the 
sequel to acute rheumatism, a systemic "influenza-like' disease, although by the late 19th 
century some scientists were recognising it to be an "independent and idiopathic" disease 
(Robertson 1890). It was generally described as separate conditions according to joint 
site, with differing aetiological factors. In 1830 James White, veterinary surgeon with the 
Royal Dragoons, described bone spavin (OA of the tarsal joints) as "a very common 
disease, consisting of a deposit of bony matter about the bones of the hocle' (tarsus) 
(White 1830). He proposed that spavin was caused by the obliteration of the synovial 
fluid producing gland situated in the distal tibia, following such long exertion that the 
synovia was consumed and the gland was unable to supply more. This resulted in 
inflammation, ulceration and ossification of the joints. In 1893 Mayhew describes spavin 
and ringbone (OA of the interphalangeal joints) as work related, man induced diseases. 
He suggested that spavin, common in carriage horses, was caused by exertion changing 
ligament into bone, and that ringbone, common in carthorses, was caused by force on the 
pastern bones causing inflammation and lymphatic effusion which changed into cartilage 
and then bone (Mayhew 1893). Smith (1893) classified ringbone and spavin as specific 
joint diseases in which "there is something in common in the nature of lesions produced 
which would lead one to suspect that the changes occurring in each are closely allied". It 
was originally thought that OA was a disease which commenced in the synoviurn or bone 
and rarely in the cartilage, since that was an avascular tissue and therefore least 
susceptible (Wortley 19 10). In 1927, Hare carried out a post-mortern survey of 34 horses 
(Hare 1927) and reported that the original abnormality in "chronic rheumatisle' was focal 
circumscribed areas of hyperaernic bone with corresponding focal areas of articular 
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cartilage fibrillation. He concluded " It is far easier to define what this arthritis is not, than 
to provide a positive definition which would find universal acceptance. " His definition of 
OA was "a disease of joints tending to chronicity, which is probably specific but due to 
no known specific cause". It seems that little has changed in this respect over 100 years. 
A recently proposed definition of OA in man, describes a disease process involving a 
disturbance in the normal balance of degradation and repair in the articular cartilage and 
subchondral bone (Goldberg et al. 1995). It has a different balance of risk factors and 
outcome at different joint sites and is characterised by the focal loss of cartilage with 
subchondral bone sclerosis, and marginal osteophyte formation (Dieppe 199 1). All these 
processes are linked, although it is not known which are primary and which are 
secondary. 
The disease has been described quite differently in human and equine OA but it is 
commonly agreed that it involves a loss in function of the articular cartilage. The relative 
age of equine patients is younger and the expectations of treatment are greater. Synovitis 
may be present in equine OA (McIlwraith 1996) whereas the disease is often cited as 
noninflammatory in human OA. 
Impact on population 
Osteoarthritis is one of the main causes of lameness in horses in the UK, causing 28% 
loss of training days in the Thoroughbred racehorse (Rossdale et al. 1985). In man the 
prevalence of radiographically defined OA ranges from 14 - 30% in men and women over 
45 years (Hart et al. 1995) but prevalence is difficult to measure because of differences in 
the definition of OA. Definition should be by a combination of clinical and radiographical 
means, since clinical symptoms do not correlate well with radiographic changes, and in 
most elderly patients OA, as defined radiographically, may be present but is often 
asymptornatic. 
Despite OA being the most common rheumatic disease, little is still known concerning its 
aetiology, natural history, and progression. Before well designed epidemiological studies 
can be carried out in order to promote greater understanding of the disease, a consistent 
well defined definition of the disease and standardised criteria for describing cases and 
measuring changes are necessary. 
2 
Joints are most commonly classified according to their degree of movement i. e. 
1) syfiarthroses - immovable joints 
2) amphiarthroses - slightly moveable joints 
3) diarthroses : movable joints 
Most of the joints in the extremities are diarthroses and it is these that will be referred to 
throughout this thesis. The joint is an organ whose purpose is to allow frictionless 
movement of the limbs while maintaining stability to the body. It is the unique properties 
of the tissues within this organ that combine to allow locomotion. 
OA is a disease process characterised by a mixture of degradative and reparative processes 
in each of the three main elements of the synovial joint - cartilage, bone , and the 
synovial/capsular lining (Dieppe 1995) . The normal anatomy and 
function of these 
tissues will be reviewed here. 
The diarthrodial (or synovial) joint 
The diarthrodial joints differ from the synarthroses and amphiarthroses in that they consist 
of at least two articulating surfaces of bone which are covered in articular cartilage and 
separated by synovial fluid within a cavity surrounded by a joint capsule. 
1. Cartilage 
Hyaline articular cartilage has a structure which is highly suited to provide distribution of 
load and resistance to compressive forces, smooth articulation and cushioning of the 
subchondral bone (Kuettner et al. 1991). It does not contain blood vessels, nerves or 
lymphatics, and appears grossly and histologically to be a simple inert tissue (Buckwalter 
et al. 1997). It consists of one t)W of cell - the chondrocyte - which produces an 
extracellular matrix made up of a meshwork of collagen fibres and proteoglycan 
molecules. It has a low level of metabolic activity and is less responsive to injury than 
bone or muscle. It varies in thickness, cell density, matrix composition and mechanical 
properties within joints, between joints and between species but the general structure 
remains the same (Buckwalter and Mankin 1997). The biornechanical properties of 
cartilage depend on the composition of the extracellular matrix, a factor which is 
ultimately under the control of the chondrocyte. 
Composition: 
Cartilage consists of approximately 60 - 80% water, with the dry weight being composed 
of approximately 60% collagen, 25-35% proteoglycans, and 5-15% noncollageneous 
proteins. Histologically it is organised in four zones (see later) in each of which the exact 
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organisation of the cartilage constituents as well as its metabolic activity differs (Wong et 
al. 1996). 
Chondrocytes 
The chondrocyte is the only type of cell in the cartilage and individually each cell is highly 
metabolically active. However, the cell density within the cartilage is very low with the 
cells occupying only 2 -10 % of the tissue volume. The chondrocyte is responsible for the 
synthesis and constant replacement of all the matrix macromolecules, and must therefore 
sense changes in the molecular environment. Chondrocytes receive their nutrition from 
the synovial fluid, and these nutrients must first diffuse through the synovial tissue and 
fluid and then across the cartilage matrix. For this reason chondrocytes function at a low 
concentration of oxygen, depending primarily on anaerobic metabolism. The enzymes 
responsible for the degradation of matrix macromolecules are also produced by the 
chondrocytes, and the presence of fragments of these degraded molecules stimulate the 
cells to increase synthetic activity. However the capacity for synthesis of some molecules 
is not adequately maintained as the chondrocytes age and this factor may contribute to 
degeneration of the cartilage with age. Chondrocytes are heterogeneous cells with those in 
different cartilage zones synthesising different amounts of molecules and acting quite 
differently to the same stimuli. 
Extracellular matrix 
The matrix surrounding the chondrocytes consists of two very different but vitally 
interactive components - the tissue fluid and the framework of structural macromolecules. 
Tissue fluid 
The interaction of the tissue fluid with the macromolecular framework gives cartilage its 
mechanical properties of stiffness and resilience. The amount of water in the cartilage 
ranges from 60 - 80% of wet weight, and the exact amount depends largely on the 
interactions between electrolytes in the fluid and the large aggregating proteoglycans 
within the framework (Mow et al. 1992). 
Structural macromolecules 
a) Collagen 
Collageps contribute about 60% of the dry weight of the cartilage and are distributed 
relatively uniformly throughout the tissue. The collagen fibrillar network is responsible 
for the form and tensile strength of the cartilage. The principal collagen in hyaline 
cartilage is Type H which accounts for 90% of the total collagen, although types VI, IX, 
X, and XI, also occur. The collagen is organised into a tight meshwork, which provides 
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tensile strength as well as trapping large proteoglycans within its structure. The strength 
of the meshwork is enhanced by covalent crosslinks between the collagen molecules. 
The type H collagen molecule is composed of three identical cc polypeptide chains wound 
in a left handed helix. Three cc-chains are further arranged in a right handed triple helix to 
form a tropocollagen subunit (Mow et al. 1992). Collagen fibrils consist of a staggered 
array of these tropocollagen units (Figure 1- 1). 






Figure 1-1: Structure of collagen fibril' 




Proteoglycans contribute about 25 - 35% of the cartilage dry weight. They consist of a 
protein core and one or more glycosaminoglycan side chains. The glycosaminoglycans 
are composed of repeating disaccharides which have negatively charged sulphate or 
carboxyl groups and these highly charged molecules attract water and exert a swelling 
pressure. Proteoglycans are thus responsible for the compressive stiffness of hyaline 
cartilage. Large aggregating proteoglycans or "aggrecan" fill most of the interfibrillar 
space, accounting for about 90% of the total cartilage matrix proteoglycan mass. Most 
bind covalently with hyaluronan and are stabilised by link proteins (small non collagenous 
proteins). Small non aggregating proteins also exist, e. g. decorin, fibromodulin and 
biglycan. These have a shorter protein core than aggrecan and are thought to influence cell 
function rather than having any effect on the mechanical nature of cartilage. There are 
three major types of glycosarninoglycans in cartilage - chondroitin-4-sulphate, 
chondroitin-6-sulphate, and keratan sulphate. The proportion of these different 
glycosaminoglycan chains vary with zone of the cartilage as well as with age, injury and 
disease. 
Gl 
KS CS-1 CS-2 
Figure 1-2: Aggrecan' 
KS = Keratan sulphate CS = Chondroitin sulphate 
G1, G2, G3 = globular domains (G1 = HA binding region) 
I Adapted from Poole AR: Cartilage in health and disease. In McCarty DJ(ed): Arthritis and Allied 








Figure 1-3: Organisation of type 11 collagen fibrils and proteoglycans 
within the extracellular matriX3 
c) Non collagenous proteins 
These proteins are less well understood. Anchorin CII may help to anchor chondrocytes 
to the collagen fibrils of the matrix (Mollenhauer et al. 1984), and cartilage oligomeric 
matrix protein (COMP) is concentrated mainly around the chondrocyte and appears to 
have the capacity to bind the cells (Dicesare et al. 1994). Fibronectin is found in many 
tissues as well as cartilage, and is thought to have a role in matrix organisation and cell - 
matrix interactions (Miller et al. 1984). 
Cartilage zones 
As previously mentioned the cartilage is arranged in four distinct zones: 
1. The superficial zone - here the chondrocytes are ellipsoid and arranged so that their 
axes are parallel to the cartilage surface. In this zone these cells produce a high level of 
collagen and a low concentration of proteoglycans in proportion to other zones (Aydelotte tý 
' Adapted from Poole AR: Cartilage in health and disease. In McCarty DJ(ed): Arthritis and Allied 
Conditions. A textbook of Rheumatology. Philadelphia, Lea and Febiger, 1993, pp279-333 
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et al. 1996). Collagen fibrils are densely arranged parallel to the cartilage surface and 
impart greater tensile strength and stiffness to this region than to other zones. These fibrils 
also form a barrier to the passage of molecules from the synovial fluid into the cartilage 
matrix. 
2. Transitional zone - this zone is usually much greater in diameter than the superficial 
zone. The chondrocytes are more spheroidal, arranged randomly, and produce a larger 
proportion of proteoglycans. Collagen fibrils have a wider diameter but are in lower 
concentration than in the superficial zone. 
3. Radial zone - here the chondrocytes are spheroidal and aligned in columns 
perpendicular to the cartilage surface. This zone contains the largest diameter collagen 
fibrils, the highest concentration of proteoglycans and the lowest proportion of water. The 
interface between this and the next zone is called the tidemark. 
4. Calcified cartilage zone - this is a thin zone of calcified cartilage which separates the 
radial zone from the underlying subchondral bone. The chondrocytes here are very low in 
number and are metabolically very inactive. 
The maintenance of the cartilage is made possible by the interaction between the 
chondrocytes and the matrix. The matrix protects the cells from mechanical damage. All 
nutrients, newly synthesised molecules, waste products and regulatory molecules must 
pass through the matrix, and the rate at which this can occur depends upon the 
organisation of the matrix, primarily the concentration and composition of the large 
aggregating proteoglycans. Matrix macromolecules are constantly being synthesised and 
degraded by the chondrocytes throughout life, and this homeostasis is thought to be 
controlled by anabolic and catabolic regulatory factors i. e. cytokines. These cytokines are 
synthesised by the chondrocytes in response to a variety of stimuli, including mechanical 
loading. It seems that maintenance of the normal composition of cartilage requires a 
minimum level of loading and movement of the joint (Buckwalter and Mankin 1997). 
2. 
-Synovium The synovium is modified mesenchyme which forms the innermost lining of the joint 
capsule. An incomplete layer of one to four synoviocytes form the intima, and these cells 
are both phagocytic (Type A or macrophages) and secretory ( Type B or fibroblasts). The 
function of the synovium is to form a selective barrier for ultrafiltration of the plasma and 
thereby determine the composition of the synovial fluid. Small molecules less than lOkDa 
equilibrate between plasma and synovial fluid and cross the synovium by simple 
diffusion. Synovial cells synthesise hyaluronan which is secreted into the synovial fluid at 
the plasma membrane. It is also likely that lubricin, which is involved in the boundary 
lubrication of cartilage, is synthesised by the synovium (Swann 1982). 
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3. Synovial fluid 
Synovial fluid is a microfiltrate of plasma and fills the synovial cavity between the 
cartilage surfaces. It is a yellow, translucent, and viscous fluid, the latter property being 
the product of hyaluronan. It contains mononuclear cells, of which 90% are synovial 
lining cells, monocytes and lymphocytes. The function of the synovial fluid is to lubricate 
the articular surfaces of the joint and provide nutrients to the articular cartilage. 
Hyaluronan 
Hyaluronan is the only glycosaminoglycan which is non sulphated and does not have a 
protein core. It has a molecular weight of 1-2 million and in solution adopts a randomly 
coiled spherical configuration causing the large molecular domains to overlap and 
entangle, which imparts a high viscosity to the synovial fluid. This viscosity enables the 
synovial fluid to resist strain and to function as a boundary lubricant to the synovium. 
Hyaluronan also functions as a barrier to small molecular exchange. 
4. Subchondral Bone 
Subchondral bone supplies structural support to the overlying articular cartilage, and its 
stiffness enables it to support relatively high loads without substantial deformation. It is 
the principal shock absorber in the joint. The rigidity of the bone is a consequence of its 
high mineral content which is in the form of hydroxyapatite and makes up about 65% of 
the total bone matrix. 25% of bone is water and the remaining dry weight is made up of 
95% (predominantly Type I) collagen and 5% proteoglycans and other noncollagenous Z) 
proteins. Remodelling of the subchondral plate and the epiphyseal bone is under the 
control of the bone cells, the osteoblasts and the osteoclasts. Osteoblasts are mainly bone 
forming, are situated on the bone surface and secrete the extracellular matrix or osteoid. 
Once surrounded by osteoid they are known as osteocytes. Osteoclasts are large 
multinucleated cells which resorb bone. 
Pathogenesis of Ostegarthritis 
Since the ordinal feature of OA is considered to be focal loss of articular cartilage, the 
pathogenesis of OA is mainly described in relation to this tissue. However it is important 
to remember that this disorder involves all the tissues of the joint and the processes 
change and vary in different tissues and in different joints. OA is not a static degenerative 
condition but also includes a high rate of synthetic activity. There is a mixture of 
degradative, reparative and inflammatory processes occurring in cartilage bone and 
synovium. The variations in the clinical presentation of OA are likely to reflect alterations 
in the balance of these processes (Dieppe 199 1). 
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In the normal joint, synthesis and degradation of the cartilage matrix are controlled by the 
chondrocyte and continue in homeostasis throughout the healthy life of the cartilage - 
However in some instances the synthesis of new proteoglycan molecules becomes 
inadequate with a net result of proteoglycan loss. This in tam leads to water loss from the 
cartilage and reduction in the compressive strength. 
There are three main stages in the process of cartilage degeneration (Buckwalter et al. 
1997). In the first stage there is disruption of the macromolecular matrix framework, 
associated with an increase in water content, which may be caused by mechanical insult, 
degradation of matrix macromolecules, or disruption of chondrocyte metabolism. The 
collagen framework may be damaged, and proteoglycan aggregation and aggrecan 
concentration decreases. Chondrocytes respond in the second stage by proliferating and 
by increasing the synthesis of proteoglycan, which may be adequate to restore the defect 
or maintain it in an unaltered state for many years. However, the third stage occurs when 
this cell response fails and can no longer maintain adequate synthesis. Loss of articular 
cartilage follows. 
Macroscopically the typical pattern of OA is characterised by progressive degenerative 
changes in the articular cartilage including yellowish discolouration, dullness, fibrillation, 
wearing or ulceration, and eburnation. The synoviurn and the fibrous layer of the joint 
capsule become thickened and congested. The first sign of disruption of subchondral 
bone in OA is increased density caused by formation of new bone on existing trabeculae. 
There is also the appearance of regenerating cartilage on the subchondral bone surface, 
most commonly at the joint periphery where osseous and cartilaginous excrescences can 
form osteophytes. The end stage of OA occurs when the articular cartilage has been 
completely lost and the articulating surface becomes dense subchondral bone. Bone 
remodelling and loss of articular cartilage result in altered joint shape which can lead to 
defonnity and instability. 
In the high motion equine joints OA changes are usually first seen grossly at the joint 
margins (McIlwraith 1982). Synovitis is frequently prominent, and there is a sequence of 
cartilage discolouration, fraying, erosion and ulceration in discrete areas. In low motion 
joints bony proliferation occurs with a tendency towards ankylosis in some cases. In OA 
of the distal intertarsal and tarsometatarsal joints subchondral bone lysis may occur, in 




Meta llopro te inas es 
Enzymatic degradation of articular cartilage is thought to precede morphological 
breakdown and plays a central role in equine joint disease. The most well known group of 
matrix destructive enzymes are known as neutral metalloproteinases which include 
collagenase (MMP-1) stromelysin (MMP-3), and the gelatinases (MMP-2 and MMP-9). 
These enzymes are produced mainly by the chondrocytes and synoviocytes after 
stimulation by the cytokine interleukin-1 (IL-I) (Morris et al. 1994) (Mort et al. 1993). 
They are secreted as latent proenzymes and activated by serine proteases. Plasmin may 
activate stromelysin and stromelysin in turn activates collagenase. MNT-1 is capable of 
cleaving Types I, II, and III collagen into small fragments. NlNW-3 has a wide range of 
substrate specificity and is therefore an important contributor to tissue destruction. It is 
involved in normal matrix turnover and in destruction by clearing the proteoglycan 
aggregate (Sandy et al. 1992) releasing large chondroitin sulphate fragments, and this in 
turn can potentiate the effect of MMP-1. MMP-2 degrades type IV collagen and may t: - 
further degrade the collagen fragments produced by the action of MUT-1. 
During normal matrix turnover there is no change in the size of glycosaminoglycan chains 
or in proteoglycan distribution. This may be because inhibitors in the local environment 
may be sufficient to block the action of the low levels of proteinases. However in the OA 
process following increases in the NBP levels , chain size changes do occur, 
implying 
inhibition of MMP inhibitors. 
The major inhibitors of matrix metalloproteinases are the TIMPS, heavily glycosylated 
proteins that bind to the MMPs and inhibit their action. A deficiency of TTMP has recently 
been found in OA cartilage (Dean et al. 1987) and it is currently thought that the balance 
between NCAPs and TIMPs is responsible for the rate of articular cartilage degeneration. 
Cytokines 
The metalloproteinases are activated by the action of mediators of inflammation known as 
cytokines. Activated macrophages, synoviocytes and connective tissue cells have all been 
shown to be capable of secretion of these inflammatory mediators, believed to be the 
primary determinants of articular damage after joint injury (Pelletier et al. 1993). 
Interleukin (EL- 1) has been isolated from the articular cartilage culture media and synovial 
fluid from many species (Morris et al. 1990). The function of IIL-1 is the induction and 
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synthesis of the metalloproteinases and the inhibition of the cartilage extracellular 
molecules, collagen and the aggregating proteoglycans. The recent demonstration of 
naturally occurring inhibitors of EL-1 in different species implies an endogenous control 
of cytokine activity (Seckinger et al. 1990) and it is therefore likely that the balance 
between EL-1 inhibitors and active EL-1 determines the degree of the inflammatory 
response. 
Other cytokines including turnour necrosis factor (TNFa), transforming growth factorp 
(TGFP), insulin-like growth factor (IGF-1) have also been shown to regulate the 
expression of metalloproteinases and TIMPS. 
Role of mechanical factors 
Mechanical forces can destroy cartilage indirectly by insult to subchondral bone, synovial 
membrane or chondrocytes. One concept (Radin et al. 1986) is that subchondral bone 
sclerosis causes a reduction in the shock absorbance of subchondral bone which then puts 
the cartilage at risk of tensile failure by damage to collaggen crosslinks, particularly under 
repetitive impact loading. In the horse mechanical stresses are crucial in the pathogenesis 
of OA and use trauma is generally accepted to be a principal aetiological factor (see later). 
Different areas of cartilage are subjected to different types of loads which results in each 
area having a different inherent biomechanical capacity and biochemical composition 
(Palmer et al. 1996). Loading stimulates the synthesis of proteoglycan and increases 
chondrocyte metabolism and is essential for the maintenance of healthy cartilage matrix. 
However, high and continually compressive loads can be damaging to the articular 
cartilage since the level of increased proteoglycan synthesis cannot be maintained. There 
appears to be a critical level after which the beneficial effect of exercise is overwhelmed 
by the harmful effects of repetitive loading, a crucial consideration in the training of 
performance horses. During light training the increase in chondrocyte potential to 
synthesise proteoglycans results in adaptive remodelling which serves to protect the 
cartilage. However the mechanical stress often encountered in equine training can 
overwhelm the adaptive response and alter the biochemical composition of the matrix. 
Increasing or maintaining exercise at this level may result in irreversible changes to the 
joint tissues, thus continued mechanical loading is a major driving force for the 
development and progression of OA. 4: 1 
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Classift: cation of ostegarthritis 
As in man, OA in the horse has been classified in many different ways. 
Type 1 Acute - associated with synovitis and high motion joints 
Type 2 Insidious - associated with low motion joints 
Type 3 Incidental or non- progressive cartilage erosion 
Type 4 Secondary to other identified problems 
e. g. a) Intraarticular fractures 
b) Dislocations/ligamentous rupture 
c) Wounds 
d) Septic arthritis 
e) Osteochondrosis 
Type 5 Chondromalacia of the patella 
Table 1-1 : Original classification of OA in the horse by McIlwraith 
(McIlwraith et al. 1988) 
Type 1 is more common in the young racehorse and affects primarily the more mobile 
high motion joints e. g. the carpus and the metacarpo/tars6 phalangeal joints. Synovitis 
and capsulitis are very common and usually precede the osteoarthritic process. 
Type 2 is usually insidious in onset and affects the low motion joints e. g. the 
interphalangeal and intertarsal joints. Type 3 describes lesions which may be identified at 
post-mortem examination but are of unknown clinical significance. Type 4 describes OA 
that develops secondarily to other joint injury and Type 5 refers to a condition similar to 
chondromalacia of the patella in man, involving fibrillation of the articular cartilage of the 
distal aspect of the articular surface of the patella. 
However this classification has now been altered in light of recent considerations. 
Type 1 Associated with capsulitis and synovitis (common in carpus, 
metacarpo/tarso phalangeal , distal tarsal and distal. interphalangeal 
joints) 
Type 2 Associated with and usually secondary to other identified injuries 
or problems 
Type 3 Incidental or non progressive articular cartilage erosions 0 
Table 1-2: Modified classification of OA in the horse (McIlwraith 1996) 
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The distinction between the original Type 1 and Type 2 categories seemed inappropriate 
since the synovitis and capsulitis which are part of both syndromes are associated with 
repetitive cyclic trauma. It was also felt that the contribution of primary pathological 
changes in the subchondral bone possibly leading to secondary articular cartilage damage 
needed to be recognised, as well as the failure of ligamentous adaptation to accommodate 
stresses to the cartilage. 
Classification of OA in man used to include primary and secondary OA, but this is no 
longer considered applicable since OA is now thought to be a disease process secondary 
to possibly unknown factors, including biornechanical changes, local influences, and 
systemic factors. OA is now preferentially classified according to joint site, i. e. knee, hip, 
or digital OA, and to the site within the joint, e. g. medial OA of the knee (MOAK), lateral 
OA of the knee (LOAK) (Dieppe et al. 1994). It is interesting to note the similarity 
between this and the late 19th century method of classification of equine OA reviewed at 
the beginning of this chapter. 
Epidemiology 
There is a lack of literature concerning the epidemiology of equine osteoarthritis, and 
most of what is understood regarding the incidence of the disease is based on anecdotal 
evidence. This highlights an area of equine medicine which requires considerable 
investigation. 
Aetiology ot ostegarthritis 
In equine studies, use trauma has long been accepted as the central aetiological concept 
(Mackay-Smith 1962). Conformation, inadequate conditioning and training regime, and 
improper shoeing are also definite aetiological factors. Chemical factors include release of 
chemical mediators by chronically irritated synovium. The initiating event may be 
mechanical or chemical and the two processes are closely inter-related, i. e. OA is caused 
by either an abnormal force on a normal joint or by a normal force on an abnormal joint 
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Figure 1-4: Factors involved in articular cartilage degradation in equine 
OA 4 
4 Diagram from General Principles of Joint Pathobiology. In McIlwraith CW, Trotter GW(eds): Joint 
Disease in the Horse. Philadelphia, W. B. Saunders, 1996, pp42 
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Risk factors 
Known risi factors for OA, taken mainly from human studies, vary according to joint 
site, and can be both general e. g. age, sex, and race, or localised, e. g. joint shape, 
trauma, or occupation. 
1) Age - In man OA is age related but not caused by age. In the horse this is also true, 
although overall the relative age of equine patients is younger (McIlwraith 1996). 
2) Sex and race - in man OA of certain joint sites has a predilection for different sexes, hip 
OA being common in caucasian males, while hand and knee OA is common in caucasian 
females (Dieppe 199 1). There is no evidence in the literature to this effect in the horse. 
3) Inherited susceptibility - although no single gene locus has been identified it is very 
likely that genetic predisposing factors are very important in man. 
4) Obesity - Knee OA is very strongly related to obesity in man with the overweight 
having a seven times greater risk of knee OA development (Felson et al. 1995). 
5) Trauma and selected activities - this certainly seems to be true in the horse (Table I- 1) - 
In man certain joints have been found to be at higher risk of OA in certain activities e. g. 
wicket keeper's thumbs. However it has been found that normal athletic activity does not 
increase risk of OA without the existence of underlying joint abnormality (Dieppe 199 1). 
It is obvious that from the difficulty encountered in reaching an acceptable definition and 
classification of OA that there are many questions to be answered. If therapies are to be 
successful diagnosis must be made at an early stage and response to therapy must be 
monitored. Effective methods of measuring change in OA are vital for accurate trials of 
OA drugs. In order for prognoses to be made following trauma or disease, methods of 
predicting possible OA changes are fundamental. 
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Diagnosis , assessment, and therapy, in equine osteoarthritis 
Aims of the thesis 
Physicians of the utmostfame 
Were called at once, but when they came 
They answered, as they took theirfees, 
"There is no curefor this disease. " 
Hilaire Belloc 1870 - 1953 
Diagnosis 
1. Clinical signs and examination 
Since radiographic features of joint disease correlate poorly with the clinical symptoms 
and stage of disease, the initial physical examination of the horse is an important part of 
the assessment of the disease. This should include a detailed history of the clinical signs 
including performance history, duration of lameness, previous injury and previous intra- 
articular therapies. Assessment of conformation should be followed by palpation of joints 
in both weight bearing and flexed positions to identify sites of heat pain and swelling. 
Crepitus originating from damaged cartilage surfaces or from soft tissues can be assessed 
by palpation, as can the degree of effusion the joint. Pain can originate from the fibrous 
joint capsule, the intra-articular ligaments, the subchondral bone , the periosteum , the 
synovium. and the periarticular ligaments, and can be detected either by a painful 
withdrawal response on palpation or by an alteration in gait on exercise. A decreased 
range of motion of a joint is commonly found in OA and can result from pain, joint 
effusion or capsular fibrosis. 
Lameness in OA is caused by pain, or mechanical restriction of the joint. The degree of 
lameness, or alteration in gait, is commonly the primary method of measurement of the 
degree of pain, or the extent of the disease process. However the degree of lameness does 
not vary directly with the extent of change observed on radiographs (Trotter et al. 1996), Z' 
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and the type of gait is not necessarily associated with the type or origin of OA. Good 
correlation has been found in one study between soft tissue changes and degree of 
lameness but correlation between articular cartilage damage and lameness was poor 
(Trotter and McIlwraith 1996). Validation of lameness in the assessment of OA is 
necessary to evaluate its use as an outcome measure. 
Regional and intra-articular anaesthesia are commonly used methods for localisation of 
lameness in the horse. Intra-articular anaesthesia is more specific in isolating the source of 
pain to the joint but false positive results may occur where regional nerves lie close to a 
synovial outpouching and similarly false negative results may be possible when the 
pathological lesion lies within the subchondral bone. 
2. Radiography 
Radiography is considered to be the primary method of OA diagnosis in man and horse 
(Spector et al. 1993; Widmer et al. 1994). 
Radiographic features of OA in the horse 
Subchondral bone sclerosis is usually a response to cartilage erosion but could also be the 
cause of cartilage degeneration. The increased thickness may be difficult to appreciate in 
the horse because most equine joints already have a naturally thick subchondral bone 
plate. Subchondral lysis is more common in the small tarsal joints than elsewhere. Lysis 
in OA is usually focal except in the tarsus where it can be seen extensively throughout the 
joint. Lytic areas with indistinct margins usually represent active lesions whereas those 
with well defined margins may be chronic and inactive. Periarticular osteophytes occur on 
the joint margins. These may be produced because of joint instability or stimulated by 
cartilage degradation products (Johnson 1962) and their relevance to the activity of OA 
has been much debated. Other periarticular bone changes include enthesiophytes which 
are the result of ligament or capsule tearing and ossification at the joint insertions. 
Articular cartilage changes are represented by narrowing of the joint space indicating 
cartilage erosion and degeneration. This narrowing may be generalised or focal and is best C. 
appreciated by comparison with the contralateral joint. However, joint width can be 
difficult to evaluate in the horse, since it is greatly affected by uneven weight bearing, 
which is a common problem in the standing horse. 
Radiography is non invasive, fast, cheap and available but it is insensitive to early 
changes and can not therefore be used to identify OA at early stages of the disease, when 
interventions may have more chance of success. It is also not ideal in monitoring response 
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to therapies as changes occur only slowly. It can reflect only the degree of bone 
destruction, joint space narrowing and deformity that occurs and provides little 
information regarding soft tissue changes that occur. It has been shown to be poorly 
correlated to other measures of outcome. In equine literature there are few reports of 
reproducibility studies. 
Radiography will be further discussed in Chapter 6. 
3. Synovial fluid analysLis. 
Analysis of synovial, fluid can provide valuable additional information but is not 
diagnostic of OA. Changes in visual appearance and increase in volume can indicate 
synovitis. Measurement of protein content is routinely done but is not particularly useful 
in OA. An increase in the protein content above 2.5g/dI is indicative of inflammation. 
Measurement of viscosity of synovial fluid gives an estimate of the quantity and degree 
of polymerisation of IIA (Persson 197 1) The white cell count may be useful but varies 
tremendously in OA depending on the degree of active synovitis. 
Studies have been carried out on the analysis of cartilage particles in the synovial. fluid and 
a positive relationship was reported between cartilage debris and lesions on the articular 
cartilage surfaces (Tew 1980). However this technique has not been widely accepted 
since doubts were expressed concerning the presence of false results (McEwraith 1980) - 
4. Arthrosco. 1 
Arthroscopy allows direct evaluation of non-osseous tissues including articular cartilage, 
synovium and intraarticular ligaments. However it requires an experienced operator and is 
an invasive technique necessitating general anaesthesia (McIlwraith 1978). Grading scales 
have been developed in both man and in horse for scoring cartilage lesions, but further 
studies have yet to be done on the validation of these scales. See Chapter 8. 
Future methods of OA assessment 
1. Scintigraphy 
Scintigraphy has been shown to be more sensitive than plain radiography in detecting 
pathological changes associated with OA of the knee (Alzaraki et al. 1975) and is 
considered highly sensitive and specific for OA (Mooar et al. 1987). It is indicated in 
cases of multiple cause chronic lameness, evaluation of cases with painful yet 
radiographically normal joints, for evaluation of joints that cannot be radiographed in the 
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standing horse, and for evaluation of the treatment response (Devous et al. 1984). To date 
there have been no reports in the literature concerning the validity of this technique as a 
measure of outcome in OA. This will be further discussed in Chapter 6. 
2. Other imaging methods 
Ultrasonography has been used extensively in the horse for the evaluation of periarticular 
soft tissue structures, muscles, ligaments, joint capsule and tendons but imaging of 
internal anatomy of joints is more limited. Computed tomography is most usefully 
employed in conjunction with radiography and provides better definition of bone lesions. 
However the equipment necessary for this technique is not yet widely available. 
Magnetic resonance imaging can provide exceptionally good images of articular cartilage 
and intra, and periarticular soft tissue structures and is an extremely promising technique 
for diagnostic imaging in equine OA. However it is not readily available for horses in 
vivo and most studies to date have been carried out on cadaver specimens (Park et al. 
1987). 
3. Molecular markers of OA in svnovial fluid and serum 
During the dysregulation of the normal balance of degradation and repair within the joint 
various molecules are released into the synovial fluid (SF) and serum. Some of the 
molecules are indicators, or "markers", of degradation, some of synthesis, some of 
synovitis, and some of increased bone turnover and these can be used as tools to detect 
levels of degradation or repair. In man, the synovial fluid level of keratan sulphate (KS) 
epitope 5D4 is a putative marker of increased cartilage ca bolism in early OA (Ratcliffe et ta 
al. 1994). The expression of the chondroitin sulphate (CS) anabolic epitopes 3B3- and 
7D4 occurs in OA cartilage and SF but not in normal joints (Caterson et al. 1990) while 
the native CS epitope 846 is found in increased levels in OA SF (Rizkalla et al. 1992). A 
change in the sulphation pattern of chondroitin sulphate in the cartilage matrix can also 
indicate early OA changes (Sharif et al. 1996) The levels of metalloproteinases in the SF 
can also be used as markers of cartilage degradation (Lohmander et al. 1993) while 
cartilage aggrecan catabolism by the as yet uncharacterised enzyme "aggrecanase, 
generates neoepitopes which can be detected by monoclonal antibodies (Hughes et al. 
1992). Increasing levels of cartilage oligomeric matrix protein (CONT) in SF has been 
found to predict progression in OA (Sharif et al. 1995). The concentration and molecular 
weight of hyaluronic acid (HA) in SF is thought to be a marker of synovial inflammation 
(Dahl et al. 1985) while bone sialoprotein (BSP) (Saxne et al. 1995) and bone specific 
alkaline phosphatase (BAP) are markers of increased bone turnover. 
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The use of marker studies in understanding the pathogenesis of OA may be a very 0 
productive use of current. marker technology, as well as in the diagnosis, prognosis and 
assessment of change in OA. The use of biochemical markers will be ftu-ther discussed in 
Chapters 7,8, and 9. 
Therapy 
1. Rest and controlled exercise 
The use of rest, alone, or combined with other therapies, has been the traditional form of 
treatment for equine OA for many years. The amount, and form of rest recommended is 
variable, depending on the extent of the disability and on the opinion of the clinician. It 
may commonly begin with a period of stable confinement, followed by gentle controlled 
exercise, i. e. walking in hand. This generally progresses to turning the horse out in a field 
to rest further before returning to active training. The economics involved with horse 0 Z' 
ownership commonly prevents the proper application of rest therapy. This reflects the 
need for increased owner education in the cost /benefit ratio of this method. 
2. Non steroidal anti -inflammatory drugs 
Phenylbutazone has been used to treat lameness in the horse for more than 30 years (Lees 
et al. 1983). Other non steroidal anti-inflammatories (NSAIDs) used in lameness cases 
include flunixin meglumine, meclofenarnic acid, and carprofen, but data concerning their 
effects on synovial metabolism in horses is lacking. All NSAIDs, to varying degrees, 
inhibit the action of cyclooxygenase, thereby interfering with the arachidonic acid cascade 
(Vane 1971). Another important action of NSAIDs is their effect on proteoglycan 
synthesis since in addition to inflammatory cascades, some NSAIDs (Muir ýt al. 1988) 
have been reported to affect cartilage anabolism, inhibiting proteoglycan synthesis. ZP 
Although there is no doubt that the NSAIDs are useful in the reduction of inflammation, 
more investigations are necessary into the effects of these drugs on osteoarthritic tissues. 
There is also a need to demonstrate the comparative efficacy of the various available 
NSAIDs in clinical cases of equine OA. 
3. Intra-articular medication 
a) Corticosteroids 
The use of corticosteroids (CSD) intra-articularly in the horse was first reported in 1955 
(Wheat 1955) and has now achieved widespread acceptance. They are potent anti- 
inflarranatory drugs and will reduce synovitis and the concentration of deleterious 
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enzymes in the joint. However, intra-articular CSD therapy was first reported to induce 
arthropathy in 1968 (O'Connor 1968) and their use continues to be controversial, the 
relative risk to benefit ratio not yet having been agreed (McIlwraith 1992). 
Little objective information exists regarding corticosteroid effects and therefore numerous 
investigations have been made recently to try to evaluate the physiological effects of 
corticosteroids, on equine joint tissues (Chunekamrai et al. 1989; May et al. 1988; Trotter 
et al. 1991). Reports from controlled clinical trials concerning their therapeutic use are 
few, however in one recent placebo controlled trial the corticosteroid trianicinolone was 
reported to have beneficial effects on degree of lameness, and on both the synovium and 
articular cartilage, in horses with carpal osteochondral fragmentation (Frisbie 1997). 
b) Sodium Hyaluronate 
Intra-articular sodium hyaluronate (SHA) is useful in the treatment of synovitis and 
capsulitis although the exact mode of action is not clear. There is experimental evidence in 
the literature that the use of this drug improves the clinical symptoms of joint disease, but 
beneficial effects on cartilag 
., e 
lesions have not been observed (Wigren et al. 1978). 
Clinical trials have indicated that horses could return to work following a single SHA 
injection, but these trials have not been double blind or placebo controlled (Phillips 1989; 
Ruth et al. 1985). A study carried out in 1995 that was placebo controlled however did 
demonstrate a significant improvement in lameness in horses treated with SHA (Gaustad 
et al. 1995) but the duration of this trial was only 7 weeks. 
The advantage of using a combination of SHA and CS for the treatment of equine OA was 
demonstrated first in 1970 (Rydell et al. 1970). More recently one study has suggested 
that the addition of SHA reduces the biochemical degradation that occurs with repeated 
CS therapy (Roneus et al. 1993). 
In a recent placebo controlled trial (Kawcak et al 1997), the use of intravenous SHA was 
found to improve lameness scores and reduce synovial pathology in horses with 
experimentally induced articular cartilage defects , but had no effect on markers of 
cartilage pathology. 
In conclusion, the use of SHA seems to be helpful in cases of mild synovitis and 
capsulitis but if articular cartilage degeneration is present, the results are unpredictable. C) 
c) Polysulphated glycosaminoglycan 
Polysulphated glycosaminoglycan (PSGAG) is a mixture of highly sulphated 4: 1 
glycosaminoglycans, the major component being chondroitin sulphate. It has been 
reported to have an anabolic effect on synovial fibroblasts and chondrocytes in vitro 
causing a marked increase in HA synthesis (Smith et al. 1986), and also to stimulate net 
collagen and glycosaminoglycan, synthesis in both normal and osteoarthritic equine ZP 
metacarpophalangeal cartilage tisses in organ culture (Glade 1990). PSGAG has been 4: 1 
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metacarpophalangeal joint by intra-articular injection (May et al. 1988). However, few 
property controlled double blind clinical trials have been carried out in horses. In 1990 in 
a trial of 109 horses, decreased lameness, synovial fluid protein content, and improved 
clinical signs were seen more frequently in the PSGAG treated group (Hamm et al. 1988) 
and in 1995 a trial reported by Gaustad (Gaustad and Larsen 1995) proved PSGAG to 
significantly reduce lameness score when compared with a placebo. In both trials cases 
were only followed for up to 7 weeks. 
PSGAG is a commonly used drug in the treatment of equine OA and because of its 
suspected chondroprotective properties is traditionally favoured where articular cartilage 
damage is suspected. Despite anecdotal reports of good clinical efficacy, laboratory 
investigations have produced conflicting reports, therefore more extensive studies on the 
effects of PSGAG on joint tissues, along with well constructed clinical trials are 
necessary. 
4) Pentosan polysulphate 
Pentosan polysulphate has been used as an antithrombotic-antilipaemic agent in Europe 
for many years, but its potential as a disease modifying drug in OA has only begun to be 
investigated in recent years. The functions and mode of action of pentosan polysulphate 
will be discussed further in Chapter 3. 
5. Surgical treatment 
Surgical treatment cannot reverse articular cartilage damage but may be done to re- 
establish pain free weight bearing in order to salvage a horse for non athletic pursuits. The 
most common surgical procedures include bone fragment removal, debridement of an 
articular cartilage surface defect and arthrodesis. Many techniques have been evaluated for 
promoting articular cartilage resurfacing. Recent studies indicate that while full thickness 
debridement and subchondral bone drilling increase blood supply and oxygenation of 
chondrocytes, it is most beneficial to preserve the subchondral bone plate, and this can be 
achieved by a new rnicrofracture technique (McIlwraith 1997). 
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Airm of the study 
It seems that despite the common and debilitating nature of OA in man and in horse, the Z' 
ability to make early diagnoses and to measure and predict changes. still eludes us. 
Although many potential therapies have been investigated, there remains no efficient and 
reliable treatment for OA in the horse. This may be due, in part, to the lack of wen 
designed and conducted clinical trials. Therefore there exists a need both for well run 
clinical trials to accurately assess new therapies, and a need for the early diagnosis of OA 
in order to treat OA before it becomes irreversible. Central to both these requirements is 
the need for valid and reliable methods of measuring outcome. This study investigates 0 
methods of conducting clinical trials in horses, identifies potential areas of difficulty and 
sources of variability, and assesses the validity of measures of outcome in OA. 
The aims of the study were as follows: 
1. To carry out a controlled, blinded, pilot clinical trial in order to assess the validity and 
reliability of the present commonly used measures of outcome in the horse, i. e. functional 
outcome and radiography, and the more recent scintigraphic and molecular marker 
techniques, as methods of measuring changes in OA occurring in horses in clinical trials, 
and to evaluate a potential disease modifying drug in osteoarthritis . 
2. To establish normal parameters of molecular markers in equine serum and in synovial 
fluid from different joints. 
3. To investigate the use of molecular marker technology to assess change in joint status 
and disease process both cross sectionally and in longitudinal change in OA. I- 
4. To investigate whether there is variation in the metabolism of different normal equine 
joints, by the examination of response of the articular cartilage to challenge. 
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ChapterThree 
Calcium pentosan polysulphate pharmacokinetics study 
Introduction 
Calcium pentosan polysulphate (CaPPS) is a potential disease modifying drug (DMOAD) in 
osteoarthritis (OA) and was the drug chosen for investigation in the clinical trial. The putative 
actions of this drug and the experimental evidence for these actions are described below. The 
purpose of this study was to ascertain whether CaPPS was reaching the joint in adequate 
concentration to perform these functions. 
Sodium pentosan polysulphate (NaPPS) has been available for over 30 years as an anti - 
thrombotic/anti-lipaernic agent (Ghosh et al. 1992). Only relatively recently has its potential 
as a disease modifying agent in osteoarthritis been recognised and the calcium derivative of 
the salt developed. Pentosan polysulphate (PPS) is isolated from beechwood hemicellulose. 
It consists of repeating units of (1-4) -linked 0 -D -xylanopyranoses in which cc -D -4 - 
methylglucopyranosyluronic acid residues are attached glycosidically at position 2 of every 
ninth xylopyranose ring. PPS has no direct analgesic properties but is said to provide pain 
relief by acting on the disease processes within the joint that cause the pain. It is therefore 
classed as a DMOAD and is known to have the following effects : 
1. Cartilage 
PPS has been found to have an affinity for cartilage. Using radioactive PPS a peak 
concentration of 4gg/g cartilage was found after a 3mg/kg injection, and therapeutic 
concentrations were maintained for up to four days post injection (Collier et al. ). 
a) Chondrocytes 
PPS has been shown to have anabolic effects on chondrocytes. Using an in vitro lapine 
model where chondrocyte injury had been induced by brief exposure to sodium iodoacetate, 
NaPPS, at a concentration range of 10 - 200gg/ml, improved proteoglycan incorporation into 
the extracellular matrix (Cotesque et al. 1986). In another study, using primary lapine 
chondrocyte monolayers NaPPS consistently stimulated proteoglycan synthesis over the 
concentration range 0.1 - 10.0 gg/ml, and stimulation of 25% over control levels occurred at 
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l. Ogg/ml (Collier et al. 1989). The concentration of PPS achieved in cartilage after 
intramuscular injection of the recommended therapeutic dose (3mg/kg) has been found to be 
approximately 1.0 - I. Sgg/ml (Burkhardt et al. 1986), therefore, according to these figures, 
the required concentration for stimulation of increased proteoglycan synthesis could be 
achieved in vivo. 
b) Metalloproteinases 
PPS is said to inhibit the actions of matrix metalloproteinases (MMPs) and to stimulate the 
synthesis of tissue inhibitors of metalloproteinases (TIMPs). At concentrations of 0.5 - 5.0 
gghnl PPS has been found to inhibit both rat and human fibroblast stromelysin (MMP-3) 
(Nethery et al. 1992). In a recent anterior cruciate ligament transection dog model of OA a 
significant reduction of active NUVIP-3 levels along with an increase in TIMP in the articular 
cartilage, was observed in dogs treated with 2mg/kg PPS IM weekly, as compared to the non 
treated control group (Rogachefsky et al. 1993). 
2. Synoviurn 
Studies have also shown PPS to stimulate the production of hyaluronan by synoviocytes. 
Maximum stimulation was obtained, using cultured synoviocytes from OA joints, at PPS 
concentrations of 0.25gg/ml but occurred between the concentration range 0.1 - 1. Ogg/ml. 
The HA produced was also of larger hydrodynamic size- than in non treated controls 
(Hutalidok et al. 1988). The rat air pouch model of inflammation was used to confirm these 
in vitro effects in vivo (Francis et al. 1993). 
3. Periarticular tissues 
PPS stimulates the release of tissue plasminogen activating factor, and suppresses the release 
of tumour necrosis factor alpha from activated monocytes which in turn decreases the release 
of plasminogen activator inhibitor (Mocking et al. 1986). These effects thereby increase 
fibrinolysis which reduces periarticular and subchondral bone thrombosis. In canine studies, 
using PPS at a concentration of 3mg/kg, clearing of plasma lipids, was demonstrated by the 
increase in plasma lipase (Brunaud 1967). This has the potential to increase joint perfusion by 
the removal of lipid from microcapillaries. 
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Toxicity 
PPS has been found to have very low toxicity - in mouse and rat the LD 50 of NaPPS and 
CaPPS given intravenously is > 600mg/kg and administered by mouth exceeds 6g/kg 
(Mocking et al. 199 1). 
Doaage 
In canine studies the dose rate of 3mg/kg NaPPS was found to be optimal with the dosages 
of 1 mg/kg and 5 mg/kg being less effective. The improvement in functional outcome 
demonstrated in treated dogs after four weekly injections was shown to be maintained for 
four weeks after the final injection (Read et al. 1996). In the horse an optimal dose rate of 
2mg/kg CaPPS has been suggested. 
Development of CaPPS 
The calcium derivative of pentosan polysulphate (CaPPS) has been found to be more easily 
absorbed after oral administration than the sodium salt (Mocking and Markwardt 1986). 
After a single oral dose of 5mg/kc,, the absorption of NaPPS after I hour was 1% while the 
blood levels of CaPPS were maintained for >4 hours indicating 10 - 20 % -absorption. This 
increased absorption of CaPPS relative to NaPPS, has been confirmed in unpublished studies 
in rabbits, dogs, and humans, using subcutaneous as well as oral routes. In man, peak blood 
concentrations of NaPPS ( 3gghnl )have been found to occur 2 hours after intramuscular or 
subcutaneous administration of a 3mg/kg dose (Dawes et at. 1986; MacGregor et al. ) while 
after a subcutaneous injection of 2mg/kg CaPPS a concentration peak of 5gghnl occurs at 4 
hours post injection (P. Ghosh - unpublished data). 
The hypothesis that CaPPS, when administered intramuscularly, achieves a similar peak 
plasma concentration to that in man, i. e. 5gg/n-d at 4 hours post injection, and can also reach 
the synovial fluid in therapeutic concentrations, was investigated by obtaining serial serum 




The aim of this study was to investigate the pharmacokinetics of CaPPS in the horse after 
intramuscular injection, and to establish that CaPPS was reaching the joint in adequate 
therapeutic concentration after intramuscular injection. 
Methods 
Six horses, four female and two male, of mixed breed, and of mean age 10.2 years (range: tl; l 
4- 20 years), were used for this study (Table 3-1). All were clinically in good health and 
were free from locomotor disorders. Each horse had haernatological and biochemical profiles 
within normal limits for our laboratory. All horses were stabled throughout the study. At time 
point 0, CaPPS at a dose rate of 2mg/kg was injected intramuscularly into the brisket. Serial 
blood samples were collected via indwelling jugular catheters at time points 0,1 hour, 2 
hours, 4 hours, 8 hours and 24 hours post injection. Synovial fluid was collected from the 
rnidcarpal joint of each horse under sterile conditions, 4 hours after CaPPS injection. Blood 
was collected into sodium citrate vacutainers (Vacutainer Becton, Dickinson). After 
centrifugation at 20OOrpm for 5 minutes, plasma was removed and aliquotted into 0.5ml 
eppendorf tubes. Synovial fluid was centrifuged for 10 minutes at 40OOrpm. to separate cells 
and the supernatant aliquotted similarly to plasma. 14 days after injection a further synovial 
fluid sample was collected by arthrocentesis from the midcarpal joint of each horse. The 
samples were stored at -20C until being sent in dry ice to the department of Professor P. 
Ghosh ( Director of the Raymond Purves Bone and Joint Research Laboratories in Sydney 
Australia) for analysis. 
tiorse Breect Age ziex weient 
2 TB 20 F 500kg 
3 TB 10 F 450k(y 0 4 Polish pony 6 F 450kg 
5 TBx 4 Mn 450kg 
6 Belgian Warmblood 6 Nb 550kg 




The samples were analysed for pentosan polysulphate using a monoclonal antibody 5B 10 and 
0-hour plasma spiked with CaPPS as standard in a validated inhibition ELISA (Kongtawelert 
et al. 1990). The intraassay and interassay coefficients of variation were 4.2 +/- 2.8 and 16.7 
+/- 13.8% respectively. All samples were assayed in duplicate and the mean value for each 
sample used in analysis. 
Statistics 
Results were normally distributed, so mean values and standard errors of the mean (SEM) 


















1 0.945 0.697 0.615 1.183 0.969 0.586 0.832 0.097 
2 1.029 1.051 1.328 1.568 0.970 0.802 1.125 0.113 
4 1.891 0.872 1.606 2.812 1.747 1.240 1.695 0.270 
8 1.428 0.434 1.128 1.421 0.940 0.566 0.986 0.172 
24 0.249 0.139 0.000 0.000 0.260 0.163 0.135 0.047 
Table 3-2: Plasma concentrations of CaPPS gg/ml 
me 
4 0.007 0.038 
8 0.280 0.351 0.005 
24 0.001 0.001 0.001 0.006 











Figure 3-1: Mean levels of CaPPS in plasma after a single 2mg/kg 
intramuscular injection. 
Overall mean level for all horses in bold line. 
Synovial fluid 
Tim Ie Hors Ie Horse Horse Horse Horse - Ho Ir- se " Me-an SE'M 
(hours) 123456 
4 0.85f--- 0-. 7f. 2--- 0.711 0.238 0.480 0.530 0-. 5-97 0.089 
Table 3-4: Mean levels of midcarpal joint synovial fluid CaPPS at 4 hours 
post intramuscular 2mg/kg injection 
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Figure 3-2: Synovial fluid CaPPS concentration for each horse, plus mean 
value at 4 hours post intramuscular injection. 
Peak plasma levels of CaPPS occurred at 4 hours post drug administration. At this time, 
mean levels of 1.7gg/ml (range 0.9 - 2.8) were achieved in plasma (See Figure 3-1) and 
0.6gg/ml (range 0.2 - 0.9) in synovial fluid (See Figure 3-2). There was no correlation 
between horse body weight and plasma CaPPS levels or between plasma CaPPS 
concentration at 4 hours and horse age. 
Discussion 
The mean peak concentration reaching the synovial fluid in this study was 0.6gg/ml. This is 
lower than the concentration of PPS found in cartilage by Burkhardt of 1.0-1.5gg/ml 
(Burkhardt and Ghosh 1986), and although the cartilage concentration was not measured 
here, it seems unlikely that it could reach this level since the ma or source of nutrition of the i 
cartilage is from the synovial fluid. However, the CaPPS concentrations achieved here would 
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1 Mean 
fall into the range reported by Collier as necessary to stimulate proteoglycan synthesis by 
chondrocytes (Collier and Ghosh 1989). 
At the mean concentration of 0.6gg/ml achieved here the production of hyaluronan could be 
stimulated according to the study by Hutalidok (Hutalidok et al. 1988). The synovial fluid 
values measured here may not be maximum as the kinetics of transfer of CaPPS into the 
equine midcarpal joint are unknown. 
Although it has been shown that a concentration of 0.5-50gg/ml is necessary to achieve 50% 
inhibition of rat and human stromelysin (MMP-3) ,a decrease in activity of the enzyme has 
been reported at concentrations of 0.05 -0.5gg/ml (Nethery et al. 1992). It would seem 
therefore that the synovial fluid concentration of CaPPS achieved in this study would be 
adequate, potentially, to have an effect on the activity of these metalloproteinases. 
Peak plasma levels of CaPPS were reached at 4 hours post injection, as in man. However, 
the peak concentration was only 1.7gg/ml (range 0.9 - 2.8 gghnl ) compared to 5gghnl 
recorded in human pharmacokinetics studies (unpublished data). It is possible that this 
difference may be due to differences in elimination or excretion of CaPPS between man and 
horse but the mechanisms for these processes in horses are not known. 
Summary 
1. The levels of CaPPS found to reach the SF were in adequate concentration to elicit a 
potential therapeutic effect by action on the synoviocytes and by reduction in 
metalloproteinase activity. The concentration potentially reaching the cartilage would probably 
be lower than previously reported although still within the therapeutic range for chondrocyte CP 
stimulation. 
2. Peak plasma concentrations occurred at 4 hours post injection but at a lower concentration 
than that reported in man. 
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Pilot clinical trial to investigate the efficacy of calcium pentosan 
polysulphate in osteoarthritis in the horse 
Introduction 
The purpose of this chapter is to describe and discuss the planning and execution of a clinical 
trial. Results of the various outcome measures used to assess the efficacy of the drug, 
including scintigraphy and molecular markers, will be discussed in detail in the subsequent 
chapters. 
A clinical trial is the preferred method to assess the effects of a chosen treatment on naturally 
occurring cases of a disease. The prospective randomised controlled trial (RCr) is the gold Z; ' 
standard method for assessing any medical therapy, but a very low number of RCTs are 
reported in the veterinary literature. A selection of these will be reviewed following an outline 
of the ideal trial design. 
Trial desi2n 
A clinical trial is a prospective study which plans to make inferences about treatment efficacy 
from a sample of representative patients (Lund et al. 1994). There are several essential 
components of a good clinical trial, each of which will be detailed below. 
1. Reduction of bias 
The ultimate aim of good trial design is to eliminate or minimise bias. The following methods 
can be employed to achieve this. 
a) Control/ Comparison 
The use of a two groups, one treated, and the other untreated or provided with an alternative 
therapy for comparison is essential in reducing bias. However, it has been reported that only 
3% of articles describing study designs used in veterinary medicine described controlled 0 
trials, the remaining being case reports (58%), observational studies (15%), uncontrolled 00 
clinical trials (9%), case series (8%) and experimental studies (7%) (Smith 1988). The cases 
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assigned to each of the groups should be as homogeneous as possible, and the management 
of each group during the trial should be identical. 
b) Randomisation and blinding. 
Allocation to treated/control groups should be done randomly in order to maintain a balance 
between the two groups in the distribution of known and unknown variables which may 
influence the outcome. Randomisation also prevents any potential bias in the provision of 
treatment by the investigator. However, if numbers in the trial are small, and known variables 
exist, stratification is a useful way of ordering the randomisation. This involves the 
randomisation of cases to treatment groups within strata based on these factors e. g. breed, 
sex, age, stage of disease (Lund et al. 1994). 
The specific treatment assignment of each case should be unknown, ideally, to both the 
patient and the investigator i. e. it should be double blind, and each assessment should be 
made by the same investigator. In veterinary medicine, where the patient is obviously the 
animal, the owner should be blinded to treatment since they have some input towards 
outcome assessment. 
c) Chronology 
Comparisons between treatment groups should always be made concurrently in order to 
prevent bias occurring from making assessments of different populations at different times. 
2. Protocol 
In the design of a clinical trial it is imperative that a proper protocol should be prepared and 
followed. 
a) Hypothesis 
The study must have both a null hypothesis and a primary outcome measure that are clearly 
defined. 
b) Numbers and duration 
The numbers of cases necessary for a trial depends upon the power of the experiment , i. e. 
the reliability with which rejection or acceptance of the null hypothesis can be made. 
Calculation of power will be discussed in more detail in the section describing statistical 
methods. Power depends upon the variability and the accepted magnitude of change in the rý 0 
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primary outcome measure chosen, so it maybe necessary to perform an initial pilot study to 
generate this data. Duration of the trial should depend upon the characteristics of the drug 
used and the primary outcome measure chosen. 
c) Inclusion c7iteria 
The definition of inclusion criteria is critical and should be strictly adhered to. Specification of 
inclusion criteria affects the external validity of the study i. e. the extent to which the results 
of the study can be generalised to wider populations, therefore the study group must be 
representative of the population to which the results will be eventually applied (Lund et al. 
1994). Chosen cases must also be relevant to the disease under study so only those that have 
the potential to benefit from the intervention and for whom there is a high probability of 
detecting the effects of the intervention should be enrolled. Diagnostic criteria for the 
condition investigated must therefore be specifically defined. Relaxation of inclusion criteria 
increases the potential both for generalisation of the results and for larger outcome 
measurement variance, thus affecting study validity (Budsberg 1997). 
d) Instructions and consent 
It is paramount that the trial protocol is carefully explained to each owner, especially if there 
is a 50% possibility that their animal may receive placebo, since this may help to reduce non 
compliance at a later stage. Once this understanding has been reached, forms consenting both 
to the trial and to the use of an unlicensed drug should be signed. ZP 
e) Drug preparation 
Preparation of the drug/placebo must be considered carefully to avoid any observable 
differences in preparation which may thereby unblind the trial. Instructions for correct drug 4> 
administration must be explained carefully to each owner and any reactions to the drug must 
be noted. 
3. Assessing outcome 
The type of drug being investigated largely dictates the choice of methodology for measuring, 
outcome. Recently drugs used in the therapy of OA have been classified as quick or slow 
acting, and the slow acting as symptomatic slow acting drugs in osteoarthritis (SYSADOAs), Cý 0 
or disease modifying osteoarthritis drugs (DMOADs) (Lequesne et al. 1994). SYSADOAs 
are defined as those drugs which improve pain and/or function with a delay of 1-2 months 
but with a persistent benefit of some duration after treatment discontinuation (Theiler et al. 
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1994). In human trials, the primary outcome variable for drugs designed to alter symptoms 
is usually joint pain as recorded by the patient. This can be done on a Likert scale or on a 
100mm Visual analogue scale (VAS). A validated Pain index can also be used e. g. the 
WOMAC (Bellamy et al. 1985), Health assessment questionnaire (HAQ) (Fries et al. 1980), 
or the Arthritis impact scale (AIMS) (Meenan et al. 1980). The definition of DMOADs in 
human OA is outlined as a therapy which prevents, retards or reverses the morphological 
cartilaginous lesions of OA as determined using in vivo studies in man. The most important 
method of measurement of this activity is therefore that which demonstrates anatomic 
variability i. e. radiography, MRI, or arthroscopy. Changes in molecular markers as 
measures of disease process (Dieppe 1995) are also more recently being used in the 
investigation of DMOADs. To date no agent has been proved to be a DMOAD in man. 
Outcome measures should be explicit and clearly defined, well established and clinically 
relevant, and valid, reliable, and responsive to change, a valid method being one which 
provides a significant discrimination power to distinguish the outcome between a placebo and 
a drug-treated group (Theiler et al. 1994). The degree of magnitude of change that would be 
considered positive and the variance of the outcome measure in the normal population must 
be known. Clinical trials should include a core of validated measures (a single primary 
response variable is considered preferable) e. g. in human studies, pain, physical. function, 
patient global assessment and radiography (Alunm et al. 1996) are commonly used. 
Scintigraphy and biochemical markers can be used as additional measures but have not yet 
been validated. In veterinary medicine little has been found in the literature referring to the 
validation of non objective scoring systems despite the most common response measurement 
made in veterinary studies being the subjective evaluation of pain or dysfunction. 
The duration of a trial intended to test a SYSADOA depends on the rate of onset of the drug, 
i. e. these trials may range from 4 weeks to several months. In order to evaluate DMOADs 
however, a longer period is necessary and it is recommended that this should be at least one 
year (Altman et al. 1996). 
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4. Statistics 
An estimation of sample size should always be made before the beginning of the trial. 
This estimation is based upon a) (x - the probability of a false positive result or Type I error 
b) 0 the probability of a false negative result or Type II error; c) the variability of the primary 
outcome measure and d) A the hypothesised treatment difference i. e. that difference between 
the treatment groups that would be clinically relevant to detect. (Lund et al. 1994). 
i. e. 
Sample size = Variabilily x FConstant 
, 
&2 
Where a= 0.05 and P= 0.1 the Constant = 10.5 (Pocock 1983) 
A Type I error will therefore detect a difference between treatment groups when no 
difference exists, and a Type II error fails to demonstrate a difference when a true difference 
does exist. Estimates of variance and hypothesised treatment differences A are obtained by 
experience, and when this is not possible, pilot studies should be carried out. The 
homogeneity of the population, the within patient variability of the outcome measure and the 
standardisation of the measurement techniques can all affect the variance . Type I or II errors 
can therefore occur when the sample size is inadequate, the outcome measurement is not 
validated, or when the measurement chosen is not appropriate to the drug being tested. 
Power (I-P) indicates the ability of the trial at the given sample size and cc level to detect 
differences between groups of a specific magnitude and its calculation is important in the 
assessment of clinical and statistical significance. 
Although these calculations are rarely reported in clinical trials, in any trial where there is a 
possibility of a Type II error, an estimate of power and 95% confidence intervals should be 
calculated. 
As well as presenting results of significance testing, the difference between treatment groups 
with the 95% confidence intervals of the difference should be stated (Ratain et al. 1990). 
Confidence intervals provide the range of values for which the result is thought to be true, 0 
enabling the magnitude of the true treatment difference to be estimated. 






Previous clinical studies 
There are very few reports in the veterinary literature describing clinical trials in equine OA, 
most OA studies in the horse using experimental ponies with experimentally induced OA. 
Reports do exist describing the treatment of horses with sodium hyaluronate (SHA) and 
polysulphated glycosaminoglycans (PSGAG). In 1976 Asheim and Lindblad (Asheim 1984) 
performed a clinical trial to investigate the effect of intra-articular SHA in racehorses. 45 
horses with OA of the carpal, metacarpophalangeal, or distal interphalangeal joints were 
enrolled to the study. Diagnosis of OA was based on scoring the following factors - initial 
lameness, capsule thickening, increase in synovia, and radiographic evidence of 
osteophytosis. All horses had previously been treated with other methods but there was no 
mention of duration of lameness at the commencernent of the trial. Some horses were given 
more than one course of treatment during the trial. A non subjective (but non validated) 
outcome measure was chosen, which involved the use of a scoring system based on the 
horse's racing capacity after treatment, by a race track veterinary surgeon. There was no 
mention of the number of different veterinary surgeons involved in this scoring however. 
The duration of the trial was adequate, being at least one year, but since there was no control 
group and no statistical analysis this study should be better described as a case series only, 
from which no definite conclusions can be drawn. In 1988 a multicentre randomised double 
blind clinical trial was carried out by Aviad (Aviad et al. 1988) to compare the effectiveness 
of two different molecular weight intra-articular hyaluronan products. Inclusion criteria are 
clearly described including lameness duration, and demographic data are clearly reported. 
Outcome measures included scoring of lameness, and joint heat, and measurement of joint 
circumference and synovial fluid protein content and viscosity. Sixty-nine horses were 
recruited to the trial but since this occurred at three different centres, different veterinary 
surgeons were employed in the evaluations which could have increased the variability of the 
already subjective scoring systems of lameness and joint heat. Statistical methods are well 
described but there is no calculation of power despite the fact that no significant differences 
were found and no use of confidence intervals. The trial duration was only 2 weeks. 
In 1989 the trial carried out by Phillips (Phillips 1989) compared five different molecular 
weight hyaluronan products. 150 horses in athletic training were selected, and inclusion and 
exclusion criteria were clearly stated. Evaluation was blinded but the outcome measure 
although clinically relevant was again unvalidated - an overall assessment of return to active 
training or racing. Duration of the trial was 6 months. No explanation of statistical methods 
was given. The most comprehensive report of a clinical study found in the literature was by 
Gaustad (Gaustad et al. 1995) which was also the only one describing the use of placebo. A 
randomised double blind and placebo controlled clinical study was carried out to compare 
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PSGAG and SHA with placebo in the treatment of traumatic arthritis. Seventy-seven 3-4 
year old standardbred trotters with moderate to severe lameness were recruited and randomly 
assigned to one of three groups. Randomisation was stratified with the number of affected 
joints per horse used as the stratification factor, however carpal, tarsocrural, 
metacarpo/metatarsophalangeal and distal interphalangeal joints were included in the trial and 
although all these were all classified as high motion joints no allowance for matching of these 
joints was made in the stratification. The method of diagnosis of arthritis and exclusion 
criteria was clearly stated. The study was carried out at one centre with one blinded assessor 
but the only outcome measure was a lameness score. Statistical methods are very clearly and 
comprehensively described but there are no calculations of power. The short 5-7 week 
duration of the trial is noted in the discussion of the paper but is justified by the explanation 
that in this time period some effect of the treatment is expected. The evaluation method is also 
noted as being subjective but the justification given for this is that the method is well 
established. 
Overall the most striking observations made from the review of these reports is the common 
use of non validated outcome measures, particularly lameness scoring, the rare use of 
placebo controls, the short duration of the trials and the lack of calculation of power of the 
studies. 
Pilot studies 
Pilot studies, involving smaller numbers of patients, should be carried out before 
commencing full scale clinical trials. These enable the suitability of the protocol to be tested, 
and highlight any potential problems. Preliminary information regarding the biological effect 
of the drug can be gained, and the choice of outcome measures can be verified. Validity and 
reliability of these measures can be assessed if necessary and calculations of sample size 
necessary to provide adequate power can be based on pilot study results. 
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Trials investigating the use of CaPPS 
Clinical studies in man. 
In a non controlled study, 23 patients suffering from OA of the hips, knees or fingers were 
given five weekly subcutaneous injections of 2mg/kg CaPPS. Symptoms of pain, and the 
consumption of NSAIDs were reduced, and functional scores increased for up to 12 weeks 
post treatment (Verbruggen et al. 1994) . Another study of 105 OA patients, which was 
placebo controlled and double blind, also demonstrated a significant improvement in 
functional outcome for up to 3 months post treatment (Edelman et al. 1994). 
Clinical studies in the dog 
A double blind placebo controlled trial has also been used to demonstrate the efficacy of 
NaPPS in the dog (Read et al. 1996). 40 dogs which had been diagnosed with OA were 
randomly placed in one of four dosage groups i. e. 0,1,3, or 5 mg/kg dosage which was 
administered intramuscularly once weekly for four weeks. This was a multicentre trial and 
assessment was made, by a number of different assessors, by functional outcome scoring 
stiffness, mobility, pain on joint manipulation and overall response. Significant differences 
were reported between treatment groups, and the study concluded that 3mg/kg was the 
optimal dosage. 
Clinical studies in the horse 
There are no published clinical trials, but Sodium pentosan polysulphate (NaPPS) 
"Cartrophen Vef' Biopharm Australia is used in Australia for treating OA in horses. 
Intramuscular NaPPS has been used in management of chronic OA in 20 Thoroughbreds 
(Little et al. 1996) . There has been no critical analysis of results but anecdotal evidence 
suggests a beneficial effect. Treatment of these horses, with 2-3mg/kg NaPPS 
intramuscularly once weekly for four weeks, improved but did not eliminate the clinical signs 
including reduced synovial effusion and lameness. However, the most notable finding was 
reduction in increased lameness post racing. These horses could therefore resume training 
sooner and the interval between races was reduced. 0 
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Calcium pentosan polysulphate 
Calcium pentosan polysulphate (CaPPS) was chosen-for several reasons: - 
1. It is a potential disease modifying drug. 
2. There have been no clinical trials to date in the horse. 
3. It is easy to administer by the owner by intramuscular route. 
4. There is minimal risk of reaction (compared with intra-articular medications). 
5. As a relatively new drug in therapy of OA it is appealing to owners. 
The mode of action of CaPPS is described in Chapter 3. 
Aims 
The aims of this pilot clinical trial were as follows :- 
1. To assess the validity, reliability, and responsiveness of lameness scoring and 
questionnaires as functional outcome measures in OA in the horse. 
2. To evaluate radiography, scintigraphy and molecular markers as methods of assessing 
structural and disease modification in OA in the horse. 
3. To make preliminary assessments on the use of a potential disease modifying osteoaffluitis 




1. Reduction of bias 
Control 
It was decided that this trial should be carried out in a double blind, high dose/low dose 
controlled manner. Initially the trial was intended to be placebo controlled, but considerable 
owner resistance was encountered to the possibility of placebo treatment therefore the 
protocol was altered so that the trial could be dose related with a high (2mg/kg) and low dose 
(0.5mg/kg) group. 
Randomisation and blinding 
Once a definitive diagnosis of OA had been made (for method see later), each horse was 
assigned randomly (by a person not involved with the trial) to either a low dose (0.5mg/kg 
CaPPS) group (A) or a high dose (2mg/kg CaPPS) group (B). This random allocation was 
performed in a stratified manner i. e. the numbers of cases of OA in particular joints was equal 
in each group. The dosage used in each group was blinded to both owner and assessor, and 
this code was not broken until the final horse had completed the trial. 
Chronology 




The null hypothesis stated that no significant difference in outcome between the two treatment 
groups would be demonstrated. 
Numbers and duration 
Time and numbers of horses recruited to the trial were limited by the period available for the 
study . This was intended to be a pilot study, so for these purposes it was decided to recruit 


























































Diamosis of OA 
Horses were recruited from a population of riding horses referred to the Department of 
Veterinary Science, University of Bristol. In order to achieve as accurate a diagnosis of 
OA as possible, recruits to the trial were required to have a positive result in two out of the 
three following diagnostic techniques i. e. scintigraphic bone scan, intra-articular analgesia, 
and radiography. 
Clinical examination 
At the first examination before final recruitment to the trial, each horse was given a full 
examination. This consisted of visual assessment, Emb palpation, and gait observation at 
the walk, trot, and lunge on both soft and hard surfaces if necessary. A lameness score at 
each gait, on a scale of 1 -10 (Wyn-Jones 1988) was given by the same assessor (CF) on 
each occasion. After flexion tests, intra-articular analgesia was performed to identify more 
accurately the site of the lameness. 
Intra-articular analmsia 
Using strict sterile technique a 19/20G xI inch needle was introduced into the joint using 
recognised approaches to each particular joint (Stashak 1987; Wyn-Jones 1988) After 
withdrawal of synovial fluid, both for sampling and for verification that the needle was 
correctly inserted, 8 -15 mls of local anaesthetic (Mepivicaine - Upjohn), depending on the 
joint, was injected. After between 5- 20 minutes , further gait evaluation enabled the result 
of the analgesia to be assessed. Significant alleviation of lameness verified that particular 
joint as the site of pain. 
Radiography 
Radiography was carried out on both the affected and the contralateral joint, using standard 
views for each particular joint. A positive result for OA was based on the presence of joint 
space narrowing, subchondral bone sclerosis, subchondral bone lysis and osteophytosis 
(Widmer et al. 1994) although the exact parameters used altered depending on the particular 
characteristics of OA occuring in different joints (See Chapter 6). 
Scintigraphy 
This procedure was carried out on all recruits at the first examination, either before intra- 
articular analgesia was performed, or at an interval of no less than 10 days post intra- 
articular injections. Each horse was injected with IOMBq/kg Technetium99m 
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diphosphonate. After an interval of 3 hours a bone phase scan was carried out on each 
limb. Results were recorded both on hard copy and on computer ( Maxi - Link systems). A 
positive result was defined by increased uptake of radioactive isotope in the subchondral 
bone of the joint (McCrae et al. 1992) indicating increased subchondral bone turnover (See 
Chapter 6) 
Instructions and consent 
Details of the trial were discussed extensively with each owner who were then required to 
sign a form consenting to both the use of an unlicensed drug and to the involvement of their 
horse in an investigative trial. 
Drug preparation 
CaPPS was provided to the owners at each of the first three visits. All doses of the drug 
were provided in identical 10 ml glass bottles either labelled "N' (low dose) or "B" (high 
dose). The low dose bottles contained 0.25g CaPPS in 10ml saline, while the high dose 
bottles contained lg CaPPS in l0rril saline. Owners were instructed to inject 10mls of the 
provided dose of CaPPS intramuscularly once weekly for four weeks. Each owner was 
instructed in the correct procedure for administering and storing the CaPPS assigned to 
them. 
During the trial each horse was examined by the same assessor (CF) on four occasions at 3 
monthly intervals over the 9 month period, (i. e. at 0,3,6, and 9 months post diagnosis). 
At each examination a full clinical and radiographical examination was performed, and 
serum and synovial fluid samples were collected. At the first and third visit a scintigraphical 
bone scan was carried out . The gait of each horse at the walk and trot was recorded on 
videotape at each examination using a camcorder. Owners were requested to fill in 
questionnaires describing their horse's lameness at the beginning and end of the trial 
( Table 4-1 ). Owners were also advised to maintain their horse in a regime of controlled 
exercise, ideally boxed, or kept in a small paddock, with regular walking in hand initially, 
increasing the exercise to ridden walking as the trial progressed. It was advised that no 
other therapeutic agents should be used during the course of the trial. 
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3. Assessment of outcome 
Parameters chosen to measure outcome were as follows: 
Measures of function/disabiliiy 
a) Lameness scores. 
Lameness at each gait was scored on a scale 1- 10 by the same assessor (CF) at each 
examination. Video recordings of the gait of each horse at each examination were 
rearranged and blinded to date order, and these were also used to score lameness by the 
same assessor (CF). A global score of improvement over the duration of the trial was given 
for each horse based on both lameness scores given at the time of examination, and those 
derived from the date blinded video recordings (Table 4-2). 




Sound all gaits 2 
Table 4-2 : Global scoring system for lameness improvement 
b) Ouestionnaires 
Owners were asked to complete two questionnaires, one based on a visual analogue and the 
other based on a Likert scale, at the beginning and end of the trial. The questionnaires were 
designed to enable each owner to grade, in their own opinion, the degree of disability of 
their animal. Each owner was given instruction as to how to fill in the questionnaires on 
each occasion, but were not allowed to view their original answers when completing the 
second questionnaire. Six months following the conclusion of the trial a further 
questionnaire was sent to each owner to investigate the progress of each horse since the end 
of the trial. 
Measures of anatomical changes in joints 
RadiogLqphy 
Radiography was carried out as described previously and in Chapter 6. Radiographs were 
scored qualitatively by four independent veterinary radiologists. See Chapter 6. 
56 
Measures of disease process 
a) Scintigraphy 
Scintigraphy was performed as described above and further in Chapter 6. Scans were 
scored qualitatively by four independent veterinary radiologists, and quantitatively by 
measuring an activity index for regions of interest on the computer. See Chapter 6. 
b) Biochemical markers 
Serum and Unovial-fluid sampling 
Serum 
At each examination, a single blood sample was taken from each horse into a plain 
vacutainer (Becton Dickinson) , the time of this sampling being recorded. Once clotted, 
blood was centrifuged for 5 minutes at 30OOrpm. The serum was then removed by pipette 
and stored in 0.5ml aliquots at -80*C until analysis. 
Synovial-fluid 
Synovial fluid samples were collected at the time of intra-articular analgesia at the initial 
examination, and then on following examinations by arthrocentesis. The colour, viscosity, 
and volume of each of these samples were recorded, before centrifugation at 4000rpm. for 
10 minutes. The supernatant was removed by pipette and aliquotted before storage at -801C 
until analysis. 
4. Statistical analysis 
All the statistical tests used in the analysis of data from the trial were non parametric and 
involved the use of matched pairs. A 5% or less level of significance and 95% confidence 
intervals of the difference between groups were stated. 
The necessary sample size and the power of the study was calculated by using the 
assumption that if a group of horses with osteoarthritis were not treated with CaPPS but 
maintained on a similar exercise regime for 9 months, 50 % of these horses would show 
some improvement using the primary outcome variable of clinical lameness improvement. 
If it is then accepted that for the CaPPS treatrnent to be deemed successful more than 70% 
of the treated group should improve, the resulting necessary sample sizes are shown in 
Table 4-3. 
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Number of horses 
improving 
Controls Treated Sample size in each group 
50% 70% 95 
50% 80% 45 
50% 90% 24 
Table 4-3 : Necessary sample sizes to provide 80% power 
From Table 4-3 it can be seen that the numbers of horses in this trial were too small to 
provide adequate power. In this trial, with 10 horses in each treatment group, the power of 
the study would only be 29% if the improvement expected in the treatment group was 90% 
compared to 50% in the controls. For this reason this clinical trial could only be assessed as 
a pilot study. 
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20 horses from those referred to the Department of Clinical Veterinary Science, University of 
Bristol for persistent lameness, that were diagnosed to be suffering from OA, were recruited 
to the study (Table 4-4). These were of mixed breed and mixed age, the mean age being 10.2 
years and ranging from 4- 21 years. The sex ratio was 13 male :7 female. The mean 
duration of OA in the population was 6.4 months. In 4 horses two joint sites were affected 
(7 - mid carpal and antebrachiocarpal, 13 - tarsometatarsal and tarsocrural, 4- distal 
interphalangeal and proximal interphalangeal, and 14 - distal interphalangeal and proximal 
interphalangeal) , but in all of these cases one of these joints was more clinically active at the 




1. Reduction in bias 
After stratification based on the joint affected these horses were randomly assigned to either 
the low dose CaPPS group (Group A) or the high dose group (Group B). In the. Group A 
there were two cases of tarsometatarsal CW joint OA, three of proximal interphalangeal 
joint OA, four distal. interphalangeal joint and one of midcarpal joint OA (See Table 4-3 ). 
The mean age of horses in this group was 10.8 years (range 7 -16) and the male to female 
ratio 7: 3. The mean duration of OA in this group was 7.2 months. In Group B there were 
three cases each of TNIT OA, PIP OA and DIP OA. There was also one case of 
metacarpophalangeal (MCP) OA. The mean age in this group was 9.6 years (range 4 -18) and 
the male to female ratio 6: 4. The mean duration of OA was 5.6 months. Both groups included 
a mixture of breeds . There was no significant difference between the age distribution nor 
between the disease duration of either group. 
The total time taken to run the trial was 22 months. Horses from each group underwent 
treatment during this period. 
2. Protocol 
Acceptance of the protocol and owner compliance with the trial was good with only one horse 
(No 11) from group A being withdrawn from the trial after the preliminary examination CP 
because of the development of laminitis and another (No 6) not completin( ,, the trial after an 
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unrelated injury necessitated euthanasia before the final examination. Three owners were 
unwilling to bring their horses to the trial centre for the final examination, but were willing C. 
for this final examination to be carried out at their own premises. Therefore 18/20 horses 
completed the trial, and 19/20 were still included at the third (6 months) examination. The 
only investigative procedure that was not always successful was arthrocentesis. In two 
horses, (10 and 17) this was not possible for safety reasons! One owner (12) would only 
consent to the trial if no arthrocentesis was performed, however in this case regional 
analgesia was used as an alternative to localise the site of lameness. In all three cases ( 10, 
12, and 17) since the diagnostic techniques of scintigraphy and radiography were both 
positive for OA the decision was made to recruit the horses despite the lack of intra-articular 
analgesia because of the dffficulty in obtaining adequate numbers in the available time. 
Low dose group High dose group 
Horse Joint IA Scan XRay Horse Joint IA Scan XRay 
1 TNff + + + 2 PIP + + + 
3 PIP + + + 4 DIP + + + 
7 MC + + + 5 TNff + + 
8 DIP + + 6 TMr + + + 
10 PIP - + + 9 DIP + - + 11 DIP + + + 12 PIP ABSB + + 
13 TMr + + + 14 PIP + + + 
16 DIP + + + 15 MCP + + + 
18 PIP + + + 17 TNT - + + 
20 DIP + - + 19 DIP + + 
Table 4-5: Diagnostic criteria 
Key: AB SB = abaxial sesamoid nerve block. 
Inclusion criteria 
17/20 (90%) of the horses included on the trial had a positive response to intra-articular 
analgesia ( Table 4-5 ). One owner (12) refused this procedure so lameness was localised 
with peripheral neural analgesia, and in the two other cases (10 and 17) analgesia could not 
be performed in the hind PIP and TMT joints for safety reasons. 18/20 had a positive scan, 3 
of these were negative for radiological changes. 2/20 horses had radiographic but not 
scintigraphic changes. 13/20 horses were positive in all three procedures. 
Drug administration 
The owners experienced no difficulties with the administration of CaPPS and no adverse 
reactions were noted. 
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3. Assessment of outcome 
These results will be discussed in the following chapters: 
1) Functional outcome - Lameness scores and questionnaires 
2) Measures of anatornical changes in joints - Radiography 
3) Measures of disease process Scintigraphy 
Biochemical markers 
Discussion 
- Chapter 5. 
- Chapter 6. 
- Chapter 6. 
- Chapter 9. 
This is the first clinical study to be carried out using CaPPS in clinical cases of OA in the 
horse. Although the importance of investigating the efficacy of this drug in clinical cases is 
paramount clinical trials are difficult to perform and many dffficulties did indeed present 
themselves during the course of this pilot study. t) 
Trial design 
1. Reduction in bias 
Com arison with a control 
This was achieved by comparison of the suggested dose of CaPPS with a low dose which 
was advised by the manufacturer (unpublished data) to be below a concentration necessary to 
produce any beneficial effect. It would have been preferable to use a placebo as a control, but 
as stated earlier, owner interest in this was poor and this factor resulted in a considerable 
delay to the start of the trial. Once a low dose control group had been introduced, owner 
compliance was good, even though it was explained to the owners that 50% of the horse 
would still be receiving a very low instead of a therapeutic dose. The lack of acceptance of the 
need for the placebo group by the owners was a major drawback, and highlighted the need 
for education of owners concerning benefits of correctly conducted clinical trials. 
Randomisation and blinding 
Initially , on the basis of the trial being placebo controlled, and in the hope that 40 horses 
could be recruited to the trial, it was intended to use a completely random process to assign 
horses to either drug or placebo, and for this purpose a computer was used to generate a 
random allocation. Numbered bottles of either 10 mls of CaPPS or placebo were provided by 
the drug company (Biopharm Australia) along with corresponding numbered sealed Cý 
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envelopes containing the identity of the bottle contents. However, this plan had to be altered 
because of the poor owner compliance and because of the ensuing time delay it became 
apparent that only half of the intended number of horses could be recruited to the trial. By 
this stage it had also become clear from other studies (Fuller et al. 1996) that different joints 
affected by OA could not be compared in the measurement of marker levels. For these 
reasons it was decided to use the system of stratified randomisation. Therefore with the help 
of a person not involved with the trial (MP), dosages of CaPPS in the bottles were 
reorganised and labelled A or B, the identification of A and B being known only to the 
independent assistant. This person then arranged an order for allocation of cases, according 
to the joint in which OA was diagnosed. This enabled, over the course of the trial , the C. 
numbers of cases of OA in different joints to be equal in each group. 
Blinding was easily achieved in this trial by the use of this independent person (MP) who 
kept the identity of dose A and dose B blinded until the end of the trial. There was no 
difference in the appearance of the drug within the bottles, and no reactions to any of the 
drug administrations were noted. 
2. Protocol 
Null hypothesis 
Whether or not the null hypothesis was rejected will be discussed in following chapters 
which relate to the results of the trial. 
Numbers and duration 
Ideally it would have been preferable to extend the course of the trial over a prolonged time 
period, but this was limited by the period of time available for the study. It would also seem 
unlikely, for economic reasons, that owners could be persuaded to keep an inactive horse for 
a lengthy time period. However, the duration of this study was longer than any of the 
controlled trials reviewed in the literature. It was not possible to extend the numbers suitable 
for the trial beyond 20 in the available time. The problem with inadequate sample size is a 
common one in veterinary clinical trials, which is often overcome by carrying out multicentre 
trials. However, the disadvantage of this is the necessary involvement of several assessors 
thus increasing variability, - in this case, one assessor (CF) was responsible for every 
assessment at each time point. 
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Inclusion criteria 
It was surprising how difficult it was to reach an accurate diagnosis of OA in many horses 
referred to the veterinary hospital with pre-cxisting diagnoses of OA (For equine OA 
diagnosis see Chapter 2). This finding indicated that without detailed and thorough diagnostic 
examinations many horses may be diagnosed as suffering from OA when perhaps the term 
joint disease may be more appropriate. In man, the gold standard for the diagnosis of OA is 
still the radiograph (Kcllgren et al. 1957) and a patient will not be diagnosed as OA until 
certain documented chanaes are visible i. e. subchondral bone sclerosis, subchondral bone 
cysts, narrowing of the joint space, and osteophytes. Atlases providing more detail for 
various joints are available (Altmwi et al. 1995). Patients suspected of having OA but 
showing no radiological signs are classified as being pre-radiological. Horses are relatively 
slow in laying down new bone and thus commonly present showing clinical signs of OA but 
without radiographic changes until the condition is very advanced. Some human researchers 
therefore believe that equine cases seen without radiological changes should be classified as 
pre-radiological and therefore cannot be classified as suffering from OA, while others believe 
that veterinarians have the advantage of seeing their patients at a much earlier stage of disease. 
However, without the help of radiographic changes, definitive diagnosis of OA can be 
problematic. Intra-articular analgesia is helpful in localising the site of pain to the joint, but a 
positive result does not necessarily mean that OA is the cause of pain, inflammation of the 
synovium only for example could be responsible. Likewise, a negative result does not 
necessarily rule out the possibility of subchondral bone pain caused by OA being present. 
Scintigraphy has been shown in man (Dieppe et al. 1993) to predict subsequent OA change in 
the human knee joint, although results must be interpreted with care to avoid influence of 
variables (Devous et al. 1984). In this study 3/20 of the horses on the trial had a positive 
scintigraphic but a negative radiographic result. 
Because of the limitations of each diagnostic technique when used alone, it was decided to 41ý 
diagnose OA on the basis of a positive result in two out of the three techniques. 
Inclusion criteria in this trial were clearly defined and were clinically relevant. It may have 
been preferable to state exclusion criteria which would have excluded those horses with a 
duration of disease already exceeding 8 months at the beginning of the trial. It would also 
have made the population studied more homogeneous if only certain breeds had been 
included, but this would not have been practical, and it may be argued that by including 
various types of horse the results of the trial may be more applicable to the general 
population. 
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Instructions and consent 
One aspect of the trial which was reflected in the owner assessment of their horses' progress, 
as will be seen later in the chapter concerning functional outcome, was their individual 
aspirations for the future of their horse. Some owner§ hoped only for their horse to continue 
to be of some use as an occasional riding horse, while others expected that a positive 
outcome to the trial would mean a return to competition fitness. This, along with their 
individual personality, undoubtedly had some unavoidable effect on their judgement of the 
trial's success. Owners were instructed to keep their horses in light exercise, however, some 
found this impractical and preferred to turn their animal away to rest at grass for the duration 
of the trial. Some increased the exercise as the trial progressed and their horse improved, and 
some varied the periods of rest and exercise with the seasons. This undoubtedly would have 
added another variable to the trial. The difficulty in persuading owners to persist with a 
particular management regime over a prolonged time period is one reason for the majority of 
clinical trials being carried out for a short duration only (Gaustad and Larsen 1995). 
3. Assessment of outcome 
Clinical trials in rheumatology are said to be only as good as their endpoints (Ratain and 
Hochberg 1990). The endpoints, or measures of outcome in a trial should be validated (Deyo 
et al. 1991) and appropriate to the drug under investigation and the properties possessed by 
that drug. One of the aims of this trial therefore was to attempt to validate one of the most 
frequently used outcome measures in veterinary clinical trials of this type, lameness scoring. 
The WOMAC scoring scale for measuring pain and physical function (Bellamy et al. 1985) 
has been validated in human studies but to date no validation studies of lameness scoring 
have been carried out in veterinary medicine. Lameness scoring in horses is a well established 
technique and is clinically relevant thus making it a suitable method of measuring outcome in 
OA, but it remains subjective. Without prior knowledge of the reliability of a measure of 
outcome, the variability in the normal population and the degree of change necessary to 
indicate a positive improvement, the power of any clinical trial cannot be calculated. The use 
of a camcorder to record lameness at each examination with subsequent independent blinded 
lameness scoring allowed the reliability of this method to be assessed, and the results of this 
are reported in Chapter 5. The use of owner questionnaires to assess equine OA has not been 
previously reported in the veterinary literature, but in a recent canine OA study a 
questionnaire has been evaluated and was found to be reliable (Innes 1997). 
This trial also provided an opportunity to assess other methods of measuring OA i. e. C' 
scintigraphy and biochemical markers, in a clinical situation. More studies need to be carried 
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out to investigate the normal variation of these parameters before either can be accurately 
validated. The use of these measures in this trial will be discussed in later chapters. 
4) Statistics 
Although sample size estimation and power is crucial to the design and planning of a 
randomised clinical trial, it is not possible to calculate this accurately without prior knowledge 
or experience of the variance of the outcome measure. It is surprising when reviewing the 
veterinary literature to find that no study made reference to these calculations. Even when 
sample size has been accurately calculated, it is often difficult to achieve when depending on 
the availability of suitable clinical cases which meet the strict inclusion criteria. Low numbers 
in the trial is one factor which can increase the chance of a Type II error being made (Ratain 
and Hochberg 1990). It has been stated that in any study where no significant differences are 
found between treatment groups, calculations of the power should be shown (Markel 199 1) 
but in the literature reviewed, this was not done. 
In this study the use of stratification was helpful for the purposes of statistical analysis 
because horses could then be matched between groups for joint site. 
Summary 
In summary, a prospective randomised and blinded pilot clinical trial was performed. This 
provided the opportunity to validate various outcome measures and to make preliminary 
assessments regarding the efficacy of CaPPS in clinical cases of OA in the horse. This study 
highlighted the problems involved both in the definitive diagnosis of OA in the horse, and 
with veterinary clinical trials, but nevertheless the experience of conducting such a trial served 
to emphasise their importance in veterinary research and the methods by which variability 
should and can be minimised. 
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ChapterFive 
The assessment of cHnical outcome. 
Introduction 
In this chapter the clinical assessment of the calcium pentosan polysulphate (CaPPS) clinical 
trial will be reported. When assessing clinical, or functional outcome, chosen measures 
should be valid, reliable and responsive (for definitions see later), and ideally they should 
have been previously published in other studies so that comparisons of results can be made. 
In the recommendations for human clinical trials of drugs used to treat osteoarthritis (Altman 
1990) it is suggested that a core of validated measures should be included with others being 
added optionally, i. e. 
Validated measures: Pain, physical function, patient global assessment, imaging (for 
studies over 1 year in duration). 
Additional measures : Quality of life, physician global assessment. 
Qptional measures: Signs of inflammation, biologic markers, stiffness, performance based 
measures, presence of flares, time to surgery, consumption of analgesics. 
For studies designed to affect symptoms the primary outcome variable should usually be pain 
as reported by the patient. For disease modifying osteoarthritis drugs (DMOADS) the primary 
outcome variable should be a measure of joint morphology e. g. imaging techniques. In man, 
the use of radiography, but not yet magnetic resonance imaging (MRI), arthroscopy, or 
scintigraphy has been validated. 
For the purposes of this chapter subjective outcome measures relating to clinical assessment 
of symptomatic osteoarthritic drugs (SYSADOAS) will be discussed. Imaging as an outcome 
measure of a DMOAD will be discussed in Chapter 6. 
I -Pain 
Pain assessment is a subjective but essential part of disease assessment in man. However it is 
difficult to quantitate, and there is considerable variability, between patients, and throughout 
the duration of the disease (Bellamy et al. 1990). According to the recommendations for the 
design of clinical trials in OA in man (Altman et al. 1996) the degree of pain can be recorded 
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on a five-point Likert scale i. e. None, Mild, Moderate, Severe and Very severe, or on a 10 
centimetre Visual Analogue Scale (VAS). There is considerable debate as to which is the 
better scale to use. 
A validated semi-objective pain questionnaire may also be used e. g. the Western Ontario and 
McMaster Universities Scale (WOMAQ (Bellamy et al. 1985), the Health assessment 
questionnaire (HAQ) (Fries et al. 1980), and the Arthritis impact scale (AIMS) (Meenan et al. 
1980). 
2. Physical function 
The function subscale of the WOMAC has been validated (Bellamy et al. 1985) and is 
recommended for use in OA of the hip and knee in man. 
3. Physician global assessment 
Global assessments are the simplest composite index. Where there is no gold standard for 
the measurement of disease activity these remain the "next best thing" and are frequently used 
in the assessment of criterion validity (Symmons 1994). Physician global assessments are 
more objective than patients assessment of their own pain, but they can still be influenced by 
personal impressions and emotions. Signal measurements, based on well defined individual 
measurements, are less subjective than global and are preferred by Bellamy (Bellamy et al. 
1990). There is much debate as to the best method when assessing arthritis in man - it seems 
to depend on the individual assessor i. e. whether a "lumper" or a "splitter" (Kirwan 1994). 
4. Patient global assessment 
This should be measured on a VAS or Likert scale although the optimal method has not been 
established. 
Recording scales 
1. Visual analome scales. 
These are probably the most popular scales used in pain assessment. Visual analogue scales 
(VAS) consist of 10cm line, which can be horizontal or vertical and is limited by endpoints 
described as severe pain or no pain. VAS scales are assumed to be more sensitive than Likert 
scales because of the infinite number of points on the scale. However there are inherent 
sources of error which can limit the accuracy of the results. Some studies have shown a 
clustering of results at the so called "golden section! ' of the scale i. e. 68% of the way from 
each end of the VAS (Dixon et al. 198 1; Hinchcliffe et al. 1985). It has also been reported 
that the precision of results along the scale can vary, results being more precise near the ends 
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of the VAS and less so near the golden section (Dixon and Bird 198 1). This is of particular 
importance when the scale is used to assess longitudinal changes in pain. 
When using VAS to record serial pain measurements it is debatable whether patients should 
be allowed access to their previous scores. It has been suggested that patients may either 
make an overestimation (Huskisson 1976) or minimise (Vandenburg et al. 1984) their pain 
when previous recordings are unavailable. However these studies indicate that access to 
previous results may cause bias, and therefore since blinding removes bias it seems more 
appropriate that previous results should not be viewed (Bird et al. 1987). 
2. Likert scales 
These five point descriptive scales were first reported by Likert in 1932 (Likert 1932) and 
then in rheurnatology by Keele in 1948 (Keele 1948) and are still the preferred method of 
some researchers today. Likert scales used in human trials of RA were found to be capable of 
consistently detecting statistical differences between active drug response and placebo 
(Bellamy et al. 1984). However other sources (Bird and Dixon 1987) report that descriptive 
pain scales lack sensitivity and a patient's pain may improve but fail to change from one 
category to another. These scales are also prone to a floor or ceiling effect (Bindman 1990) 
and it has been reported that the maximum category possible may not correlate accurately with 
that indicated by a VAS scale (Welsh et al. 1993). 
3. Other scales 
These include numerical rating scales which are similar to the Likert but use numerical values 
instead of descriptive terms, and the pain faces scale which shows a range of faces in varying 
degrees of pain and was designed primarily for use in children. The McGill questionnaire 
uses a more complex pain index to investigate the sensory, affective and evaluative qualities 
as well as the degree of pain (Melzack 1975). 
Assessment of outcome measures 
The characteristics of a good outcome measure include: - 
1. Validi1y. 
The validity of a measure is the ability to measure what is intended . There are different 
categories of validity, i. e. 
a) Content validity - the completeness of an index to cover all the important areas that should 
be measured. 
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Face validity - one form of content validity, an assessment of whether the index is 
meaningful and relevant. 
b) Criteria validity - the correlation with another validated measure or gold standard. 
c) Construct validity - the plausible relation to other measures used. 
2. Reliabilijy 
The reliability of a measure is the ability to consistently produce the same results. 
To measure reliability, intra- and inter- observer variation should be calculated. This is best 
done by test and retest at one to two week intervals (Deyo et al. 199 1). The variability of 
qualitative measurements should be calculated using the Kappa statistic (Fleiss 198 1) while 
for quantitative measurements the Intraclass correlation coefficient (ICC) (Deyo et al. 199 1) is 
more suitable to measure the concordance i. e. the strength of the correlation and also whether 
the slope and intercept vary from replicate measures. The ICC is mathematically equivalent to 
kappa (nominal data) and weighted kappa (ordinal data). 
3. Responsiveness 
The responsiveness of an index is the sensitivity to change. Any measure chosen should be 
able to change and should have a small standard deviation (Symmons 1994). The 
responsiveness of a measure can be assessed by using it to measure change following an 
intervention with a known outcome. 
Trials in animals 
Obviously in any trials performed in veterinary medicine no outcome measure can be purely 
subjective because response must be measured by owner or physician. Outcome assessed by 
physician is generally accepted to be more object ive than owner assessments which are often 
affected by emotional or economic involvement. In equine trials the most commonly used 
outcome measure is an index of physician assessed pain, indicated by lameness (Asheirn 
1984; Aviad et al. 1988; Gaustad et al. 1995; Verschooten et al. 1997; White et al. 1994) and 
although this is a well established and relevant method, there are no reports of validation of 
this method in the literature. Another outcome measure commonly used is that of return to 
athletic performance (Asheirn 1984; Phillips 1989; Verschooten and Desmet 1997; White et 
al. 1994) . Efforts have been made to quantify lameness in the horse both by kinematic 
methods (Buchner et al. 1993; Pourcelot et al. 1997) and by the use of force plates (Auer et 
al. 1980; Aviad 1988; Gingerich et al. 1979) . In one study (Back et al. 1993) lameness 
scoring by one clinician compared favourably with results from kinematic apparatus. 
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Although questionnaires, or metrology, are a widely used and validated method of acquiring 
information and measuring change in human trials, no reports of the use of questionnaires in 
the assessment of such trials in horses have been found in the literature. 
VAS scales have been used recently in the assessment of postoperative pain in animals 
(Lascelles et al. 1994) and there are reports of Likert scales being used in the assessment of 
chronic pain caused by foot rot in sheep (Ley et al. 1994). A comparison of a VAS and a 
numerical rating scale in the assessment of lameness in sheep was made in 1993 (Welsh et al. 
1993) which concluded that both scales compared favourably with respect to repeatability, 
reproducibility and use by 2 observers, but the VAS scale was inherently more sensitive. 
Patient assessed pain obviously becomes owner assessed pain in veterinary trials and thus the 
accuracy of these results will depend on the observational skills of the owner. Recently in a 
study investigating use of questionnaires in the assessment of canine lameness following 
surgery (Innes 1997) a questionnaire was designed and found to be reliable and responsive, 
although the relationship between owner and veterinary surgeon assessments was poor. 
Aims 
1. To assess the reliability of lameness scores as a system of clinical assessment, intra- and 
inter-observer. 
2. To assess the use of owner questionnaires as valid measurement tools. 
3. To assess the relationship between owner and physician impression of lameness. 
4. To measure the functional outcome in the calcium pentosan polysulphate trial. 
Materials 
Mepivacaine Hydrochloride - "Intraepicaine", Arnolds Veterinary Products, Shrewsbury 
Camcorder- Sanyo VMD-66P video camera recorder. 
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Methods 
1. Physician assessment 
Details of diagnostic and inclusion criteria and demographic variables are described in 
Chapter 4. In this chapter only the assessment of functional outcome will be reported. 
As described in Chapter 4 horses recruited to the clinical study were examined in the same 
way on four occasions at 3 monthly intervals over a9 month period. Each examination was 
carried out in the Department of Clinical Science, University of Bristol, by the same 
investigator (CF) on each occasion. Before any clinical examination began a full history of 
the disease process was acquired from the owner of each horse. A visual examination of the 
horse was then followed by palpation of the limbs, making particular note of the range of 
motion of the joints, the degree of synovial effusion and periarticular thickening of the joints, 
and the degree of pain on movement (Figure 5-1). The gait of each horse was observed and 
recorded with a camcorder first at the walk and then at the trot in a straight line on a level 
concrete surface, both moving away and then returning towards the investigator. Each horse 
was then trotted on the lunge in a circle, on both reins, first on a soft and then on a hard 
surface. 
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OA CASES - DATA SHEET. 








NO OF JTS 
Name: Study No : Hospital No: 
Owner: Scan No: X-ray No: 




Previous athletic performance: 
Diagnostic procedures and results: 
Treatments and response: 
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CLINICA AMINATION. 
Joints affected: Coffin Pastern Fetlock Carpus 
LF 
RF 





Scoring system: 0= No I= Mild 2= Moderate 3= Severe 
Range - Normal / Less Extension/Less Flexion 
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Nerve block performed - Result: 
Figure 5-1: Example of data record sheet used during trial 
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Lameness was assessed based on observation of head movement, and symmetry of stride and 
pelvic movement according to the system described by Wyn-Jones (Wyn-Jones 1988). A 
score from 0- 10 ranging from sound to non weight bearing lameness was given for each 
gait on each occasion. At the end of the trial a global score of the overall change in lameness 
scores was given. 




Soun all gai 2 
Table 5-1: Global scoring system for lameness improvement 
2. Owner assessment 
Questionnaires 
Two questionnaires were designed to provide a measure of change in degree of lameness as 
viewed by the owner. These were given to each owner on the first and last visit. The 
questions in each questionnaire were similar but the first was based on a 10 centimetre Visual 
analogue and the second on a four or five point Likert scale. Owners were instructed in their 
use before being given the questionnaires. When filling out the second questionnaire they 
were not reminded of their responses to the first questionnaire ( Figure 5-2a and b). One 
question was repeated in each questionnaire in order to provide a calculation of the reliability 
of the owner in accurately recalling information. 
Six months after finishing the trial, each owner was sent a third questionnaire. Questions in 
this form were designed to check reproducibility of the system as well as providing a measure 
of the progress of the horse since finishing the trial (Figure 5-3a and b). 
When assessing the results of the questionnaires, the extremes of the VAS scales were 
measured either from 0- 10cm, or from -5 to +5 cm, depending on the question. The 
descriptive terms used in the Likert scales were converted to numerical values, i. e. either 
from 0 to 3 for the four point scales, or from -2 to +2 for the five point scales. 
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Before the lameness Name: 
How much exercise was he given ? 
II 
None Constantly in use 
Since the lameness 
1. How much exercise do you give him now ? 
II 
Complete rest Exercise as usual 
2. If still at work, or at the lunge - does the stiffness wear off with exercise 
II 
Not at all Completely 
3. How well can he move around when free i. e. in the stable / field ? 
II 
Stands still all the time Moves normally 
4. How much time does he spend lying down ? 
II 
All the time Never seen lying down 
5. What degree of stiffness / lameness do you think he shows ? 
a) At the walk 
II 
Completely lame Completely sound 
b) At the trot 
II 
Completely lame Completely sound 
Figure 5-2a: Visual analogue scale questionnaire - outset of trial 
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Please tick the one response which best describes the situation. 
1. Before the problem, how much None Occasional Frequent Regular 
work was your horse given ? 
------- ------- ------- ------- 
2. Since the onset of lameness, 
how much work does he do 
now ? 
3. Does the stiffness/lameness, 
wear off with movement ? 
4. How well does he move in 
field/stable when free ? 
5. How often is he seen lying 
down? 
6. How lame do you think he 
is ? 
a) At walk 
b) At trot 
None Occasional Frequent Regular 
No Slightly Mostly Completely 
----- ------- ------- 
Extreme Much Some No 
Difficulty Difficulty Difficulty Difficulty 
All time Frequently Occasionally Never 
------- ------- ------- -- ---- 
Extremely Very Slightly Sound 
------- ------- 
Figure 5-2b: Likert scale questionnaire - outset of trial 
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Before the lameness Name: 
How much exercise was he given ? 
II 
None Constantly in use 
Since the end of trial 
1. How much exercise do you give him now ? 
II 
Complete rest Exercise as usual 
2. If still lame, what degree of stiffness / lameness do you think he shows ? 
a) At the walk 
Completely lame Completely sound 
b) At the trot 
II 
Completely lame Completely sound 
3. At the end of the trial (coWared to the beginning), do you think he was 
III 
Much worse Same Much better 
4. How do you think he is now (compared to the end of the trial 
III 
Much worse Same Much better 
5. How successful do you think the CaPPS treatment was ? 
II 
No use ExceHent 
Figure 5-3a: Visual analogue scale questionnaire issued 6 months following 
the end of the trial. 
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Please tick the one response which best describes the situation. 
1. Before the problem, how much None Occasional Frequent Regular 
work was your horse given ? 
------- ------- 
2. Since the end of the trial, 
how much work does he do 
now ? 
3. How lame do you 
think he is now? 
a) At walk 
b) At trot 
4. At the end of the trial 
(compared to the 
beizinnin do 
you think he was 
5. How do you think he 
is now (coinpared to 
the end of the trial) 
6. How successful do 
you think the CaPPS 
treatment was ? 
None Occasional Frequent Regular 
Extremely Very Slightly Sound 
Much Slightly Same Slightly Much 
worse worse better better 
Much Slightly Same Slightly Much 
worse worse better better 
Useless Poor Moderate Good Excellent 
------- ------- ------- ------- ------- 
Figure 5-3b: Likert scale questionnaire issued 6 months following end of the 
trial. 
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Name of horse : 
1. How long ago did you finish the trial ? 
2. Do you still own the horse ? 
3. If not, do you know how he is now 
4. If he is still lame, how lame, and on which leg ? 
Date : 
5. If he is sound, for what purpose are you now using him ? 
6. Have you used any further treatment for his OA since the trial ? 
7. If so which one ( CaPPS, Adequan, Hyonate for example) 
8. What was the effect of this treatment ? 
9. Please add any other information relating to the lameness that you feel may be 
relevant ...... 
Figure 5-4: Information request included with questionnaires issued six 
months following the end of the trial. 
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Validation of outcome measures 
The chosen gold standard for improvement in functional outcome was the global scoring 
derived from the video recording of lameness. Other parameters were compared against these 
scores in order to test their criterion validity. 
Interobserver variation of lameness sggdng. 
At the end of the trial the camcorder recordings of the gaits, of the horses were copied onto 
two videotapes. On one videotape (Vl) the recordings for each horse at each examination 
were kept together , in order, but the allocation of each horse to a particular treatment group 
was kept blinded. This videotape was then viewed, in single sittings, by three independent 
veterinary clinicians and a global score of improvement during the trial (Table 5-1) was given 
to each horse. 
Intra-observer variation of lameness scorinz 
To measure intraobserver variation, one clinician (CF) scored the same videotape (Vl) on 
two occasions, 14 days apart. 
Reliabilijy of lameness scoring at the time of examination 
The same investigator who scored all the horses for lameness at the time of examination (CF) 
viewed a second videotape (V2) on which the recordings of lameness were blinded to date 
order for each horse. The agreement between the results was calculated using the kappa 
statistic. 
Statistics 
Comparisons between outcomes were made using the paired students t test where results 
were normally distributed and the Wilcoxon signed rank test where results where skewed. 
The difference in global score of outcome between the high and low dose groups was 
compared using Fishers exact test. 
Intra and inter-observer variation of global lameness scores was measured using the Kappa 
statistic (K) (Fleiss 198 1) and was calculated using Microsoft Excel on a Macintosh computer. 
Weighted kappa values should be calculated for ordinal variables whereas if variables are 
nominal unweighted kappas should be used. If disagreements between ordinal variables are 
rarely more than one category, it is acceptable to use unweighted kappas. A kappa value of 
below 0.4 was considered unacceptable variability, whereas a value of over 0.75 was 
considered excellent . 
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Reliability of owners in using questionnaires was assessed by using the Intraclass correlation 
coefficient (Deyo et al. 1991) to measure the concordance between responses to repeated 
questions on questionnaires with quantitative values i. e. the VAS. Kappa values were 
calculated to assess the reliability of questions with ordinal values i. e. Likert scales. 
Correlation between the various parameters assessed by the questionnaires was calculated 
using the nonparametric Spearman correlation coefficient and confidence intervals were stated 
at 95% and significance at 5%. For these correlations the statistics software Instat was used. 
For power and sample size estimations see Chapter 4. 
Results 
1. Physician assessment 
Lameness scores as measure of functional outcome 
There was no significant difference between the high and low dose groups in lameness scores 
at the outset of the trW. Lameness scores were then analysed cross sectionally at the 4th 
examination, and there were still no significant differences in lameness scores (Students t- 
test) between groups (Table 5-2). 
Low dose group High dose group Both groups 
n=9 n=9 n=18 








Significance 0.04 0.06 0.006 
Table 5-2: Mean (Standard deviation) lameness scores at beginning and end 
of the trial for each treatment group and overall change. 
7/9 horses in the low dose group and 6/10 horses (Table 5-3) (Horse 6 not shown in Table 5- 
2 since it did not complete the trial but the global score to 3rd exam = 2) in the high dose 
group improved to some extent during 9 months of the trial. There was no significant 
difference (Fishers exact test) between the improvement in horses in either group as measured 































Figure 5-5b: Longitudinal changes in lameness in high dose group 
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oint 
Low dose I Ifigh Dose 
13 Finn TNff -1 17 Omar TMr 1 
3 Matt PIP 2 2 Denzil PIP 1 
10 Cassie PIP 1 12 Jolly PIP 0 
18 Breeze PIP 1 14 Beau PIP 1 
8 Folly DIP 2 9 Susie DIP 1 
16 Tosh DEP 1 19 Snoopy DIP -1 
20 Happy DEP 1 4 Sam DIP 0 
7 Smudge MC -1 15 NIax MCP 0 
Table 5-3: Physician global scores for horses matched by OA joint. 
Key : TUT = tarsometatarsal joint, PIP = proximal interphalangeal joint, DIP = distal 
interphalangeal joint, MC = midcarpal joint, MCP = metacarpophalangeal joint. 
Scoring system relating to the change in lameness during the trial was as follows 







Figure 5-6: Global scores of improvement for matched joints in low (A) and 
high (B) dose groups 
Key : TMT = Red 
PIP = Green 
DIP = Blue 
MCP and MC = Black 
Scoring system relating to the change in lameness during the trial was as follows 






Reliabfliiy of gold standard video scores : 
Intra-observer varjabilijy 
The weighted kappa value for intraobserver agreement of lameness scoring was 
ic = 0.78 95 % CI = 0.64 - 0.82 
which was considered excellent. 
Inter-observer variabilijy 
Observers Weighted 95% CI 
Kappa value 
CF v AB 0.74 0.50-0.97 
ABVBB 0.45 0.11-0.79 
CF V BB 0.61 0.31-0.89 
The overall weighted ic = 0.60,95% CI = 0.37 - 0.83 
This was also considered very good agreement. The system of global scoring was judged 
therefore to be a reliable method of measuring improvement in lameness. 
Criterion validity of global scoring of lameness 
This could not be measured directly since there was no validated gold standard with which to 
compare this method. However, since the global scoring of improvement was found to be 
reliable from scoring blinded video recordings, it was chosen as the "gold standard" within 
this study with which to compare other methods. 
The variation of the global score derived from the lameness scores given at the time of 
examination with the global score assigned from the video recordings of lameness for one 
observer (CF) was 
ic = 0.58 (unweighted) 95% CI = 0.51 - 0.65 
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There was a very significant positive correlation between change in lameness score given at 
the time of examination (change in lameness between examination 1 and 4) with the global 
score given from the video of lameness (Spearmans correlation coefficient r, ). 
r, = 0.79 95% CI = 0.51-0.92 p=0.0001 
The variation between lameness scores given at the time of examination with those from the 
time blinded video for one observer (CF) was 
x=0.52 (unweighted) 95% CI = 0.48 - 0.63 
The above figures imply good agreement between lameness scoring at the time of 
examination with subsequent scoring from blinded videos, which indicates that lameness can 
be consistently and reliably graded by one observer at 3 month intervals. 
Responsiveness 
This could not be measured directly without the opportunity to test the global lameness 
scoring by using an intervention of known outcome. However, in this case, from clinical 
experience it would be acceptable to assume that 9 months would be sufficient to detect a 
difference using lameness scoring as the outcome variable. 
2. Owner assessment 
Questionnaires 
Two horses did not complete the trial (6 and 11) and therefore only the first questionnaire at 0 
months was completed. One owner (9) failed to complete either questionnaire despite being 
sent reminders. One question (No 3) was disregarded from the questionnaire since 9 owners 
felt it was not applicable. 
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As measures of outcome 
No significant differences in outcome between the two treatment groups were found as 
measured by VAS or Likert scales for any signal or global measurement although both scales 





Figure 5-7: Owner global score of horse improvement during trial (Likert 
scale) 
TMT = Red 
PIP = Green 
DIP = Blue 
MCP and MC = Black 




Reliability of Questionnaire 
The Intraclass correlation coefficients (ICC) for question 1 on the questionnaire 1,2 and 3, 
and for question 6 on questionnaire 2 and 3 are given in Table 5-4. 
Question Questionnaire ICC Weighted Kappa 
(VAS) (Likert) 
1. Before the lameness, 1,2,3 Comparing 1-2 CoMparing 1-2 
how much work was he 0.82 0.44 
given? 
Comparing 2-3 CoMparing 2-3 
= 0.94 = 0.50 
2. At the end of the trial, 2,3 0.88 0.61 
do you think he was, 
worse, sarne or better? 
Table 5-4: Intraclass correlation coefficients and weighted kappa values for 
questions repeated on questionnaire 1,2, and 3. 
Owners were found to be reliable when answering questions at time intervals of 6 months. 
The weighted kappa for ordinal values should be mathematically equivalent to the ICC for 
quantitative values. Although there was good correlation between the two scales for the 
replies given to these questions ( r, ranging from 0.63 - 0.93) it was deduced from these 
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Criterion validijy of guestionnaire 
From Table 5-5 it can be seen that there was very poor correlation between the VAS recorded 
signal measurements and the physicians global outcome score. However the correlations 
between the Likert measurements and the physicians global score for outcome and change in 
lameness at the walk and trot and for change in how well the horse moved when free were 
significant. 
Correlation of individual changes (Signal) v owner's global scores 
There was no significant correlation between the owners opinion of change in lameness 
during the trial and the owners own global score of improvement during the trial when using 
the VAS scale, but when using the Likert scale the correlation was significant: 
r, = 0.73 95% CI = 0.36 - 0.89 p=0.001 (Likert) 
Correlations since end of trial 
There was a significant correlation between the owners global score of improvement since 
ending the trial and the owners perceived change in lameness since the end of the trial. 
r. = 0.62 95% CI = 0.17 - 0.86 p=0.01 (VAS) 
There was also a very strong correlation between the owners overall impression of the trial 
once the dosage had been unblinded (recorded on 3rd questionnaire 6 months after the trial) 
and their global score of improvement given at the end of the trial. 
r, = 0.7 95% CI = 0.34 - 0.9 p=0.00 1 (VAS) 
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Figure 5-8b: Comparison of Likert and VAS scores for owner assessed 
global score of change. 
Correlation between the two scoring methods was good (Figure 5-8a), i. e. for owner 
assessed global change: 
r. = 0.78,95% Cl = 0.33-0.93 
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Responsiveness of scoring methods 
The VAS scale appeared to be more sensitive cross-sectionally than the Likert which was 
prone to a "ceiling" effect (Figure 5-8a and b). However, an indication of the responsiveness 
of the two scoring methods was obtained by comparing the standardised response mean 
(SRM) on the scores for change in lameness at the trot during the duration of the trial. 
Likert scale VAS 
Mean change 1.29 2.74 
Standard deviation (SD) 1.36 3.64 
SRM (Mean/SD) 0.95 0.75 
Significance of change 0.004 0.007 
Paired Students t test 
Table 5-6: Comparison of SRM and significance of change for two methods 
of scoring 
From table 5-6 it can be seen that although both methods had a high degree of sensitivity to 
change the Likert scale was actually slightly more sensitive. 
The use of the global measurement in the questionnaire in this study were found to have 
criterion validity when compared to the chosen global standard i. e. physician global score of 
improvement. However, unlike the VAS, the use of the Likert scale proved to be valid for 
comparison of the signal measurements also, both with the owners global score and with the 
physician's global score. The Likert scale was also shown to be more responsive despite 
seeming less reliable than the VAS. 
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3. Owner v physician assessment 
The correlation between the owners global score, and the physicians global score of 
improvement as measured from the video recordings, was significant using both scales. 
VAS - r, = 0.5 1,95% CI = 0.02 -0.80, p=0.04 
Likert -r. = 0.59,95% CI = 0.15 - 0.84 p=0.01 
However the correlations (Likert scale) between the owners global score and the physicians 
score deduced from the lameness scores at the time of examination were slightly stronger 
Likert - r, = 0.65 95% CI = 0.23 - 0.86 p=0.005 
This implies that the owner may have had an effect on the physician's impression of 
improvement. 
The correlation between the owner's overall impression of the trial and the physicians global 
score of improvement was only just significant for the Likert recorded measurements 
however. 
r, = 0.5 95% CI = 0.01-0.79 p=0.04 
4. Questionnaire derined outcome 
The results from the questionnaires did not demonstrate any difference in outcome between 
the treatment groups but they did provide information relating to the future of horses 
following the trial. 
At the end of the trial, out of the 13 owners who answered the question on overall 
improvement, 11/13 thought their horses were better compared to the beginning of the trial 
(516 B group and 6n A group) (Table 5-7). 
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Horse Group Owners global 




6ms after trial 








VAS Likert VAS Likert VAS Likert VAS Likert, 
I A 52 -4.4 -2 4.1 2 no 
2 B 1.5 1 1.4 0 0 0 yes 
3 A 4.6 2 4.2 2 3.7 2 yes 
4 B 0.1 0 1.9 1 0 0 (yes)# 
5 B 4.4 2 4.9 2 4.9 2 5 2 yes 
7 A -4.6 -2 -2.5 -1 3.7 2 -5 -2 no 
8 A 4.7 2 52 5 2 5 2 yes 
10 A 5 2 52 0 0 4.8 1 yes 
12 B 2.3 2 3.1 1 1.8 1 0 0 yes 
13 A 5 2 52 5 2 5 2 yes 
14 B 2.5 2 -0.7 -1 -1 -1 -5 -2 no 
15 B 0 0 0 -1 0 0 -5 -1 no 
16 A 5 2 
17 B 5 2 2.4 1 5 2 4.6 1 yes 
18 A 4.85 2 4.8 2 0 1 4.8 2 (yes)0, 
19 B 1.5 1 0.9 1 0 0 0 0 no 
20 A 3.8 2 42 0 0 15 2j yes I 
Table 5-7: Owner impression of improvement in horse physical function as 
determined by owner completion of VAS and Likert scales 
KEY: *= No reply given on questionnaire 
#= This horse remained sound as long as maintained in light exercise 
a= This horse had received one more course of low dose treatment 
VAS scale: -5 to +5 = Much worse/Useless to Much better/Excellent 
Likert scale: Much worsefUseless = -2, Slightly worse/Poor = -1, Same/Moderate =0 
Slightly better/Good = 1, Much better/Excellent =2 
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Six months after end of trial 11/16 horses were sound (as assessed by owners). 6/8 of these 
were from the low dose (A) and 5/8 from the high dose group. 9/16 owners thought CaPPS 
very useful, 7/8 of these being in group A and 2/8 in group B. One owner from group A (7) 
and 2 owners from group B thought CaPPS was no use (14,15) and 4 (12,4,19 and 2) from 
group B thought it may have helped. Three owners in B group assessed their horses as being 
sound but remained sceptical about the value of the treatment (2,4, and 12) while one owner 
in A group thought the CaPPS treatment good despite her horse still being lame (1). 
Discussion 
This study has shown that the clinical assessment of lameness is a reliable method both intra- 
and inter-observer when used as a global score of longitudinal change. The agreement 
between the lameness scores given at the time of examination with those given from the video 
recording where lameness recordings were blinded to time was also good indicating that at 
least intra-observer assessment of individual cross sectional lameness scores is reliable. The 
good correlation between the global scores deduced from the lameness scores given at the 
time of the examinations and those from the videotape indicates that it is possible for one 
observer to score lameness changes reliably in horses presented at 3 month intervals. Since 
clinician scoring of lameness is the most common method of assessing limb pain and 
disability in the horse, this is an extremely important finding which is previously unreported 
in equine medicine. 
It was decided to use questionnaires in the trial as a method of providing information relating 
to the owners own assessment of their animal's progress, and to investigate the validity of the 
use of owner questionnaires as measures of outcome in equine clinical trials. Owners were 
found to be reliable in completing the questionnaires, even with intervals of 6 months instead 
of the recommended 14 days for retesting procedures, and both the VAS and Likert scales 
were found to be sensitive to change during the trial period. When assessing criterion 
validity, the Likert scale was found to be superior for signal and global measurements . The 
owners signal measurements also showed better correlation with the owners overall global 
score of improvement when the Likert scale was used. The correlation between owner's 
score of lameness at the end of the trial did correlate with the global score indicating that it 
was the resulting degree of lameness rather than the change in lameness that influenced their 
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global score. There was also a good correlation between the physician and owners perception 
of lameness change. Correlation between owner and physician global assessment of 
improvement was good indicating that owner questionnaires can be a reliable method of 
assessing outcome. 
In this clinical trial no significant difference in outcome was found between the high and low 
dose treatment groups using either physician assessment of lameness or owner questionnaires 
and therefore this trial did not demonstrate that CaPPS is successful as a SYSADOA. 
Obviously the reason for this lack of difference could be because this was the true result, i. e. 
accepting the null hypothesis, or alternatively it could indicate a Type II error, i. e. failure to 
reject the null hypothesis when it is untrue. It has already been discussed (Chapter 4) that the 
power and sample size of this trial was too small for it to be accepted as anything but a pilot 
study, and this could have been the reason for the lack of difference detected. 
As already stated it was not possible to use a placebo treated group as a control rather than 
carrying out a dose related study, and in this case any potential effect of a low dose of 
CaPPS must be further investigated. It is interesting to note that one owner (18) gave her 
horse another course of CaPPS following the trial at a low dose and judged the effect to be 
successful. 
Another cause of possible Type H error could have been the choice and validity of the 
outcome measure. The use of lameness scoring as a measure of the degree of pain and 
impairment of physical function are traditionally used in equine medicine and is a clinically 
relevant measurement thus indicating face validity to the system. As previously stated, when 
used as a global score of longitudinal change, lameness scoring was found to be reliable. In 
this study time did not allow for the inter-observer agreement of cross-sectional lameness 
scores to be calculated from the time blinded videotape. To do this would be a useful 
indication of the reliability of cross sectional comparison of severity of lameness which 
would be applicable to multi-centre and therefore possibly also multi-rater clinical trials. 
However although cross sectional lameness scores may vary between raters it would still be 
possible for the overall global score of improvement during the trial to be in agreement which 
was judged to be the more important measurement in this case. 
The reason for the poor correlation between some of the signal scores on the questionnaires 
could have been because of the choice or the form of those questions. The design of the 
question was derived from one used in human studies where questions are related to the 
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ability to perform physical tasks. In horses the main indication of pain or physical disability is 
lameness which was well observed by the owners . The lack of correlation of the other 
questions i. e. "how much time is spent lying down7 and "how well does he move when 
free", to the gold standard, may have been because these questions were not clinically 
relevant, but also could have been because they were less well observed by the owners. 
Despite the fact that there was good correlation between owner and physician global 
assessment of improvement, correlation between the owner impression of the trial overall, 
however, and the physician assessment of lameness improvement only just reached 
significance. Correlation does not necessarily equal agreement however and in two cases in 
particular (13 and 14) the physician and owner assessments were in direct opposition. The 
owner's overall impression of improvement and the success of the trial takes into account the 
performance of the horse over a longer time period while the physician's assessment is 
dependent on one examination every 3 months, so it could be argued that the owner's 
assessment is therefore more relevant. It would have been interesting to ask the owners to 
view the videotape recordings of lameness and then to re-evaluate their opinion. It was 
noticeable that the owner's opinion of the trial success was influenced greatly by their future 
intention for their horse, some owners expecting their horses to become sound before rating 
the trial a success, while others being satisfied with any degree of improvement. For this 
reason it seemed that the physician's more detached assessment of change was likely to be 
more accurate to use as a gold standard. 
It was possible to evaluate the reliability of owners in answering questions over time, by 
comparing the responses to two questions which were repeated on the questionnaires. It 
would have been preferable however to have requested that a sample of the owners complete 
every question on two identical questionnaires at an interval of 14 days, thus enabling the 
reliability of the questionnaire itself to be assessed. 
In this trial the Likert scale showed better criterion validity than the VAS, although both 
scales were found to be reliable and sensitive to change. When assessing reliability of the 
scales the ICC was used to measure the agreement in answers on the VAS scale while the 
weighted kappa was used to assess variability in Likert responses. Although the ICC and 
weighted kappa are supposed to be mathematically equivalent, the kappa statistic is influenced 
by very uneven marginal distributions. For example in question 1, most of the Likert scores 
were 3 with very few scores of 0 or 1. A disagreement in the scores at the low end of the 
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scale would tend to have a big negative effect on the kappa value which may have been the 
reason for the discrepancy between the ICC and kappa results. 
Despite there being no difference in outcome between the two treatment groups 13/17 owners 
scored their horses as having improved during the trial, and 11/16 owners thought the CaPPS 
treatment was useful even though 6 of these owners had horses in the low treatment group. 
The physician global assessment judged 12/18 horses to have improved clinically during the 
trial. Many of these owners had tried alternative treatments e. g. intra-articular hyaluronan and 
polysulphated glycosaminoglycans before the trial without success and only one of these 
owners felt it necessary to repeat the CaPPS treatment during the 6 months following the 
trial, and this was done at the low dose. The potential effect of the low dose of CaPPS, 
possibly as a periarticular anticoagulant, should be investigated further, although there are no 
reports of efficacy at this dose in the literature. It is possible that the controlled exercise 
regime instigated during the trial was sufficient to produce a clinical improvement in these 
horses during the 9 months of the trial and it must be remembered that the traditional 
treatment of restricting exercise in lame horses may have produced a clinical improvement in 
this percentage of cases without any other intervention. 
Summary 
1. Scoring of lameness was found to be a valid and reliable measurement of outcome. 
2. The owner questionnaire using the Likert scale was also found to be a valid measurement 
tool. Owners were found to be reliable in providing information over time - 
3. There was good correlation between physician and owner global assessment of lameness 
improvement. 
4. There was no significant difference in outcome between the high and low dose treatment 
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Chavter Six 
ImaginR methods for assessing disease outcome 
Introduction 
In this chapter two methods of measuring outcome by imaging the osteoarthritic joint, 
which were used in the calcium pentosan polysulphate clinical trial (Chapter 4) will be 
discussed. Radiography, measuring structural changes in the joint, has long been 
accepted as the gold standard for diagnosis of ostcoarthritis (OA), while scintigraphy, a 
relatively new technique, provides a measurement of joint physiology and remains to be 
validated as a reliable outcome measure in clinical trials in OA. 
1. Radiography 
The Kellgren and Lawrence radiographic grading scheme (K&L) for OA (Table 6-1) 
(Kellgren et al. 1957) was developed in 1957 and was accepted by the World Health 
Organisation in 1961 as the gold standard for both cross-sectional (Cooper et al. 1992; 
Spector et al. 1993) and longitudinal studies (Spector et al. 1992) in OA. Despite the fact 
that radiography has the limitation that it can only be used in diagnosis at a relatively late 
stage of disease, it has long been considered the primary method of diagnosis in OA. Its 
accuracy in measuring progression in OA however has only been investigated more 
recently (Ravaud et al. 1996). 
The radiographic signs of OA in the horse and in man include narrowing of the joint 
space, ost6ophytosis, enthesiopathy, subchondral bone changes, synovial effusion, and 
thickening of the joint capsule (Cobby et al. 199 1; Widmer et al. 1994). However, not all 
of these signs are necessarily present in OA, and there is no particular order in which they 
may occur. 
RadiogLaphic features of OA in the horse 
Joint space narrowing: The joint space is essentially a measure of cartilage thickness and 
can therefore potentially be used to assess cartilage loss. The size of the joint space varies 
in the normal horse depending on the joint imaged (Widmer and Blevins 1994). Proximal, 
distal and tarsometatarsal joint spaces are usually very thin, while the distal 
interphalangeal joint space is wide, and the metacarpophalangeal joint is narrower than the 
interphalangeal joint spaces. In young horses the joint spaces tend to be wider, and 
marked changes can occur with weight bearing. The exact orientation of the x-ray beam 
can also produce artificial narrowing of the joint space. 
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Osteophytosis : Osteophytes are bone deposits within the joint margins caused by 
secondary osteoarthritic change. Although osteophytes are a reliable radiographic sign of 
OA, OA may present without osteophytes and they are not indicative of severity or stage 
of cartilage loss. 
Subchondral bone changes : Subehondral bone sclerosis is commonly observed in OA 
joints but the pathophysiology remains unclear. Identification can be problematic, 
requiring excellent quality radiographs and sound knowledge of normal variations. 
Changes may occur at different stages of OA, depending on the joint involved, being 
common in the proximal phalanx in early metacarpophalangeal OA, and in the third and 
central tarsal bones in the late stages of OA. Unlike man, subchondral bone cysts are rare 
in OA in horses. Subchondral bone erosions that do occur are most common in the 
carpal and tarsal joints. 
The features described are used both in the initial diagnosis of OA and also in the 
quantitative analysis of change in OA. In the horse there is no well defined system 
described in the literature although various schemes have been used in different studies. 
In human studies the K&L scheme is still the mostly widely used in OA assessment, but 
there are doubts about its suitability and reliability. 
Grade Features 
0 Nonnal No features 
I Doubtful Minute osteophytes of doubtful significance 
2 Minimal Definite osteophytes but unimpaired joint space 
3 Moderate Moderate diminution of joint space 
4 Severe Joint space greatly impaired with sclerosis of subchondral bone 
Table 6-1: Kellgren and Lawrence grading scheme 
This is a global scoring scheme which depends heavily upon the osteophyte in 
classification of the disease, and assumes a linear progression of disease. It also takes no 
account of differences in OA occurring in different joints. However, OA is a 
heterogeneous group of diseases displaying various signs and progressing at various 
rates. No correlation has been found between one diagnostic radiographic sign and 
another, and no one feature has particularly discriminatory value (Cobby et al. 1991) 
which infers doubt about the suitability of global scoring schemes. This method of 
grading of OA from radiographs also implies a spectrum of disease progressing in a 
continuous manner, with the relationship between systems remaining constant. However, 
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it has been shown that OA is initially a rapidly destructive disease with subsequent slow 
deterioration, not all joints being active or in phase (Hutton 1989). More recently newer 
scoring schemes for human radiographic studies have been devised which rely more on 
individual feature scores and allow for differences between joints. Kallman et al (KaUman 
et al. 1989) produced an atlas and scoring system to grade OA of the hand, and compared 
radiographic grading of individual features, i. e. osteophytes, joint space narrowing, 
subchondral cysts, subchondral bone sclerosis, lateral deformity and cortical collapse, 
with the Kellgren and Lawrence (K&L) scheme. Cross-sectional and longitudinal 
reliability of the grading system was assessed and found to be good, with all features 
performing well for intra-observer reliability but osteophytes, joint space narrowing and 
the K&L scheme showing better inter-observer agreement than cysts, deformity and 
collapse. The individual feature grading scheme compared well with the K&L global 
scheme. In conclusion this study confirmed that the osteophyte was the best method of 
defining hand OA. Altman et al evaluated methods of grading OA progression of the 
hand hip and knee (Altman et al. 1987) and assessed the contribution of individual joints 
or joint compartments towards the evidence of radiographic progression as well as the 
reliability and sensitivity of their method in detecting change. From the results they were 
able to advise on the most sensitive positioning for radiography of each joint. Their 
results also indicated that the most useful radiographic variables differed according to joint 
site and supported the view that there should be different approaches to the evaluation of 
OA progression at specific joint regions. They recommended that in hip OA joint space 
narrowing and sclerosis were the most sensitive features to change while in the knee 
osteophytes were more valuable than joint space narrowing in diagnosing OA. Joint space 
narrowing however was preferable in detecting OA progression. Recently Altman has 
produced an atlas of OA change in the hand, hip and knee (Altman et al. 1995). Cooper et 
al (Cooper et al. 1992) reported on the intra- and inter-observer reproducibility of 
commonly used radiographic features in assessment of OA of the knee and found that 
joint space narrowing, osteophytes and bony contour in the tibiofemoral compartment 
were more reproducible than subchondral sclerosis and cysts. 
From these studies it is clear that no single global grading is suitable for the assessment of 
OA in all joints, and different measures should be given different weights in different 
circumstances. 
Rei2roducibiliiy studies 
It can be seen from the above review that in any scheme it is important to establish the 
intra- and inter-observer reproducibility of each feature to be scored. The reproducibility 
of each feature can be significantly affected by the positioning of the joint during 
radiography, and the extent of weight bearing. It is vital to aim to reduce the variability 
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caused by such factors. Development of a system for radiographic grading of OA requires 
knowledge of the reproducibility of individual component features (Cooper et al. 1992). 
Cross-sectional grading of radiographs has been widely studied but longitudinal grading 
less so (Ravaud et al. 1996). Grading of a feature must be reproducible intra- and inter- 
rater and have good sensitivity to change. It has been shown that training sessions are 
extremely useful in increasing reproducibility (Altman et al. 1987). 
No studies of reproducibility in equine OA radiographic grading have been found in the 
literature. In a canine study investigating stifle OA, global assessments together with 
osteophytosis and intra-articular mineralisation were found to be more reproducible than 
subchondral bone sclerosis (Innes 1997). 
Current recommendations 
In a recent recommendation for assessing progression of OA in the knee and hip joints it 
was agreed that at present radiography should remain the major outcome measure (Dieppe 
1995), while including certain provisions to standardise, the technique. Advice on patient 
positioning for radiography is given and the following recordings suggested: 
Hip Joint space narrowing (JSN) - this should be measured as well as scored on a 
scale from 0-3 
: Osteophytes should be graded from 0-3 
: Subehondral bone changes scored +/- 
: Global score should also be included 
Knee : As for hip but medial, lateral and patellofemoral joint spaces should be scored 
separately. 
Reproducibility: There should be from I-3 scorers, the radiographs should be blinded, 
and read centrally. Training and the use of atlases is recommended. 
2. Scintigraphy 
Scintigraphy is a relatively new imaging method which provides information regarding 
the physiology, rather than the anatomy of the joint. It is said to be capable of predicting 
the initiation of structural abnormalities resulting from ongoing pathological activity 
(Attenburrow et al. 1989). Bone scintigraphy depends upon the intravenous circulation of 
a pharmaceutical agent which has been bound to a gamma emitting radioactive isotope. In 
equine scintigraphy the most commonly used agent is methylene diphosphonate which is 
labeled with Technetium? 9'. Methylene diphosphonate is a salt which has a high affinity 
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for hydroxyapatite crystals in bone and therefore it preferentially binds to those areas of 
bone undergoing active metabolic change. The radioactivity level or "counts" emitted from 
an area of bone are detected by use of a gamma, camera and so the concentration and 
distribution of the isotope can be assessed. It has been recognised for many years that 
bone tracers localise to OA joints (Bauer et al. 196 1). Studies in man (Hoffer et al. 1976; 
Hutton et al. 1986) and animals (Christensen 1985; Metcalf 1985; Ueltschi 1977) have 
shown scintigraphy to be a very sensitive technique in joint disease, although not as 
specific as radiography. It is possible to detect only 10-13 g radiopharmaceutical, but bony 
lesions can only be detected by radiography when destiuction/formation of bone occurs in 
grams (Devous et al. 1984). Radioisotope uptake depends on osteoblastic activity, and 
also blood flow and vascular permeability. The "hot" areas of increased isotope uptake 
seen on a bone scan are a consequence of the metabolic response to osteoblastic activation 
and can therefore be seen within hours of a bone response (O'Callaghan 1991). 
Scintigraphy has been used in horses for the investigation of occult lameness increasingly 
during the last 20 years (Ueltschi et al. 1977; Weaver 1995). The advantage of this 
imaging method is that subchondral bone changes may be diagnosed before radiological 
signs of OA can be detected. In man it has been found that scintigraphy can be predictive 
of OA progression (Dieppe et al. 1993) in the knee and in the hand (McCarthy 1994). 
In equine practice scintigraphy has become a popular diagnostic aid in cases of lameness 
that can not be localised by other methods. It is the method of choice for imaging the 
spine and pelvis i. e. regions that are difficult to examine radiographically, and protocols 
for the assessment of navicular disease by scintigraphy are being developed. At present 
scintigraphy is not commonly used as a primary method to diagnose OA. 
Radioisotope uptake has been found to have a good correlation with radiographic data in 
the dog (Innes et al. 1996) but can also provide additional information. The pattern of 
isotope uptake in OA has been found to be important (McCrae et al. 1992). In man it has 
been reported (McCrae et al. 1992) that a tramline pattern may indicate osteophytes at the 
joint margins, a linear pattern of uptake was indicative of sclerosis in later stage OA, 
while the more generalized pattern of uptake related to early OA. In the dog the marginal 
pattern of uptake in stifle OA was associated with instability of the joint, osteophytes, and 
intra-articular mineralisation (Innes et al. 1996). 
It is important to appreciate that the relative uptake of isotope by bone may be affected by 
various factors other than that of increased metabolic activity. An alteration in blood 
supply may affect the distribution, as can variations in the age or work of the animal 
(Devous and Twardock 1984). 
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No reports have been found in the equine literature concerning the grading of scans. In a 
canine study (Innes et al. 1996) however, scans of cases with stifle OA were assessed 
using a three grade score of isotope uptake and a two grade score of pattern, and the 
reproducibility of this technique was found to be good. 
3. Scintimetry 
Scintimetry is the name given to the serniquantitative analysis of changes detected on 
scans. This allows comparison of scans and correlation of scintigraphy results with other 
measures. The quantification of bone scans remains problematic with positioning, dose of 
radioisotope, and the counts measured having the potential to cause considerable 
variability between scans. For this reason scintimetry has not been commonly used as a 
marker of change in OA trials. The most commonly used method is to measure the ratio of 
counts at the OA joint relative to a local reference bone site (Metcalf 1985; Olsen et al. 
1988). There are many references to the use of scintigraphy in the investigation of equine 
lameness but few which have used scintimetry in their analysis of longitudinal data. In 
1993 Todhunter (Todhunter et al. 1993) used scintimetry measurements over a period of 
17 weeks to evaluate the effects of exercise and intra-articular medication on joints with 
experimentally induced carpal cartilage defects. 
Relationship between imaging and clinical outcome 
Despite radiography being accepted as the gold standard measure of outcome in OA in 
man, it is rare to find reports of significant correlation between radiological and clinical 
signs in the literature. In the Bristol "OA500" study, a3 year study involving 415 patients 
with knee OA, there was no correlation between radiographic and clinical changes. It was 
concluded that clinical and radiographic changes may not be in phase with each other in 
the progression of OA and that radiographic change may not be a good surrogate for 
clinical outcome in established OA (Dieppe et al. 1997). In a canine stifle OA study, 
scintigraphy was found to be associated with clinical findings, but neither scintigraphy 
nor radiography were predictive of change in disability score (Innes 1997). In a study of 
synovitis in the human proximal interphalangeal joint, changes in scintimetry indices were 
found to correlate with clinical changes (Olsen et al. 1988). 
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Aims 
1. Comparison of diagnosis of equine OA by radiography and scintigraphy. 
2. Evaluation of the reliability of the radiographic scoring scheme. 
3. Evaluation of the reliability of the scintigraphy scoring scheme. 
4. Assessment of the use of scintimetric quantitative analysis of scans. 
5. Relationship of scintigraphy patterns with radiographic changes. 
6. Correlation of radiography and scintigraphy with clinical changes. 
7. Use of radiography and scintigraphy as measures of outcome in the CaPPS trial. 
Methods 
Radiography : 
On each examination each horse underwent radiography of both the clinically active 
osteoarthritic and the contralateral joint. Horses were radiographed in the standing 
position under light sedation. On the first examination this was done using four standard 
views of the joint i. e. dorsopalmar, lateromedial, dorsolatero-palrnarornedial oblique and 
palmerolateral-dorsomedial oblique. On the three subsequent examinations the views that 
had been found most useful in highlighting the pathology were repeated each time. On the 
first examination, in order to make a diagnosis of osteoarthritis, the radiographs were 
examined for signs of narrowing of the joint space, osteophytosis, subchondral bone 
changes, and soft tissue swelling indicative of synovial effusion or joint capsule 
thickening. 
Quantification : 
The following scoring system was devised (Table 6-2): 
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Feature Score 
Joint space narrowing 01 
Osteophytosis 0123 
Subchondral bone sclerosis 01 
Subchondral bone erosions 0 
Global score 023 
Table 6-2: Radiographic scoring system 
The radiographs were blinded to case identification and to date order. Three experienced 
veterinary radiologists were then asked to examine and score each affected OA joint, and 
its contralateral, at each of the four time points of the trial. Inter-observer variation was 
then calculated from these scores using the kappa statistic. One radiologist was asked to 
score ten sets of radiographs again after an interval of 14 days. The resulting second set 
of scores allowed intra-observer variation to be calculated. 
Scintigraphyr, - 1 
Materials: 
Metomidine - "Domosedan" Pfizer Ltd., Sandwich, Kent. 
Gamma camera - "Maxicamera" IGE Medical systems., Slough, Berkshire. 
Tc99mMDP - Radiopharmacy, Bristol General Hospital. 
MAPS 2000 computer 
MAPS 5000 image processing software - Link Medical Ltd., Marlow, Buckinghamshire. 
Nuclear Diagnostics computer 
Methods: 
Bone phase scans were acquired of the clinically osteoarthritic and the contralateral joint 
from each horse on the first and third i. e. 0 and 6 month visit. On the first visit the whole 
of the lame leg was scanned to check for any other abnormalities. Each horse was injected 
intravenously with lOMbq/kg Technetiurn '9' methylene diphosphonate (TC9"MDP). 
After three hours, horses were sedated with detomidine hydrochloride (Domosedan Pfizer 
Ltd) 10 gg/kg and led from the isolation stable to the gamma camera room where they 
were positioned to stand in stocks. Using a low resolution collimator and acquiring 
between 50000 counts for metacarpophalangeal (MCP), proximal interphalangeal (PIP), 
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and distal interphalangeal (DEP) joints, and 75000 for midcarpal (MC) and tarsometatarsal 
(TMT) joints, lateral images were acquired from each joint. In cases of DIP joint OA, Z-ý 
solar views were also acquired by placing the affected foot on top of the gamma camera. z: 1 
Images were stored both on the computer and on xray film. The counts measured and the 
time taken to collect the image were recorded on each occasion, taking care to standardise 
the number of counts collected for each horse on subsequent occasions. 
Scoriu, scheme: 
A scoring scheme (Table 6-3) was devised to quantify the degree and pattern of uptake of 
isotope for each joint on each occasion. Four veterinary surgeons experienced in 
scintigraphy were asked to score all 19 sets of scans both of the OA and contralateral 
joint. The scores were then analysed for inter-observer variation by the kappa statistic. 
One observer (CF) scored all the scans on two occasions at an interval of 14 days in order 
to allow intra-observer variation to be measured. 
Table 6-3: Scintigraphic scoring scheme 
Scintimetry 
The second method of quantification of the scans was by measuring the counts in a given 
region of interest drawn onto the computer generated images (Figure 6-1). On each 
image, a line was drawn on the computer image to encompass the "hot" area of greatest 
isotope uptake around the joint. This region was labeled "A". Another region, "B" was 
drawn to enclose as much as possible of the diaphyseal bone proximal to the joint. The 
number of counts per area A and B were then calculated by the computer. Comparison of 
these two values i. e. A/B indicated an activity index (AI) for the joint i. e. the degree of 
increased uptake of isotope around the joint as compared to that in the neighbouring ZD Z: > 
reference bone (Figure 6-1). The activity index for both the clinically affected OA joint 
and the contralateral joint were calculated on each occasion. To measure the 
reproducibility of this method, 10 images were re-measured after an interval of 14 days ZD 
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Figure 6-1: Schematic diagram to demonstrate calculation of activity index 
in a case of osteoarthritis of the intertarsal joints (bone spavin) 
Statistics 
To investigate reproducibility the agreement between measurements was calculated using 
the kappa statistic (K) (Fleiss 198 1). AK value of below 0.4 was considered unacceptable 
and aK value of above 0.75 considered excellent agreement. Reproducibility of 
scintimetric Al measurement was measured using the intraclass correlation coefficient 
(ICC) (Deyo et al. 199 1). For further discussion of these measurements see Chapter 5. 
For comparison of group outcome the Wilcoxon signed rank test was used for 
nonparametric results, the paired students t test for parametric results, and Fishers exact 
test for dichotomous variables. 
Spearmans correlation coefficient (r, ) was used for correlation of nonparametric and 
Pearsons correlation coefficient (rP) for correlation of parametric variables. 
An estimate of the sensitivity of outcome measures was made where appropriate with the 
standardized response mean. 
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Results 
For demographic variables relating to the study group of horses see Chapter 4. Horse 11 
was withdrawn from the clinical trial following the first examination and therefore results 
from this case were not included in the imaging analysis. 
Radiography 
Paired radiographs from 19 horses were available for scoring at entry. The results from 
these are shown in Table 6-4. 
From these radiographs, 17/19 horses and 28/38 joints had radiological signs of OA. 
Three horses (5,8, and 19) had no radiologic OA changes in the clinically affected joint. 
11/19 horses had bilaterally symmetrical radiological signs of OA and in only 6 horses 
(4,5,7,15,17,20) were the changes unilateral. The most common features were 
osteophytes which were detected in 27/28 radiologically OA joints. Joint space narrowing 
was only judged to be present in 8/28, subchondral bone sclerosis in 2/28, and 
subchondral bone erosions in 5/28 OA joints. Only 2 horses showed all the radiological 
features to be scored in the clinically affected joint (6,13). From Table 6-5 it can be seen 
that the TNTF joints scored more highly for osteophytes and subchondral bone erosions, 
and received the higher global scores for radiological OA than the other joints. Bilateral 
changes were most commonly seen in the PIP joints. 
RadioUa 12hy as a measurement of outcome in the trial 
Two horses in the low dose (1 and 20) and 1 horse (4) in the high dose group were 
judged to show radiological improvement in. the clinically affected joint during the 9 
months of the trial. No horses showed radiological deterioration and 16 remained 
unchanged. 
There was no significant difference (Students-t test) between the treatment groups for 
radiological global scores at the beginning or end of the trial, and no significant difference 
in change in global radiological score (Fishers exact test). 
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joint space 01 Mean 
narrowing 
Joint TMT (8/5) 2(3) 2(l) 0.5(0.25) 
affected MC (1/1) 1 0 
(Jts/horses) MCP (1/1) 1 1 
PIP (12/6) 4(4) 2(2) 0.33 (0.33) 
DIP (6/6) 3(2) 1 0.25 (0) 
Osteophytes 23 Mean 
Joint TMT (8/5) 2(3) 3 1.6(l) 
affected MC (1/1) 1 1 
(As/horses) MCP (1/1) 1 0 
PIP (12/6) 6(5) (1) 1(1.2) 
DIP (6/6) 4(2) 1 1 11 (1) 
Subchondral bone 0 Mean 
sclerosis 
Joint TMT (8/5) 3 
affected MC (1/1) 1 
(its/horses) MCP (1/1) 1 
PIP (12/6) 6 (6) 





Subchondral bone 012 Mean 
erosions 
Joint TMT (8/5) 1(4) 2 1 l(O) 
affected mc (1/1) 1 0 
(Jts/horses) MCP (1/1) 1 1 
PIP (12/6) 6(5) 1 0.14 (0) 
DIP (6/6) 1 4(2) 1 1 1 10 
Global score 013 Mean 
Joint TMT (8/5) 1(4) 2 1 2(l) 
affected MC (1/1) 1 1 
(Jts/horses) MCP (1/1) 1 1 
PIP (12/6) 6(6) 1 (1) 
DIP (6/6) 4 (2) 1 (1) 
Table 6-5: Summary of numbers of scores achieved for each feature, plus 
mean scores, in different OA joints. 
All 28 joints found to have radiographic signs of OA included, clinically active in bold 
and contralateral in bracketed italics. 
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Feature Raters 
MC v AB MC v BB ABvBB OveraU 
Joint space IC 0.32 0.22 0.48 0.48 
narrowing 95%CI +/-0.33 +/-0.33 +/- 
0.01 0.01 
Osteophytes x 0.61 0.43 0.53 ic 0.52 
0.09 +/- 0.08 +/- 0.07 95%Ci +/- 0.06 
Subchondral K 0.17 0.38 0.12 Ic 0.19 
bone erosions +/-0.22 +/-0.18 +/-0.13 95%CI +/-0.18 
Subchondral IC 0.28 0.45 0.38 ic = 0.42 
bone +/-0.52 +/-0.22 +1-0.51 95%CI +/-0.19 
sclerosis 
'K 0.62 0.37 0.51 0.47 
Global score +/- 0.09 +/-0.07 +/. 0.08 95%CI 0.05 
Table 6-6: Inter-rater reliability (cross-sectional) of radiological scoring 
(unweighted kappa values) 
(Kappa values and confidence intervals indicating good agreement highlighted in bold) 
Reproducibility of scoring method 
Inter-observer rel2roducibili! y 
Cross-sectional agreement 
The kappa values for cross-sectional reproducibility of the different radiographic features 
scored are shown in Table 6-6. Scoring of JSN, osteophytes and global score was 
acceptably reproducible. Although the kappa value for subchondral bone sclerosis was 
above the minimum acceptable value of 0.4, the confidence interval was unacceptably 
large. 




The inter-observer agreement for longitudinal changes in radiographic scores was 
unacceptable for all features e. g. 
JSN ic = 0.26 
Osteophytes ic-- 0.38 
Global ic =- 0.08 
It was not possible to check the responsiveness of the scoring system since this can only 
be done by using the system to score the response to an intervention of known outcome. 
However to provide an indication of the sensitivity of the system, the standard response 
mean was calculated i. e. Mean value of score change between radiographs at beginning 
and end of the trial / Standard deviation of that change. For all features and for the global 
score the SRM was unreasonably low. However rather than indicating a failing of the 
scoring system, this may have been because of the short duration of the trial and the slow 
progression of radiological change. 
Relationship between radiology and clinical outcome 
There was no correlation between the clinical global score of improvement in lameness of 
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Paired scintigraphical bone scan films were available for scoring from 19 horses at entry 
to the trial and at the third examination 6 months later. Of these cases 17119 horses and 
32/38 joints were found to have positive scintigraphy changes based on increased uptake 
of isotope in one or morejoints at entry. In 14/17 horses -the scintigraphical changes seen 
were bilateral (Table 6-8). 
It can be seen that the global score (Table 6-9) closely reflected the score of uptake of 
isotope and was not affected by the pattern of isotope distribution. Scintigraphical 
changes in the TMT and the PIP joints were bilateral and the uptake (and global) scores 
for these joints tended to be higher than for the other joint types. It was also more 
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Scintigraphy as measurement of change in trial 
There was no significant difference between high and low dose groups for uptake in lame 
or sound limbs at the beginning or end of the trial and therefore no significant difference 
in the change in uptake between the beginning and end of the trial. 
Uptake Score 0123 Mean 
Joint TMT (1015) (3) 4(2) 1 2.2(l. 4) 
affected mc (1/1) (1) 1 l(O) 
(jts/horse) MCP(1/1) (1) 1 l(O) 
PIP (12/6) 3(3) '3 (3) 1.5(l. 5) 
DIP (8/6) 2(2) 4(4) 1 1 1 0.67(0.67) 
Pattern of isotope Normal General Linear 
distribution 
Joint TMT (1015) (2) 1(3) 4 
affected mc (1/1) (1) 
(As/horse) MCP(1/1) (1) 
PIP (12/6) 1(0) 5(6) 
DIP (8/6) 1 2(2) 12(l) 11 (2) 
Global score 0123 Mean 
Joint TMT (1015) 3 4(2) 1 2.2(l. 4) 
affected mc (1/1) (1) 1 l(O) 
(jts/horse) MCP(1/1) (1) 1 l(O) 
PIP (12/6) 3(4) 3(2) 1.5(l. 33) 
DIP (8/6) 1(3) 4(4) 1 1 1 0.8(0.6) 
Table 6-9: Summary of numbers of scores achieved for each feature, plus 
mean scores, in different OA joints at entry. All 32 joints found to have 
scintigraphic signs of OA are included, clinically active in bold and 
contralateral in bracketed italics. 
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Reproducibilily. 
Weighted kappas were used for the measurement of isotope uptake where the 
discrepancies in agreement between raters were more than one grade (Table 6-10). 
Intra-observer variation: 
Cross-sectionaL 
The cross-sectional intra-rater reliability for scoring pattern and uptake was considered 
acceptable : 
Pattem (unweighted) ic = 0.54 
Isotope uptake (weighted) ic = 0.63 
(95% CI = 0.39 - 0.69) 
(95% CI = 0.49 - 0.76) 
Longitudinal. 
The longitudinal reliability of the scoring scheme, measured by unweighted kappas on the 
global changes between the first and second scan was also good: 
ic = 0.58 (95% CI = 0.51 - 0.65) 
Inter-observer variation: 
Cross-sectional. - 
Raters MCvAB MCvBB MCvCF BBvCF ABvCF BBvAB 
Disagree- 1 10 367 22 
ments 
Table 6-10: No of inter-rater disagreements in score of more than one 
grade 
The inter-rater reliability was unacceptably low with an overall kappa value of 
Pattem (unweighted ) ic = 0.23 ( 95% CI = 0.18 - 0.27) 
Isotope uptake(weighted) ic = 0.37, (95% CI = 0.32 - 0.42) (Tables 6-11,6-12) 
Global scoring closely reflected uptake scoring for all except one rater (BB). 
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Rater I Rater 2 Unweighted kappa 95%CI 
mc AB 0.37 0.25-0.49 
mc BB 0.17 0.05-0.21 
mc CF 0.46 0.32-0.60 
BB CF 0.08 0.01-0.16 
AB CF 0.26 0.21-0.31 
BB AB 0.16 0.12-0.21 
Table 6-11: Inter-rater kappas (unweighted) for pattern scoring 
Rater I Rater 2 Weighted kappa 95%CI 
mc AB 0.50 0.38-0.62 
mc BB 0.33 0.21-0.46 
mc CF 0.53 0.39-0.66 
BB CF 0.34 0.20-0.48 
AB CF 0.35 0.24-0.46 
BB AB 0.24 0.15-0.34 
Table 6-12: Inter-rater kappas (weighted) for uptake scoring 
There was also overall poor cross-sectional agreement inter-rater on a simplified scale of 
normal or abnormal uptake. 
Longitudinal agreetnent: 
The longitudinal inter-observer reliability of the scheme was measured using unweighted 
kappas on a simplified score of improvement v no improvement between first and second 
scans. For this measurement the agreement between two raters (CF and MC) was 
considered excellent (ic = 0.75) , but the agreement between every other combination of 
the four raters was unacceptably low. 
Analysis was therefore made on the results of one rater (CF) for which the intra-rater 
reliability was reasonable. 
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Cross-sectional difference in scan pptake between lame and contralateral joint 
The difference in uptake between sound and lame limbs at the beginning of the trial was 
not quite significant ( p=0.06 Paired student t test). There was a significant correlation 
between the scores of scan uptake in the clinically active and contralateral joints, i. e. 
rp = 0.64,95% CI = 0.26 - 0.85 p=0.002 
Correlations between scintigraphy and radiology 
There were significant positive correlations between the radiographic global score of OA 
severity and the scan radioisotope uptake score, i. e. 
rp = 0.46 95% Cl = 0.16 - 0.68 p=0.004 
However there was no longitudinal correlation between the change in global radiography 
score and the change in scan uptake score between the first and second scan (6 months 
interval). 
Association between scintigrWhy score and radiological pattern. 
The con-elation between increasing osteophyte score and linear pattern was not quite 
significant 
r, = 0.44,95% CI = 0.03 - 0.75 p=0.06. 
There was no correlation between duration of lameness and generalised or linear pattern. 
Relationship between scintigraphy and clinical outcome 
There was also no correlation between the change in uptake of the scans and the global 
score of clinical lameness improvement. 
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Scintimetry 
Computer images for 19 horses at entry to the trial were analysed quantitatively. Images 
for only 18 of these were available at the third examination, i. e. 6 months later. 
Joint n Lame 1 Contra 1 Lame 6 Contra 6 
Group A- Low dose 
TNIT 2 1.85 2.34 2.04 1.51 
mc 1 5.8 2.67 2.24 1.88 
PIP 3 2.23 1.96 1.66 1.54 
DIP 3 1.96 2.30 1.99 1.86 
Group B- High dose 
TUT 3 2.38 2.39 1.84 2.11 
MCP 1 1.16 1.23 2.11 1.99 
PIP 3 2.03 1.83 1.87 2.02 
DIP 3 2.09 1.64 1.46 1.41 
Table 6-13: Mean activity indices for different joints in both treatment 
groups at first and second scans 
Lame 1= Al from clinically active OA joint at first scan 
Contra 1= AI from contralateral joint at first scan 
Lame 6= AI from clinically active OA joint at second scan 
Contra 6= AI from contralateral joint at second scan 









DIP 6 2.03 1.97 
Mc I-5.8 2.67 
MCP I IA6 1.23 
Table 6-14: Overall mean AI values for different joints at entry to trial. 
ScintimeLry as measurement tool of trial 
There was no significant difference in activity indices (AI) of the clinically OA joint 
between treatment groups A and B at the beginning or end of the trial. 




The reliability of this method of quantitation of the images, calculated by intraclass 
correlation coefficient (ICC) = 0.7 1. This was considered good. 
Difference in AI between lame and contralateral joint. 
(A Contralateral 
Figure 6-2: Comparison between activity index of clinically active OA 
joint and contralateral. 
There was no significant difference in AI between the clinically active OA joint and the 
contralateral, but this may have been because in 82 % horses the disease was 
symmetrically bilateral. The correlation between Al values from the lame and contralateral 
limbs was significant however: 
0.59 (95%Cl = 0.19 - 0.83) p=0.007 n= 19 
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This result indicates that there may have been a systemic effect affecting the AI values. 
There was no significant difference between the normal reference bone in the active (mean 
15.19 counts / area ) and the contralateral (mean 15.85 counts/area) limbs. 
Correlation between scinti&Laq2hy and scintimeta 
There was a significant positive correlation (Spearmans coefficient -r, ) between the scan 
scoreof uptake and the activity index of the joint. 
r, = 0.32 95% CI = 0.08 - 0.52 p=0.006 n=74 
There was no significant longitudinal correlation between the change in uptake score from 
the scans and change in activity index. 
The score for linear pattern uptake was only weakly correlated with activity index of the 
joint: 
0.24 95% CI = 0.03 - 0.45 p=0.04 n=74 
Correlation between scintime! Qý and radiology 
There was no significant correlation (Spearmans) between the activity indices and the 
radiological scores nor was there any correlation between the change in AI and the change 
in radiology scores. 
Correlation with age or duration of lameness. 
There was no correlation between AI and age of the horse, nor duration of lameness. 
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Correlation between scintimetry and clinical outcome 
Using the non parametric Spearmans coefficient the correlation between the global score 
of change in lameness throughout the trial and the change in AI of the clinically active OA 
joint was just significant (Figure 6- 3) 
r, =0.47 95%Cl =-0.01 - 0.77 p=0.049 
Figure 6-3: Correlation between global score of clinical improvement and 




In this study the scoring scheme used was found to be reliable cross-sectionally both 
intra- and inter-rater for scoring joint space narrowing, osteophytes and for global score. 
Radiography has been validated in human trials, but no such reports could be found in 
the equine literature. Although radiography is generally accepted as the gold standard 
method of assessment of OA in equine medicine, its validation is fundamental to its use 
in the accurate assessment of OA in equine clinical trials. 
No difference in outcome between the two treatment groups in the CaPPS trial was 
demonstrated by radiography. However, as discussed in chapter 4, the sample size of the 
trial was too low to provide adequate power and therefore the chances of Type R error 
were increased. Outcome is also affected by the validity of the measurement tool. The 
method of scoring used in this study was reliable cross sectionally both intra- and inter- 
rater for joint space narrowing, osteophytes and for global score. The fact that 
subchondral bone changes were not found to be reliable could have been affected by the 
low numbers of OA joints in which these features were noted (< 18%). Longitudinally 
however, the scoring scheme was not found to be reliable and only 3 horses showed any 
longitudinal change in radiographic score during the 9 months of the trial. Apart from the 
obvious possibility that the scoring system may not have been sensitive enough to detect 
change, this could have been because of the short duration of the trial. It has been stated 
in the recommendations for clinical trials (Altman 1990) that any trial in which imaging 
methods are used should be at least 1 year in duration, and in fact Ravaud recommends 2- 
3 years (Lequesne et al. 1994) for radiographic studies. It may also be that in the 
population of clinical cases of OA that were used in this trial 16/19 horses had lameness 
of more than 3 months duration and could therefore be considered to have chronic OA 
changes. It has been noted previously (Ravaud et al. 1996) that in the later stages of OA, 
scoring systems such as the K&L scheme, i. e. dependent on the osteophyte, may reach a 
plateau, since if scored highly at onset of the trial these schemes do not allow for further 
changes. However despite the fact that the global scoring scheme ranged from 0-3, only 
one horse was scored as 3 (Horse 6), and two horses scored 2( Horses 1 and 13) at entry 
to the trial. Of all the other cases, scoring 0 or 1, no cases increased their score during the 
trial i. e. showed worsening radiological signs of OA. This finding therefore seems to 
contradict the theory that the chronicity of the disease had caused a ceiling effect in the 
scoring system, and indicates that it is more likely that too short a duration of the trial was 
the reason for the lack of detection of radiological changes. 
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Another factor which may have affected the reliability of longitudinal scoring was the 
method of reading the radiographs. In this study all the radiographs were read blinded to 
date order, but it has been recommended (Ravaud et al. 1996) that when assessing 
longitudinal change visualising the two sequential radiographs together would improve 
assessment of longitudinal change where changes are slight. 
Some differences in radiological features commonly detected were -found between 
different joints, osteophytes being scored more highly in the TMT joints for example. 
Subchondral bone erosions have been said to be most common in the tarsal joints - in this 
study 3 out of the 5 joints scored as having erosions present were TNff joints. Although 
subchondral bone sclerosis is regarded as one of the primary OA signs it was only noted 
in 2/28 OA joints in this study. It seems likely that for adequate scoring of radiological 
changes different features should be scored according to joint but a larger sample size 
would be necessary to investigate this further with stricter control over the duration of 
OA in each joint. 
The scoring system used in this study is similar to the Kellgren and Lawrence scheme in 
that the osteophyte seems to have the most influence over the global score. Osteophytes 
were found to be very common, being scored as present in 27/28 OA joints. 
Scintigraphjy 
Scintigraphy was useful in the diagnosis of OA in cases where there were no radiological 
signs of OA. However, although the scoring system used here to quantify the degree of 
OA was found to be reliable intra-observer, it was unreliable inter-observer both cross- 
sectionally and longitudinally. 
No difference in outcome between the two treatment groups in the CaPPS trial was 
demonstrated by scintigraphy. The reason for this may be, as previously mentioned, 
because of the inadequate sample size of the study. However, it could also be in this case 
because the scoring system was found to be unreliable inter-observer. It was surprising 
that there was not even agreement as to the normality or abnormality of the scans. A 
training session as such was not used in this study, which in retrospect could have been a 
cause of poor reproducibility, but since each rater was commonly involved in assessing 
scintigraphs this had not been considered necessary at the time. It was interesting that two 
raters showed good agreement throughout (MC and CF) while one rater showed 
consistently poor agreement - this may indicate a difference of opinion in the interpretation 
of the scans rather than a failing of the scoring system itself. Scintigraphical bone 
scanning is being used increasingly to investigate equine lameness at many centres, and 
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variation between clinicians in the interpretation of scans is an area of concern which 
requires considerable further attention if this method of imaging is to become a valid 
measurement tool. 
There was no significant correlation between type of scan pattern and radiographic feature 
although it did seem that linear patterns were more common in the PIP and TMT joints 
and were almost significantly correlated with a higher osteophyte score. A larger study 
should be made to clarify this finding. 
It was not possible to measure the sensitivity of the scoring system to detect change 
without a known outcome measure with which to compare it - however it may well be that 
the interval of 6 months between scans was not long enough to detect change once a joint 
had become scintigraphically "hot". 
The use of scintigraphy was useful in detecting increased subchondral. bone activity in 
three horses (5,8, and 19) in which there were no radiological signs of OA despite the 
lameness in two of the cases (5 and 19) being of more than 18 months duration. 
7he lack of difference in sensitivity between scintigraphy and radiography for diagnosis 
of cases of metacarpophalangeal and tarsal OA has previously been reported (Lamb et al. 
1989) but the prevalence of chronic cases of OA in which radiological signs of OA were 
already present could have accounted for this finding. However in that study, as in this 
one, scintigraphy was useful in some cases where radiographic changes were not present 
and was therefore considered a valuable additional diagnostic aid. 
Scintimetry 
The calculation of AI was found to be reproducible but did not show any significant 
change between the first and second scans for either treatment group. It was unexpected 
that there was no significant difference between the clinically active OA joint and the 
contralateral, but this may have been because of the larger number of cases in which the 
disease was bilaterally symmetrical. 
There was a strong correlation between the scintigraphy score of uptake and the AI cross- 
sectionally but not longitudinally - this may have been because of the reasons mentioned 
above i. e. poor detection of change demonstrated by the scintigraphy scoring or 
inadequate duration of the trial. 
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An interesting finding was the positive correlation (although only just significant ) 
between global improvement in lameness and the AI change of the clinically active joint. 
This finding implies that a clinical improvement correlates with an increase in subchondral 
activity. If this is a true finding it would be in opposition to the commonly held view that 
an increase in subchondral bone activity represented by increased uptake of isotope 
represents worsening of the OA condition. It is possible that the increase in isotope uptake 
in these cases is a reflection of adaptive bone remodelling. 
The lack of difference between the normal reference bone in the lame and sound leg was 
unlike that reported previously (Attenburrow 1997) where the sound leg often has an 
increased uptake, understood to be because of increased weightbearing. In this study this 
may have been because of the high incidence of bilateral disease. 
Summary 
1. Radiographic scoring of JSN, osteophytes and global signs of OA was found to be 
reproducible cross-sectionally both intra- and inter-observer. 
2. Scintigraphy was useful as an additional method of -OA diagnosis when used in 
combination with clinical and radiographic methods. 
3. The scintigraphy scoring system was only found to be reliable intra-observer. 
4. The use of scintimetry was found to be reliable cross-sectionally and correlated well 
with scintigraphy scores but provided little additional information. 
5. There was no correlation between radiography or scintigraphy changes and global 
change in lameness. Scintimetry was weakly positively correlated with global lameness 
change - this finding requires ftirther evaluation. 
6. No correlation could be detected between scintigraphy patterns and radiographic 
features of OA. 
7. In this study a difference in outcome between the two treatment groups in the CaPPS 
trial has not been detected by radiology nor scintigraphy. 
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Chapter Seven 
Variation of biochemical markers in nonnal equine -ioints. 
Introduction 
During normal metabolism joint tissue macromolecules or fragments thereof are released into 
the synovial fluid, blood and urine. Biochemical or immunochemical assays can be used to 
detect these molecules. In osteoarthritis (OA), changes in metabolism can produce 
compositional changes in newly synthesised molecules and the resulting neoepitopes can be 
detected by immunochernical methods. The aim of molecular marker research is to use these 
molecules or epitopes as markers to detect early OA changes at a stage at which other 
diagnostic techniques may be ineffective, to monitor progression of the disease, and to 
prognosticate on the outcome. Although these aims have not yet been realised, investigation 
into these markers in itself is providing a wealth of information regarding the metabolism of 
the joint and the pathogenic mechanisms involved in the development of OA. 
Marker interpretation 
Cartilage matrix macromolecules initially undergo extracellular degradation, after which a 
proportion of these molecules or fragments are taken up by the chondrocytes and further 
degraded. Others reach the synovial fluid by diffusion. Here they may be degraded by the 
synovial cells or flow on into the lymph with the synovial fluid (Fraser et al. 1988). A large 
proportion of macromolecules are removed or at least further degraded by the lymph nodes. 
The remaining are removed from the circulation by liver cells, with exception of the collagen 
cross links, which are resistant to degradation and are finally eliminated in the urine. 
The concentration of a cartilage or other joint tissue marker within the synovial fluid provides 
information only regarding the condition of the tissue within that joint, while joint marker 
measurement in serum is related to the whole body or all the joints in the body, depending on 
the origin of the marker. Although the ultimate aim would be to find a serum marker, because 
of the ease with which samples can be obtained, there are obviously several disadvantages to 
marker measurement in this compartment. A large proportion of macromolecules produced by 
the joint tissues will have been degraded by the time the circulation is reached, and those that 
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do arrive in the blood are diluted by similar markers from healthy joints. The concentration of 
markers is much lower than is found within the joint and this may cause problems in 
detection, since the circulating concentrations of some markers may be below the sensitivity 
of the assays. 
The concentration of a marker in joint fluid or serum cannot be interpreted quantitatively until 
the kinetics of its production and clearance from the joint are known (Levick 1990). Although 
the lymphatics are the major clearance pathway for these macromolecules, the relative rate of 
phagocytosis by the synovial lining cells is not known. In the diseased joint it is not only the 
rate of marker production that is affected but also the rate of synovial fluid turnover, and 
these rates may vary between different joints and in different types of joint disease. Different 
markers may also have different clearance kinetics, since the permeability of the synovial 
membrane is not uniform to all macromolecules (Levick et al. 1995). Great caution should 
therefore be applied when interpreting data on cartilage markers (Wallis et al. 1987). In order 
to make some allowance for these unknown variables in many studies markers are expressed 
as ratios to other markers. 
Marker validation 
The "ideal" marker of cartilage degradation is one which is not found in normal cartilage or 
in any other tissue. It is also one which can be validated against another form of 
measurement, validity being defined as "the extent to which any instrument measures what it 
is supposed to measure" (Carrnines et al. 1979). There are a number of different 
classifications of validity but criterion validity is considered the most applicable test for 
biological phenomena i. e. does the marker measure the ongoing biological activity it is 
supposed to measure? This must correlate with a gold standard such as radiography or 
magnetic resonance imaging (NW. 
A set of modified "Koch's postulates" for biochemical markers of the state of OA have been 
proposed (Felson 1995): 
1) A marker is biologically credible. 
2) A marker is regularly (universally) found in patients with OA of the joint. 
3) Normal values for marker by age are defined sensibly. 
4) With change in the state of OA, markers change appropriately. 
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Many of the putative markers of OA are not markers of existence or non-existence of disease 
but rather markers of disease dynamics or severity. These are often classified as prognostic 
markers. Suggested criteria for validation of prognostic markers of OA are as follows : 
1) There should be a strong biological rationale. 
- The marker is identifiable in cartilage or periarticular bone. 
- If the marker is a measure of OA dynamics, its role in the pathogenesis of OA must 
be at least partly understood. 
- If the marker is a measure of disease severity, it must correlate with disease severity 
as determined by imaging and/or functional assessment. 
2) A marker measured at baseline in a body fluid predicts the course of OA. The course of 
OA at baseline and follow up is determined independently of marker measurement using 
conventional clinical means. 
3) The marker must be validated in patients with spectrum of mild/severe disease and OA of 
different aetiologies (e. g. post-traumatic v primary). 
4) Marker measurement is reliable (repeatable) and described in sufficient detail as to be 
replicable by others. 
Another function of markers is as predictors of responsiveness to therapy. These markers 
should be assayed at baseline in a longitudinal study , and those patients who responded to 
treatment, defined independently of the marker, should have different marker levels at 
baseline than those who did not respond. Markers of response to therapy are different - here 
the difference between marker level before and after treatment is important. 
Types of marker 
A large number of potential markers of joint tissue turnover have been identified - as wen as 
the macromolecules produced by cartilage and bone turnover, these include the cytokines, 
enzymes and their inhibitors involved in joint metabolism. The choice of marker depends on 
the development of sensitive and specific assays with which to measure them. Markers have 
been classified in many different ways but here they will be described under their currently 
understood function. 
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1. Markers of cartila2e matrix tumover 
a) Cartilaze matrix macromolecules 
Proteoglycans: 
Proteoglycan (PG) and PG fragments released into the SF during normal cartilage matrix 
turnover can be measured by ELISA. These substances have been found to be increased in 
human knee joints in post traumatic injuries and early OA (Lohmander et al. 1989; Ratcliffe et 
al. 1988). In dogs with experimentally induced OA the SF PG concentration was found to be 
increased (Heinegard et al. 1985) while in the horse the PG level in carpal and 
metacarpophalangeal joints was increased in chronic OA (Alwan et al. 199 1). 
Total glycosaminoglycans: 
The level of total glycosaminoglycans (GAG) in the synovial fluid and serum have been 
measured, usually by the direct dye binding method (Famdale et al. 1986) in many studies 
and are thought to reflect cartilage destruction in OA (Alwan et al. 1991). Increased levels 
have been found in the SF, serum and urine of horses with OA, in the SF but not in the 
serum of dogs (Arican et al. 1994). 
More specific studies have been made of individual glycosaminoglycans by more sensitive 
methods, in particular immunoassays. Caution must be employed when comparing results of 
these assays from different laboratories since differences in the epitopes measured are 
connnon. 
Keratan sulphate (5D4): 
Keratan sulphate (KS) is a sulphated GAG which is covalently attached to the protein core of 
the proteoglycan molecules. Some KS chains have a highly antigenic oversulphated epitope, 
which is specifically recognised by the monoclonal antibody (1/20/5D4) used in this study 
(Caterson et al. 1983). The significance of the levels of this KS epitope in the synovial fluid 
and the serum and the changes related to joint disease have been studied widely (Campion et 
al. 1991; Sweet et al. 1988; Thonar et al. 1992; Todhunter et al. 1993). Traditionally it was 
believed that KS was a marker of cartilage degradation since serum levels were found to be 
higher in OA cases compared to normal controls (Sweet et al. 1988; Thonar et al. 1992). 
However, since more recent studies, the more broad description of KS as a marker of 
cartilage turnover has been used. In a study by Todhunter (Todhunter et al. 1997) , KS 5D4 
concentrations, measured by ELISA, were found to be lower in OA joints compared to 
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normal controls. Breed, gender, and type of other joint disease were found to affect the 
marker concentration however. 
b) Noncollagenous 12roteins 
Cartilage oligomeric matrix protein: 
Cartilage oligomeric matrix protein (COMP) consists Of five 100 kDa subunits and was first 
isolated from bovine articular cartilage (Hedbom et al. 1992). It is found throughout all types 
of cartilage and also in non cartilaginous tissues e. g. tendon (Smith 1997). Little is known 
about its specific physiological function although it has been shown to bind chondrocytes 
(Dicesare et al. 1994) and could play a role in contacts between extraceffular matrix and 
chondrocytes. It is thought to be a marker of cartilage matrix turnover. 
Studies have been carried out investigating this marker in SF and serum in four types of 
arthritis in man, using immunoassays, and in all four diseases CONP was higher in SF than 
serum, suggesting local production of this protein in joints (S axne et al. 1992) . High COMP 
levels have also been found in patients shortly after knee injury (Lohmander et al. 1994). 
More recently a study has demonstrated serum COMP increased significantly in the first year 
of follow up only in those patients whose knee OA progressed (Sharif et al. 1995), and 
another reports that serum concentrations of COMP correlated strongly with scintigrapl-& 
scores in OA (Petersson et al. 1995). Nothing could be found in the literature regarding 
COMP in equine OA, or concerning possible variation in synovial fluid COMP from normal 
joints. 
Fibronectin: 
Fibronectin is a small protein synthesised and accumulated in OA joints in increased amounts 
(Lust et al. 1987) . 
YKL-40: 
This is a 40kDa protein secreted by human articular cartilage cells and synoviocytes and is 
present in increased concentrations in OA (Johansen et al. 1993). 
ca EnZymes 
Meta Iloprotein as es: 
The levels of metalloproteinases (MMPs) in the SF can be used as markers of cartilage 
degradation (Lohmander et al. 1993). These enzymes are produced by the synovium. and 
articular cartilage. In man it has been found that concentrations of stromelysin (MMP-3) in 
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knee SF were raised for many years following knee injury (Lohmander et al. 1993). The ratio 
of MMP-3 and tissue inhibitor of metalloproteinases (TEIAP) was also found to change from 
an excess of MAV-3 in the injured joint to an excess of TEMP in the normal reference joint 
(Lohmander et al. 1994). In an equine study, the enzyme activity of the gelatinases MNT-2 
and MMIP-9 was measured by gelatin zymography and was found to be increased in synovial 
fluids in septic and non-septic joint disease compared to normal controls (Clegg et al. 1997). 
Aggrecanase: 
Cartilage aggrecan catabolism by the as yet uncharacterised enzyme "Aggrecanase" generates 
neoepitopes which can be detected by monoclonal antibodies (Hughes et al. 1992). BC-3 and 
BC-4 are monoclonal antibodies that recognise the N terminal in the interglobular domain of 
the aggrecan molecule, generated by the unknown enzyme Aggrecanase and the new C 
terminal in the interglobular domain (IGD) generated by the NUAPs. 
dLCollagen 
Monoclonal antibodies are now available to measure the level of type II collagen synthesis 
and degradation by detection of an intra-a-chain epitope (Poole et al. 1995) in the helical 
region of the denatured molecule. These antibodies show no reactivity with the intact tdple 
helical type H collagen (Hollander et al. 1994). 
2. Markers of cartilage synthesis 
Chondroitin sulphate: 
The monoclonal antibodies 3B3 and 7134 can be used to identify subtle biochemical 
differences on newly synthesised chondroitin sulphate chains in OA cartilage. 3B3(+) 
recognises as its epitope a non reducing terminal unsaturated uronic acid residue adjacent to 
N-acetylgalactosaniine-6-sulphate after the CS chains have been digested with 
chondroitinase. 3B3(-) recognises a mimotope containing a saturated glucoronic acid residue 
at the nonreducing terminal that occurs in CS chains in osteoarthritic cartilage. Proteoglycans 
containing the 3B3(-) epitope occur only infrequently in normal cartilage (Caterson et al. 
1990). Another epitope, for antibody 7D4, is less well recognised, but is also more prevalent 
on OA cartilage (Slater et al. 1995). The 846 antibody recognises a native epitope that also 
has increased expression in proteoglycans from OA cartilage (Rizkalla et al. 1992). 
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Expression of these neoepitopes seems to reflect a switch in the articular cartilage phenotype 
as a result of the tissues attempt to repair. These markers have been investigated in body 
fluids in animals and man (Poole et al. 1994; Ratcliffe et al. 1996; Ratcliffe et al. 1993). 
Concentrations in SF are considerably higher than those in serum, and SF levels correlate 
inversely with the levels of KS (Poole et al. 1994). 
A change in the sulphation pattern of chondroitin sulphate in the cartilage matrix can also 
indicate early OA changes. The ratio of chondroitin 6-sulphate (C6) to chondroitin 4-sulphate 
(C4) decreases as more of the immature isomer C4 is produced (Sharif et al. 1996; Shinmei 
et al. 1992). 
Collagen: 
The C-propeptide (P11P) of type H collagen has been investigated as a marker of collagen 
biosynthesis (Shinmei et al. 1993). It is present in joint fluids in osteoarthritis and although 
these levels are not very elevated over serum levels, they may reflect local cartilage changes 
(Poole et al. 1995). Inverse changes in levels of PIIP and KS have been noticed which may 
suggest the existence of phases of net cartilage synthesis and degradation (Poole et al. 1995). 
3. Markers of bone tumover 
a) Bone formation 
Bone specific alkaline phosphatase: 
Significant improvements have recently been made in the measurement of alkaline 
phosphatase (AP), which has been used as a marker of bone formation for many years. 
Serum total alkaline phosphatase activity is the most cornmonly used marker of bone 
formation (Delmas 1995). However several tissues contain alkaline phosphatase, liver and 
bone isoenzymes being the major contributors to the serum levels, although the intestine, and 
placenta in the pregnant animal are also contributors. For these reasons total AP lacks 
specificity and sensitivity as a marker. Recently a monoclonal antibody that recognises 
preferentially the bone isoenzyme (BAP) (Hill et al. 1986) has been developed. 
BAP is located on the cell surface of osteoblasts and there is evidence to suggest that BAP 
plays an important role in bone mineralisation ( Yoon et al 1989, Brixen et al 1989, Caswell 
1991). In man it has been shown that its activity increases with ageing in adults, and 
especially in women after the menopause (Crilly et al. 1980). BAP has been measured in 
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serum and synovial fluid in patients suffering from both OA and rheumatoid arthritis (Sharif 
et al. 1995) and although no normal controls were included, SF BAP levels were found to be 
lower than those in serum, and the BAP concentration in OA SF was lower than that in RA 
SF. There does not appear to be a diurnal rhythm for serum BAP in man (Crornier 1995). 
No studies could be found in the literature concerning the measurement of BAP in equine 
synovial fluid but equine serum BAP has been reported to decrease with age particularly 
during the first 2 years (Price et al. 1995). 
Many different methods have been used to measure BAP in horse sera, including the wheat 
germ precipitation test (Hank et al. 1993) and the immunoradiometric assay (Tandem -Ostase 
Hybritech Belgium) (Jackson et al. 1996). As yet there are no published data concerning the 
use of the assay employed in this study (Alkphase-B Metra Biosystems) on equine samples. 
Investigations into the use of this assay with human serum samples have shown (Gomez et 
al. 1995) no cross reactivity occurring with intestinal or placental alkaline phosphates, and 
only 3 -8% cross reactivity to the liver isoenzyme. The assay has been used successfully in 
canine studies (Innes 1997) in both serum and synovial fluid in which BAP activity was 
found to be increased in clinically active OA joints. 
Osteocalcin : 
Osteocalcin (OC) is a small bone specific noncollagenous protein synthesised by osteoblasts 
with a high affinity for hydroxyapatite, and recent results have shown a positive correlation 
between serum OC and scintigraphical bone scans (Sharif et al. 1995). A diurnal rhythm has 
been demonstrated in man (Gundberg et al. 1985) and in the horse (Lepage et al. 199 1). 
Bone sialoprotein : 
Bone sialoprotein (BSP) is a bone specific molecule produced by osteoblasts, and constitutes 
12 % of the noncollagenous proteins of bone matrix. Its function is unknown but it binds to 
hydroxyapatite. It shows the highest level of synthesis at the cartilage bone interface of 
growth cartilage and is markedly enriched at the cartilage bone interface, the tidemark and in 
mineralising osteoid (Debri et al. 1995; Hultenby et al. 1994; Riminucci et al. 1995). 
Significant increases in the SF concentration of BSP have been reported in connection with 
acute joint trauma (Saxne et al. 1995) and there is a positive association with the degree of 
joint damage in RA patients (Saxne et al. 1995). BSP levels increase over time in RA patients 
with progressive joint disease (Mansson et al. 1997). In OA an increased level is thought to 
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be associated with remodelling of the cartilage bone interface and subchondral bone 
(Lohmander et al. 1996). 
b) Bone resoiption 
Collagen crosslinks: 
The collagen crosslink deoxypyridinoline is primarily found in bone and is a more specific 
marker of bone resorption than pyridinoline, which is also present in cartilage and other 
connective tissues. The levels of these markers have been found to be raised in the urine of 
OA patients (Seibel et al. 1989) and correlate positively with the Kellgren and Lawrence 
radiography scale (Thompson et al. 1992). 
4. Markers of synovial actiDýV 
Hyaluronan: 
Hyaluronan (HA) is a GAG produced by the synovial lining cells, and by chondrocytes in 
cartilage, having important roles in the mechanical properties of the synovial fluid and, as the 
backbone to proteoglycan aggregates, in the compressive stiffness of the cartilage. It differs 
from other GAGs in that it is a linear polysaccharide, lacking sulphated side chains and not 
being covalently linked to protein. It is a very large molecule (K 10'kD) with theological 
properties showing both viscoelasticity and shear dependence which are connected with its 
lubricating properties in the joint. Although HA is synthesised by fibroblasts in several 
tissues it is found in highest concentration in the synovial fluid (SF). It passes through the 
synovial membrane to the lymphatics and then in part to the circulation from where it is 
cleared by the endothelial cells of the liver and kidney (Woessner 1991). 
The use of HA as a biochemical marker of osteoarthritis has been investigated in man and 
horse in serum and synovial fluid. Specifically it is reported to be a marker of synovial 
membrane activity. It has been shown in man that there is a diumal rhythm of serum HA 
(Engstrom-Laurent et al. 1987), but no such information exists for the horse. The 
concentration of HA has been found to be significantly lower than that in normal controls in 
osteoarthritic equine carpal joints (Hilbert et al. 1984; Tulamo et al. 1994) and in man 
(Hedin et al. 1991). HA in equine serum is positively related to age (Tulamo et al. 1990) and 
in man serum HA is significantly increased in OA cases (Hedin et al. 1991) and correlates 
with both degree of cartilage damage and disease duration (Sharif et al. 1995) - Serum HA 
has also been found to be a predictor of disease progression in OA of the knee (Sharif et al. 
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1995). While it has been noted that there is a wide variation in SF and serum values of HA in 
the horse (Saari et al. 1989) the potential difference in SF HA between different normal joints 
has not been reported in the literature. This information is essential for meaningful 
interpretation of HA values. 
Having reviewed the available literature it is clear that only a limited amount of data on 
reference concentrations and longitudinal and cross sectional marker variations has been 
published, and there is a need for more information on reference ranges of these markers in 
the normal population, along with the effect of variables on these values, i. e. age, gender, 
disease duration, exercise and joints affected. The future of markers as outcome measures in 
clinical trials of new treatments for OA will require the general availability of reproducible 
assays and data on the "normal" or base line range of concentrations of these markers in 
reference populations (Lohmander et al. 1997). 
The investigation into normal variation, which was the objective of the present study, can 
also provide information about the metabolism of cartilage within different joints. 
In this study it was decided to investigate the markers KS, GAG, and CONT as markers of 
cartilage matrix turnover, BAP as a marker of bone formation, and HA as a marker of 
synovial activity. 
The aims were as follows: 
Aims 
1. To establish a normal range of values of KS, GAG, HA, CONT and BAP in equine 
synovial fluid, and to investigate whether there was any variation in levels between different 
normal joints . 
2. To establish the variation in the normal levels of these markers with age. 
3. To establish the normal range of values of HA in equine serum. 
4. To establish whether diurnal rhythm exists for equine serum HA. 
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Methods 
Horse and sgmple collection 
Synovial fluid samples were taken, immediately following slaughter, by needle aspiration 
from the joints of 53 horses which had been destroyed for reasons unrelated to locomotor 
system disorders. The total volume possible to remove and the viscosity of the SF were noted 
in each case. The samples were taken from the distal interphalangeal (DIP), proximal 
interphalangeal (PIP), metacarpophalangeal (MCP), metatarsophalangeal (MTP), 
tarsometatarsal (TMT), tarsocrural (TC), femoropatellar (FP), and antebrachiocarpal (ABC) 
joints. In a subgroup of 11 horses values for KS , GAG, COMP and HA were obtained for 
the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal 
/metatarsophalangeal from the same limb in each animal. Following sampling each joint was 
dissected open and examined visually for any abnormality. Any joint showing signs of 
osteoarthritis or any other joint disease was excluded from this study. 
7be age of each horse was assessed by an examination of the eruption and table 
appearances of the teeth. In some cases ages were verified by available passports. Horses 
were assigned to a group according to age, i. e. 5-10 years , 10 - 15 years etc. This was to 
allow for recently recognised inaccuracies in the technique of ageing horses by examination 
of the teeth (Richardson et al. 1995). The synovial fluid samples were centrifuged at 
40OOrpm for 10 minutes to remove cells and debris. The supernatant was then aliquotted and 
stored at -20* C initially, and then -80*C until analysed. 
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Keratan Sulphate Assay 
Samples were analysed by ELISA inhibition using a method similar to that described by 
Thonar et al 1985 but with a few minor modifications (Creamer et aL 1994) (Figure 7- 1). 
The antibody used was a mouse IgG monoclonal 5D4 (Caterson et aL 1988) which 
recognises a sulphated epitope on certain keratan sulphate chains. The standard antigen 
was chondroitinase ABC treated porcine proteoglycan. The 96 well assay plate was 
coated with 200gl per well of 48ng/ml PG antigen, diluted 1: 10,000 in 50MM 
Carbonate/Bicarbonate buffer at pH 9.6. This was incubated for two hours at room 
temperature and then overnight at 40C. On a separate dilution plate, porcine proteoglycan 
antigen was added in duplicate in double dilutions to produce a standard curve in the 
range 200ng/ml - 1.9 ng/ml. Phosphate buffered saline was used for dilutions with 
0.02% Sodium Azide, 1% BSA and 0.05% Tween 20 added at pH 5.3.125gl of each 
sample, appropriately diluted in this buffer ( dilution ranged from 1: 1000 to 1: 8000 ) 
were added in duplicate to the plate. A control sample of known value was used in each 
assay. Two blank wells consisting of buffer only and two inhibition wells consisting of 
antibody and buffer only were included. 1251il of 5D4 Antibody, diluted 1: 25000, was 
added to each well before incubation for 1 hour at room temperature and then overnight at 
4*C. On the second day of the assay, the antigen-antibody complex was transferred to the 
coated plates. 200gl of conjugated alkaline phosphatase anti-mouse IgG (Sigma A-2179) 
diluted 1: 2500 was added to each well and incubated at room temperature for 1 hour. 
After washing the plates thoroughly in phosphate buffered saline, 200gl alkaline 
phosphate substrate solution (Sigma 104) was added to each well. The absorbance of 
each well was read after a further incubation of 30 minutes, at 405nm. 
The concentration of keratan sulphate in the synovial fluid samples was calculated using 
only the straight portion of the standard curve and all samples were assayed in duplicate. 
Interassay coefficient of variation was calculated using both the 50% inhibition point of 
each assay, and the value of the control sample, and this proved to be < 10%. The intra- 
assay variation was < 5%. 
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Figure 7-1: Diagram describing process of KS(5D4) ELISA 
Total Glycosaminoglycans AsaRy 
GAG levels were measured by dimethylmethylene blue assay described by Famdale 
(Famdale et al. 1986) and using a standard bovine trachea chondroitin sulphate for 
calibration. 50pI of synovial fluid, diluted if necessary up to 1: 4 with disodium. hydrogen 
phosphate buffer, were n-dxed with 5OW papain which had been diluted to 32.6 U/ml in 
the same buffer. The samples were incubated in stoppered tubes for 2 hours in a 65"C 
waterbath to allow protein digestion to occur. A standard bovine trachea chondroitin 
sulphate was used for calibration and this and the digested samples were added in 20pl 
aliquots in duplicate to a 96 well ELISA plate. Buffer was used for blanks. Dirnethylene 
Blue buffer was prepared by mixing 16mg Dimethylene Blue (DNIB) ( Serva 20335), 
3.04g Glycine and 2.37g NaCl in 1L distilled water. The pH was adjusted to 3.0 with 
concentrated HCL 200gl of this DUB buffer were added to all wells on the ELISA plate 
and the absorbance at 525nm and 690nm wavelengths was read immediately in a 
spectrophotometer. 
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All samples were assayed in duplicate. The interassay and intra-assay coefficient of 
variation were < 7% and < 12% respectively. 
Cartilage oligomeric matrix protein assay 
CONT' concentrations in the synovial fluids were measured using an inhibition ELISA 
and a polyclonal anti equine CONT (etCONI[P) antibody (Smith 1997). 200gI of equine 
tendon purified etCOXT was added to each flat bottomed well of a 96-well Maxisorp 
ELISA plate (Nunc). Coating was achieved by overnight incubation at room temperature. 
On a second plate (Sterilin 96 well plate (Labsystems)) a standard curve using 115gi of 
the standard etCONT purified from equine tendon with concentrations of 0.2gghnl to 
0.00625gg/ml was set up . Appropriately diluted synovial fluid samples were added in 
115gl aliquots to remaining wells. 1150 of anti etCONV antibody was then added to all 
wells. All standards and samples were assayed in triplicate. After 1 hour incubation at 
room temperature, 2000 of resulting well contents was transferred to the previously 
coated plate. 200gl alkaline phosphatase conjugated goat antirabbit IgG (Orion 
Diagnostica) was then added to each well. Following a further 1 hour incubation 200gI of 
the substrate p-nitrophenyl phosphate (Sigma 104 phosphatase substrate -Sigma Chemical 
Co) was added before reading the absorption of each well irnmediately at 405nm on a 
Labsysterns Multiscan plate reader. 
Bone specific alkaline phosphatase assay 
This was carried out using a capture immunoassay available as a cornmercial kit 
(Alkphase -B; Metra Biosystems). The assay uses a monoclonal purified murine anti BAP 
IgG antibody coated onto a microtitre stripwells to capture BAP in the added sample. The 
enzyme activity of the captured BAP is detected by a p-Nitrophenyl phosphate (pNPP) 
substrate. BAP standards used are purified from osteosarcoma SAOS -2 cells in a 
buffered solution. High and low controls of known value were provided. 125gl of assay 
buffer containing magnesium chloride and zinc sulphate was added to each antibody 
coated well. Following this, 200 of standard, control or synovial fluid sample were 
added and mixed by gentle swirling. After an incubation period of 30 minutes at room 
temperature the strips were emptied and wells washed with a non-ionic detergent buffer. 
150gl of pNPP substrate solution was then added to each well before further incubation 
of 30 minutes at room temperature. After adding 100gl of NaOH stop solution the optical 
density of each well was read at 405nm using an automatic plate reader. Quantitation 
software (Deltasoft) with a quadratic curve fitting equation was used on a Macintosh LC 
computer to interpret values of unknowns from a linear standard curve. 
I This assay was carried out by Dr Roger Smith, Royal Veterinary College. 
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Hyaluronan assay 
This inhibition ELISA assay was adapted from a method described by Goldberg 
(Goldberg 1988). 96 well polystyrene plates ( outermost wells were excluded) were 
coated with 2000 of hyaluronan (Sigma) in a 20mM Sodium Carbonate buffer. The 
plates were incubated overnight at 40C before blocking with 1% bovine serum albumin 
(BSA)-PBS, and further six hour incubation at 4"C. Before use plates were washed twice 
with 0.05% Tween -PBS. HA was diluted in 0.05% Tween - PBS/1% BSA and double 
diluted to make a standard curve ranging from 20OOng/mI to 0.977ng/ml. Samples were 
diluted (serum 1: 4 to 1: 8) and 1000 added in duplicate to the wells. PBS buffer was 
used as a blank, and a control sample and an inhibition well were added to check assay 
variation. 1000 of lgg/ml Human PG was added to all wells except the blanks. After 
shaking for 20 seconds the plates were incubated overnight at 4*C. The plates were 
washed four times with Tween -PBS before adding 2000 5D4 antibody (ICN) to all 
wells and incubating at 37*C for an hour. After four further washes in Tween -PBS 2000 
of anti-mouse IgG alkaline phosphatase conjugate (Sigma A-2179) in Tween - PBS/BSA 
was added to each well. Plates were washed four times in Tween -PBS and then 200gl 
of Alkaline phosphatase substrate was added to each well. After allowing 30 minutes at 
room temperature for development of colour the colour absorbance of the plates were read 
on an automatic ELISA plate reader at 405nm. The interassay and intraassay coefficients 
of variation for SF were 22% and 11 % respectively and for serum were 12% and 7.2%. 
157 























Figure 7-2: Diagram describing process of Hyaluronan inhibition ELISA. 
Diurnal rhythm. 
Six horses, two male and four female, aged between 4 and 20 years , were used for this 
study. None of the horses showed any clinical signs of musculoskeletal disease and each 
horse had haernatological and biochemical profiles within normal limits for our 
laboratory. They were all stabled throughout the study period. Blood was sampled via 
indwelling jugular catheters at two hourly intervals over a 24 hour period. After 
centrifuging for 5 minutes at 30OOrpm, the serum was removed and stored at -80C until 
analysis of HA concentration by ELISA. 
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Statistical Analysis 
Inter joint variation : 
Statistical analysis was by the Wilcoxon matched pairs test on matched samples 
i. e. those samples taken from joints in the same horse. The distribution of all values were 
skewed despite logarithmic transformation so the median (+ semi interquartile ranges ) 
were chosen to demonstrate results. When joints from more than I leg in a horse were 
sampled, the results from only 1 leg, chosen at random, were used. Analysis of 
correlations were made by the Spearmans correlation coefficient (r). 
Diurnal fthm 
The potential effect of diurnal rhythm on HA serum concentrations was analysed by the 
use of z scores (Z), where 
Z= (value of serum HA at one time point - mean serum HA all time points) / standard 
deviation (SD) 
This value provides a degree of fluctuation of serum HA throughout the day, relative to 
each horse. Logarithmic transformations were used to reduce the amount of variation in 
concentration. The Friedman repeated measures test were used to compare scores. 
esults 
Horse Volume Volume Volume 
Number Mcp (MIS) PIP (MIS) DIP (mls) 
2 2.5 0.5 0.3 
3 1.7 0.3 0.3 
4 2.5 1 0.5 
5 3 0.5 0.3 
17 3.5 11 
is 4 1 2.5 
20 1.5 0.75 1 
21 4 1.5 1.5 
25 5 11 
26 4 1.5 2 
46 2 21 
Table 7-1: Volumes of synovial fluid (mls) removed from each joint in 
matched group 
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Keratan sulphate and total 21yeosaminoglycans study 
The mean age of horses in the study was 17 year& but the sexes of the horses were not 
known. Results are expressed as KS (gg/ml), GAG (gg/ml), and KS: GAG ratio to allow 
for effects of synovial fluid volume. Values for equivalent joints from fore and hind legs 
were found to have the same median value and therefore were grouped together for 
analysis. 
There was good correlation between the KS and GAG values for each joint sampled e. g. 
for the metacarpophalangeal joints r=0.62. 
Results of total samples 
The results for KS, GAG and the KS: GAG ratio for all joints sampled are shown in Table 
7-2 and the variation of KS is shown in Figure 7- 1 
It is clear from these results that there were differences in the median value of KS and 
GAG between different joints. The median ratio between KS epitope and total GAG 
remained relatively constant in the metacarpophalangeal/metatarsophalangeal, 
tarsometatarsal, tarsocrural, femoropatellar, and antebrachiocarpal joints but it increased 
in the proximal interphalangeal and distal interphalangeal joints. 
Joint n KS gg/rril GAG gg/ml Ratio KS/GAG 
Metacarpo/tarsophalangeal 60 20.6(6.75) 79.7 (13.5) 0.25(0.05) 
Proximal interphalangeal 42 53.6(20.7) 151(35.8) 0.35(0.08) 
Distal Interphalangeal 25 144(28.4) 268(81.8) 0.47(0.09) 
Tarsornetatarsal 23 12.6(7.4) 57.9(30.4) 0.22(0.07) 
Tarsocrural 8 24.9(21.3) 142(31.8) 0.24(0.08) 
Femoropatellar 9 55.9(25.6) 210(63.3) 0.29(0.04) 
Antebrachiocarpal 11 33.7(10.3) 104(30.3) 0.22(0.08) 
Table 7-2: Median values plus semi interquartile ranges for all joints 
sampled 
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Figure 7-3: Variation of KS (5D4) plus median value in all joints 
Key: MCP = metacarpophalangeal, PIP = proximal interphalangeal, DIP = distal 
interphalangeal, TMT = tarsometatarsal, TC = tarsocrural, FP = femoropatellar, ABC 
antebrachiocarpal joint. 
Variation between metacarpophalangeal, proximal interphalangeal and 
distal interphalangeal joints. 
The variation between metacarpophalangeal, proximal interphalangeal and distal 
interphalangeal joints was investigated in a group of 11 horses, mean age 17.2 years, in 
which each of these three joints had been sampled in each horse. The results are shown in 
Figures 7-4a and b, and from these it can be seen that there were highly significant 
differences between KS and GAG levels and the KS: GAG ratio for each of the 3 joints 
with all three parameters increasing in median value from metacarpophalangeal to 
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Figure 7.4a: Variation in KS SF concentration between normal matched 
joints 
For abbreviations see Figure 7-3 
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Figure 7-4b: Variation in GAG SF concentration between normal matched 
joints 
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Figure 7-4c: Median KS and GAG plus semi-interquartile range in normal 
matched joints. 
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Figure 7-5a: Variation in KS : GAG ratio between normal matched joints 
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Figure 7-5b: Median KS: GAG ratios plus semi - interquartile ranges in 
normal matched joints. 
For abbreviations see Figure 7-3 
- - 
KS GAG Ratio 
MCP - PIP F- v alue 
- 
0.001 0.001 0.007 
MCP - DIP F value 0.001 0.001 0.001 
PIP - DIP P-value 0.003 0.001 10.01 
Table 7-3: Significance values for differences between matched joints 
For abbreviations see Figure 7-3 
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Variation between other joints sampled. 
The samples from the tarsometatarsal, tarsocrural, femoropatellar, and antebrachiocarpal 
joints were not matched and therefore accurate statistical analysis could not be carried out. 
However, although there were differences in KS and GAG values for these different 
joints, the ratios between these 2 measurements were nearly constant (Table 7-2) and 
similar to that of the metacarpophalangeal joints. 
Variation with age 
No significant changes were found between KS or GAG levels and age in any joint 
(Fig 7-6). 
80- - 
Age groups 1= 0- 5 
2= 6- 10 
70- - 3=11-15 
4= 16-20 
60- - 5=21-25 
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Figure 7-6: Variation of SF KS in MCP joint with age 
r= -0.33 95%CI = -0.53 - 0.04 p=0.08 
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Other markers measured 
Marker MCP PIP DIP 
KS gg/ml Median (SIQR) 19.92 (10.97) 65.62 (40.78) 144.09 (63.59) 
Range 10.24 - 76.89 15.45 - 195.80 77.59 - 272.70 
GAG gg/rnl Median (SIQR) 79.21 (22.78) 165.99 (57.84) 255.62(156.92) 
Range 65.09 - 275.44 117.85- 478.78 160.45 - 505.97 
COMP gghril Median (SIQR) 7.61(l. 65) 11.33 (4.74) 22.55 (6.09) 
Range 4.47- 13.88 5.29-27.64 13.39 - 53.29 
BAP Units Median (SIQR) 4.09(l. 15) 4.94(l. 09) 4.80(l. 18) 
Range 2.18-5.96 3.76-23.79 2.23-12.79 
HA gghnl Median (SIQR) 1177(238) 926(247) 767(160) 
Range 578-2309 612-1914 371-1785 
Table 7-4: Summary of normal synovial fluid marker levels and ranges 
reported in this study 
Abbreviations: HA = hyaluronan, COMP = cartilage oligorneric matrix protein, KS 
keratan sulphate (5D4 epitope), GAG = total glycosarninoglycans, 
BAP = bone specific alkaline phosphatase, SIQR = semi interquartile range 
The synovial fluid samples assayed in these studies were taken from the same matched 
MCP, PIP, and DIP joints from the group of 11 horses used in the KS and GAG study. 
However because of lack of volume of some samples, the HA and the BAP studies only 
included samples from 10 of the 11 horses, thus altering the mean age of horses in the 
latter group to 17.6 years. 
Cartilage oligorneric matrix protein 
The median and range of COMP concentrations found in each joint are given in Table 
7-4. There was a significant difference in SF concentration of CONT concentration 
between all joints, 
i. e. MCPTIP p=0.002, MCP: DIP p=0.001, 
and PIP: DIP p'= 0.014. ( Figures 7-7a and b). 
The differences in total COMP between the MCP and PIP and between the PIP and DIP 
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Figure 7-7a: Variation of SF COMP concentration in matched normal 
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Figure 7-7b : Variation in median SF COMP concentration (plus semi 
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Figure 7-7c : Total gg COMP in SF from MCP, PIP, and DIP joints 
There was a positive correlation between SF CONT and grouped age in the PIP joint 
(r, = 0.82,95%CI = 0.42 - 0.95, p=0.002) (Figure 7-7d), but not in the other joints, 
although the COMP concentrations in the DIP joint did show a positive but not significant 












Age gr oups 
Figure 7-7d : Correlation between SF COMP in PIP joints and grouped 
age. 
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Bone specific alkaline phosphatase 
The median and range of values of SF BAP are shown in Table 7-4. The difference 
between SF concentrations in the MCP and PIP joint only just reached significance 
(p--0.048) as did the difference between the MCP and DEP joint (p=0.037). 
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Figure 7-8b: Median (+ semi interquartile range) SF BAP concentration in 
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Joints 
Figure 7-8c: Total BAP (units) in MCP, PIP, and DIP joints 
There was a significant difference (p=0.002) (Figure 7-8c) between the total BAP in the 
MCP and that in the DIP joint. 




A significant difference was found between the synovial fluid from the MCP and PIP 
joints (p=0.02), and between the MCP and DIP joints (p=0.006). There was no 
significant difference between the concentration of HA in the PEP and DIP joints although 
in 8 out of the 10 pairs of joints sampled the HA concentration in the DIP joint was lower 
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Figure 7-9a: Concentration of HASIT in normal matched equine MCP, PIP, 
and DIP joints. 
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Figure 7-9b: Variation between median values (plus semi-interquartile 
range) of HASF in normal matched joints. 
There was a positive but not significant correlation between' HASF and grouped age in the 
MCP joint (r = 0.58,95%CI = -0.08 - 0.89, p=0.08) but no correlation between HA 
concentration and age in the other joints. 
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Serum - Diurnal rhythm 
Horse Breed Age Sex Weight 
1 Arab 15 F 450kg 
2 TB 20 F 500kg 
3 TB 10 F 450kg 
4 Polish pony 6 F 450kg 
5 TBx 4 NIn 450kg 
6 Belgian Warmblood 6 Nb 550kg 
Table 7-5: Age distribution and breeds of horses used in HA diurnal 
rhythm study. 
Horse 123456 
Man 0.23 4.69 1.51 2.17 1.04 0.37 
AgInil 
SIQR 0.04 0.19 0.09 0.14 0.08 0.02 
Range 0.19-0.37 4.27-5.63 1.22-1.82 1.93-2.59 0.88-1.46 0.33-0.46 
Table 7-6: Median values and range of serum HA concentration in 
different horses 
There was no correlation between median serum HA concentration and age in this group 
of horses. 
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Figure 7-10b: Logarithmic transformation of diurnal plasma HA 
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Figure 7-11a: Variation in median z scores for all six horses, plus semi 












Figure 7-11b: Variation in median z scores plus semi interquartile range 
throughout day for each horse 
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Although there was a large range in the normal concentration of serum HA between 
horses, (0.25gg/ml - 4.75gg/ml) statistical analysis of the z-scores (value of fluctuation 
from the mean ) for each horse and each time point showed no significant differences. 
The Friedman repeated measures statistic comparing Z scores at different time points was 
not significant , p=0.83, indicating that there was no significant fluctuation in HA 
concentration between different time points (Figure 7-11 a) . Comparison of the 
fluctuation throughout the day between different horses was also not significant, the 
Friedman statistic being not significant at p=0.36 (Figure 7-1 lb). The mean coefficient 
of variation of all six horses was 13.7%. Therefore there appears to be no diumal rhythm 
in the concentration of serum HA in the horse. 
Discussion 
Keratan sulphate and total glyCosaminoglycans 
In this study the monoclonal antibody 5D4 was used as an indicator of keratan sulphate in 
the synovial fluid. The highly sulphated epitope ( also known as 5D4 ), which occurs in 
KS chains of greatest length and highest charge density, is antigenic to 5D4 (Caterson et 
al. 1989). The assay used therefore provides not a value for the number or mass of KS 
chains, but a quantity of these oversulphated sequences. This quantity is influenced by the 
structural presentation of the antigen, the chain length, and the degree of sulphation 
(Caterson et al. 1989; Mehmet et al. 1986; Poole et al. 1987; Seibel 1989) and these 
factors vary in KS from different tissues and different individuals (Hardingham et al. 
1990; Hascall et al. 1987; Stuhlsatz et al. 1989). 
In human cartilage KS chains are found to increase in number and length with increasing 
age up to maturity (Bayliss 1991; Stockwell 1989). No such differences have been found 
in bovine cartilage and no age related changes were found in this study. The majority of 
horses in this study (80%) were adult i. e. between 8 and 30 years old, and therefore 
changes occurring in the earlier years remains a possibility. 
The data reported in this study show that there are differences in the KS and GAG levels 
between all the joints sampled. There are significant differences in the KS: GAG ratio 
between the distal limb joints i. e. metacarpophalangeal/metatarsophalangeal, proximal 
interphalangeal, and distal interphalangeal joints, but not between the 
metacarpophalangeal/metatarsophalangeaI and the other joints sampled. These results have 
important implications in 2 main areas. The first is in the development of this epitope as a 
176 
marker of cartilage turnover and its potential use in the assessment of osteoarthritis. In 
human osteoarthritis (Sweet et al. 1988; Thonar et al. 1985; Thonar et al. 1992) and in 
equine studies (Alwan et al. 1990), the measurement of serum levels of KS(5D4) has 
been found to be useful in the assessment of cartilage turnover. However, in view of the 
differences found in equine synovial fluid levels of KS (5D4) in different joints, the use 
of KS(5D4) as a serum marker of osteoarthritis in the horse needs to be re-evaluated. If 
the change in synovial fluid concentration of KS (5D4) is used as the only indicator of 
altered joint condition, the difference in normal levels between different joints in the horse 
and the higher levels in the distal limb joints must be appreciated. The ratio between KS 
(5D4) and total GAG may be a better parameter to use, since this remains at a more 
constant level in all joints measured except the proximal interphalangeal and distal 
interphalangeal joint. 
The second major implication is the significance of the variation in the levels of epitope in 
synovial fluid from different joints of the horse with regard to the metabolism of articular 
cartilage that may be occurring within these joints. There are many reasons that could 
account for these differences but their relative importance is unclear. They may be caused 
by 1) differing amounts of KS in the cartilage, or 2) differing proportions of 5D4 on the 
KS chains. The concentration of KS or total GAG in a joint could be affected by factors 
such as synovial fluid volume or cartilage mass, but these parameters in themselves are 
unlikely to affect the ratio of 5D4 epitope to total GAG, which is clearly seen to alter 
between the three distal limb joints. No evidence for selective degradation or selective 
clearance of KS from joints could be found in the literature. 
The differences in synovial fluid analysis, reported here, provide strong evidence for an 
alteration in the metabolism between these joints, resulting in an increased level of KS, or 
expression of 5D4 epitope, in the cartilage of the proximal interphalangeal and distal 
interphalangeal joints. Evidence for environmental changes i. e. pH, oxygen, loading and 
m overnent of the joint having an effect on the selective expression of certain GAGs has 
been described (Bayliss 1991; Stockwell 1989) . For example, cartilage thickness has an 
effect on KS concentration, with higher levels being found in the deep regions of thicker 
cartilage, and those areas with decreased hydration and oxygenation. Ifigher proportions 
of KS are also found in weight bearing areas of cartilage. It could be, therefore, that 
environmental factors are relevant to the observed differences in KS : GAG ratio. 
It is clear from the data presented that considerably more investigation is necessary in 
order to reach satisfactory explanations for these findings, especially with respect to the 
particular conditions existing within these joints. 
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Other markers measured 
Cartilage oligomeric matrix protein 
The changes reported here could be a factor of synovial fluid volume, which is largest in 
the MCP joint but decreases in the PIP and DIP joint. When compared to KS and GAG 
concentrations in the same joints (data not shown), there are no significant changes in the 
COMIP: GAG or CONT: KS ratios between joints. The differences in CONT 
concentration are more likely to be correlated with mass of cartilage (See Chapter 10) - 
when the concentration is multiplied by the volume to provide the total amount of COMT 
present in the SF, the distribution is similar to that of cartilage mass differences in these 
same joints. 
Bone specific- alkaline --phosphatase There were no significant differences found in the SF from these joints. When the total 
units of BAP in the different joints was calculated however, there was a significant 
difference (p=0.002) between the MCP and DIP joint. This distribution cannot be 
connected to synovial fluid volume or cartilage mass, understandably, and the reason for 
this difference is not understood. 
Hialuronan 
Synovial fluid 
The trend in reduction of HA concentration from the MCP to the PIP and then to the DIP 
joint is in opposition to the changes found in the levels of KS: GAG and COMP. These 
changes cannot be related to synovial fluid alone since the volume of synovial fluid 
possible to remove on arthrocentesis was greatest in the MCP joint and decreased in the 
PIP and DIP joints. Synovial fluid removed from the MCP joints was always more 
viscous than that from the PIP and DIP joints so this result could have been expected. 
Viscosity is a function of both the concentration and the molecular weight of the 
hyaluronan. The concentration of any marker within a joint is related to the rate of 
synthesis, degradation, and mobilisation of the marker from that joint. There is no 
evidence for differences between the rates of synthesis and degradation in different joints, 
but since the rate of clearance will be affected by molecular size, it is possible that larger 
molecular weight chains are cleared to the lymphatics more slowly and therefore result in 
an increased concentration of the molecule within the joint. It has been shown that the 
turnover of HA in the carpal joints is more rapid than that in the MCP joints and this 
finding has been attributed to workload of the joint, range of motion, vascularisation and 
anatomy of the synovial membrane (Lindholm et al. 1996). There is also evidence for 
more rapid metabolism in smaller joints (Ekman et al. 198 1). It seems likely therefore that 
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on or a combination of these factors is the reason for the synovial fluid differences 
detected here. 
Correlation between COMP, BAP, and HA with age in the SF. 
There was a significant correlation between CONT and age in the PIP joint only. There 
was no correlation between SF BAP and age in any joint. Apart from a trend towards 
significant correlation between HA and age -in the MCP joint, no other significant 
correlations were found. It is known that the concentration of HA in cartilage increases 
with age (Holmes et al. 1988) but release of HA from the cartilage is only of minor 
importance to the SF content (Hedin et al. 199 1) so it is unlikely that this would affect any 
possible correlation. It seems that in this study there were too few horses with too small 
an age range to make any firm conclusions. 
It appears that although the reasons for the differences in marker concentrations between 
these joints remains unclear, the fact remains that differences do exist, and these must be 
taken into account when interpreting marker concentrations. The range of normal values 
for all the markers identified here will serve as an essential baseline from which to 
compare changes in the OA joint. 
HA Diurnal rhythm 
Unlike previous findings in man and rat there appeared to be no evidence of diumal 
rhythm in the horse. In man the increased levels of serum HA occuring following 
morning rising are believed to be due to increased mobilisation of HA from the joints after 
a period of rest. The behaviour of horses, sleeping only for short periods and often in the 
standing position may preclude this effect. It was possible that the disturbance of the 
horses in order to take the blood samples on each occasion may have affected the results, 
but apart from keeping the animals stabled there was no other way to reduce movement 
practically. The large range of values found in each horse during a 24 hour period, plus 
the large range of values between normal horses, implies the need for caution when 
interpreting serum HA levels. One horse (2) had a much higher serum level. This was the 
eldest horse in the group, and serum HA is known to relate to age (Tularno et al. 1990). 
With age, more HA of lower molecular weight (MW) is synthesised, and since the liver 
has an affinity for higher MW molecules, these lower MW HA remain in the circulation 
longer thus increasing the concentration (Tengblad et al. 1986). It is also known that even 
light walking can affect the serum HA (Tulamo et al. 1990), however there was no 
correlation in this study between the HA levels and the more active horses. 
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Summary 
1. A normal range of values for KS, GAG, HA, COMP and BAP in equine synovial 
fluid and for HA in serum has been established. Differences in the normal concentration 
of KS, GAG, and more importantly the KS: GAG ratio, HA, and CONP have been 
demonstrated in different equine joints. 
2. The variation of these markers with age remains inconclusive. 
3. A normal range of HA in equine serum has been established, and found vary widely 
between horses. 
4. There does not appear to be a diurnal rhythm of serum HA in the horse. 
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Chapter Eight 
Biochendcal markers in osteoarthritis : 
Cross-sectional studies 
Introduction 
The background to the markers measured here is detailed in Chapter 7. Having 
investigated the ranges and variations of these biochemical markers in normal joints, in 
this chapter the changes in these markers which occur in osteoarthritis (OA) are explored. 
1. Serum markers 
In human studies the level of serum hyaluronan (HAS) has been found to con-elate with 
the radiographic OA score in the knee (Campion et al. 1991) and with clinical joint 
symptoms (Takei et al. 1996). In OA in man HAS has been found in increased levels 
(Campion et al. 199 1), and it has also been shown to be predictive of OA progression 
(Sharif et al. 1995). However, results from an equine study indicated that there i's a large 
range of normal values for HAS between horses and serum levels can be affected by 
even mild exercise (Tulamo et al. 1990). In both horse and man HAS correlates positively 
with age (Campion et al. 199 1; Tulamo et al. 1990). No diurnal rhythm has been found in 
the horse (Chapter 7). 
2. Synovial fluid markers 
Synovial fluid hyaluronan (HASF) has been reported to be lower in equine OA joints 
when compared to normal controls (Hilbert et al. 1984). No correlation has been detected 
between HASF and the degree of lameness (Tulamo, et al. 1994) but a negative correlation 
has been reported between articular cartilage damage and the HASF concentration 
(Tulamo et al. 1996). The 5D4 epitope of keratan sulphate (KS (5D4)) is lower in equine 
OA joints (Todhunter et al. 1997) than in normal controls and can be affected by breed 
and gender of horse. Total glycosaminoglycans (GAG) has been reported to be higher in 
OA joints when compared to normal controls in animals (Alwan et al. 199 1; Arican et al. 
1994) and in man (Saxne et al. 1987). No correlation has been detected between GAG 
and articular cartilage damage (Tulamo et al. 1996). 
In a canine study bone specific alkaline phosphatase (BAP) was found to be increased in 
actively OA stifle joints when compared to the contralateral joint but no correlations were 
found between BAP concentration and background variables (Innes 1997). 
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Since the degeneration of articular cartilage has long been accepted as the pivotal 
diagnostic feature of OA, correlation between the degree of cartilage damage and the 
change in concentration of any biochemical marker from normal, in serum or synovial 
fluid (SF) will obviously give criterion validity to that marker. Arthroscopy, although 
more invasive than radiography or magnetic resonance imaging, allows direct 
visualisation of the cartilage, and various methods of scoring the degree of damage have 
been described. Many have not been accepted because of their complex nature, especially 
regarding the number of cartilage locations assessed, the determination of cartilage lesion 
diameter, and the often poor definition of depth criteria. A suitable system must be simple 
enough to be highly reproducible both intra and inter-observers., and grading decisions 
should be unambiguous and objective (Marshall 1996). Ayral (Ayral et al. 1996) found 
global arthroscopy scoring using a visual analogue scale to correlate well with the Societe 
Francaise d'Arthroscopie grading system -a composite index accounting for depth, size, 
and localisation of cartilage lesions, thereby suggesting good intrinsic validity of the 
arthroscopic variables. The arthroscopy score correlated well with radiographic variables. 
Intra. -observer variation was good, and better than the variation inter-observer. 
Longitudinal change in score correlated significantly with functional changes. In 1996, 
Ratcliffe et al (Ratcliffe et al. 1996) reported that in an arthroscopic study of the 
glenoliumeral joint in man, using a global grading scheme, measurement of GAG, KS, 
and 3B3(-) correlated well with the arthroscopic diagnosis of OA. Most scoring systems 
in the veterinary literature rely on the increase percentage loss of cartilage in the joint 
without taking account of the localisation of lesions (McIlwraith et al. 1987) (Tulamo et 
al. 1996). Results from the veterinary studies have been variable. In one study comparing 
arthroscopy and radiology in assessment of carpal OA (Kannegieter et al. 1990) 
correlation between the two measurements was poor, while in another study radiological 
changes in subchondral bone were found to corTelate well with arthroscopic findings 
(Steinheimer et al. 1995). The degree of cartilage damage in the joint has been reported to 
correlate negatively with the HASF concentration (Tulamo et al. 1996) in the horse. 
Once the criterion validity and normal range of a marker have been assessed, any variation 
of that marker with background variable e. g. age, duration of OA, and exercise must be 
established to allow meaningful interpretation of changes in marker levels in disease 
states. In chapter 7, the variation of normal marker levels with age was investigated but 
without conclusive results. In this chapter, correlation between markers and age and 
duration of OA will be re-examined. 
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Aims 
1. To investigate the cross-sectional differences existing between biochemical markers in 
normal and OA synovial fluid and serum in two different populations of horses with 
early, and later stage, OA. 
2. To ascertain whether any relationship exists between the markers and the level of 
articular cartilage damage in the joint. 
3. To investigate the correlations between markers and background variables. 
Methods 
During this study, synovial fluid and serum samples were collected from three different 
groups of horses. The first group was a sample of Thoroughbred racehorses in training, 
which underwent arthroscopic exan-dnation of their carpal joints after short periods of 
lameness. The second group were horses diagnosed with OA after referral to the 
Department of Clinical Veterinary Science, University of Bristol. The third group was the 
selection of 20 horses recruited to the CaPPS clinical trial. The second and third groups, 
being of similar types and duration of OA, were grouped together for analysis. 
I. Arthroscopi cases 
Twentytwo horses, the majority of which were Thoroughbreds in racing training 
underwent arthroscopic examination of their carpal joints following recent onset 
lameness. In each case the degree of cartilage damage in each joint was scored, by the 
same observer in each case, according to a scale adapted from that used by McIlwraith 
(McEwraith et al. 1987) (Table 8-1). Synovial fluid, from both the clinically affected and 
the contralateral joint, and serum samples were collected at the time of surgery, while the 
horses were under anaesthesia. These samples were processed for storage and analysis as 
described in Chapter 7. Normal serum controls used in this study were taken from 15 
racehorses in training which showed no clinical signs of lameness. 
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Score Degree of articular cartilage damage 
0 Normal * 
I Minimal articular cartilage degeneration. 
2 Articular cartilage degeneration affecting up to 30% of the articular surface of 
the bone. 
3 Loss of up to 50 % of the articular cartilage from the affected carpal bone. 
4 Severe loss of cartilage affecting more than 50% of the articular surface. 
Table 8-1: Scoring system used for the assessment of degree of cartilage 
damage 
Hyaluronan ( HA) was measured in all serum samples, and HA, 5D4 epitope of keratan 
sulphate (KS (5D4)), total glycosaminoglycans ( GAG) and bone specific alkaline 
phosphatase (BAP) was measured in all SF samples. Assay methods are described in 
Chapter 7. 
2. OA cases 
Samples of serum and SF were collected from horses for which the cause of lameness 
had been diagnosed as OA. Diagnosis of OA was made as described in Chapter 2 i. e. by a 
combination of clinical examination, intra-articular analgesia, radiography, and in some 
cases scintigraphy. Included in this cohort were the horses recruited for the CaPPs trial, 
from which the samples collected at their first examination were included in the cross- 
sectional marker investigation. Normal synovial fluid samples used for controls in this 
study were those used in the study of normal joint variation (Chapter 7). Normal serum 
controls were from the six horses used in the diurnal rhythm study (Chapter 7) and from 
four other horses resident in the Department of Clinical Science which showed no clinical 
signs of locomotor disease. HAS and HASF, KS(5D4), GAG, and BAP were measured 
in all samples. 
Statistics 
Distribution of markers were found to be skewed, even after logarithmic transformation, 
so for statistical analysis, nonparametric methods were used. In comparison of markers in 
paired joints in the arthroscopy group, Wilcoxon signed rank tests were used. For 
comparison of different groups the Mann Whitney U test was used, and correlations were 
made using the Spearmans correlation coefficient (r). Values were considered significant 
at or below 0.05, and confidence intervals were stated at 95%. 
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esults 
1- Arthroscopy data 
Out of 22 horses which underwent bilateral arthroscopic examinations, paired synovial 
fluid samples were available from 19 cases. Serum was available from 15 of these cases. 
The mean age of the horses in this group was 3.6 years and the duration of lameness in 
any case did not exceed 3 months. 17/22 horses were Thoroughbreds in racing training. 
Of the 22 pairs of joints examined, 15 were midcarpal (MC), 4 were antebrachiocarpal 
(ABC), and 3 were metacarpophalangeal (MCP) (Table 8-2). 
Case Age Breed Joint Left score Right score 
1 ? ? MC 1 1 
3 2 TB MC 2 1 
4 9 Amb MCP 0 2 
5 4 TB MCP 0 2 
6 ? Hunter ABC 2 0 
7 3 TB MC 2 1 
8 7 TBX ABC 1 0 
10 4 TB MC 2 1 
14 2 TB MC 3 1 
15 2 TB MC 1 2 
16 4 TB MC 3 1 
17 2 TB ABC 2 1 
18 2 TB MC 2 1 
19 2 TB MC 2 1 
20 ? TB MC 1 3 
21 ? TB MCP 1 0 
22 5 TB MC 3 0 
23 ? TB MC 0 0 
24 3 TB MC 1 0 
25 3 TB MC 0 3 
28 13 Conn ABC 3 0 
29 4 TB mc 3 0 
Table 8-2: Arthroscopy cases with scores of cartilage damage. 
Abbreviations: 
TB = Thoroughbred, TBX = Thoroughbred Cross, Conn = Connemara MC = midcarpal, ABC = antebrachiocarpal, MCP = metacarpophalangeal 
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Synovial fluid markers 
a ffialuronan 
Paired samples from 18 cases were analysed for HA. The median HA concentration plus 
the serni interquartile range (SIQR) in clinically active joints was 741.6 Rg/n-d (222) and 








Clinically active Contralateral 
Figure 8-1: Comparison of HASF concentration between paired clinically 
active and contralateral joints in arthroscopy group. 
The red line indicates the median values. 
There was a significant increase in HASF concentration from the clinically active OA to 
the contralateral joint ,p=0.0 1, (Mann Whitney -U test) 
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Clinically active Contralateral 
Figure 8-2: Comparison of BAP concentration in clinically active OA and 
contralateral joints. 
The red line indicates the median values. 
The median (SIQR) concentration of BAP in clinically active OA joints was 21.75 (6-22) 
units and in the contralateral joints was 12.35 (4.07) units. The difference between the 
joints was significant, p=0.002 (Wilcoxon signed rank ). 
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Figure 8-3: Cross sectional comparison of KS in matched joints. 
The red line indicated the median values. 
The median KS(5D4) concentration in clinically active joints was 8.79 (1.96) ýLg/ml, 
while the median KS concentration in the contralateral joint was 16.39 (5.65) Rg/ml. 
This was a significant increase from the clinically active to the contralateral joint, 
p=0.001 (Wilcoxon signed rank). 
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Clinically active Contralateral 




















Figure 8-4: Comparison of GAG concentration in paired clinically active 
OA and contralateral joints. 
The red line indicates the median values. 
The median GAG concentration in clinically active joints was 46.85 (14.24) gg/mI while 
the median concentration in contralateral joints was 45.22 (9.2 1) ýtg/ml. There was no 
significant difference between paired joints. 
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Clinically active Contralateral 
Figure 8-5: Comparison of KS: GAG ratio in paired clinically active OA 
and contralateral joints. 
The red line indicated the median values. 
There was a significant increase in KS: GAG ratio from the clinically active OA joints , in 
which the median ratio (SIQR) = 0.198 (0.04) to the contralateral, median = 0.309 
(0.102), p=0.002 (Wilcoxon signed rank) 
There was no correlation between the clinically active and the contralateral joint for 




fluid markers with cartilage damage 
Marker HA BAP KS - GAG KS: GAG 
Ratio 
Correlation -0.25 0.57 -0.57 -0.016 -0.49 
95%CI -0.53,0.08 0.31,0.75 -0.75,0.29 -0.34, - 0.31 -0.7,0.19 
p-value 0.13 0.0001 0.0002 0.92 0.002 
Table 8-3: Correlation (Spearmans) between marker concentrations and 
severity scoring of articular cartilage 
From Table 8-3 it can be seen that the synovial fluid concentration of BAP was positively 
correlated, and the KS, and the KS: GAG ratio were negatively correlated to the degree of 
cartilage damage within the joint. 
Serum markers 
Hy-aluronan 
The median (SIQR) concentration of HAS in the arthroscopy cases was 0.18 (0.06) 
gghnI and the median (SIQR) in the 15 normal control horses was 0.34 (0.05) gg/nil 
which was significantly higher, p=0.001 (Mann Whitney). 
There was no correlation between the SF and serum concentrations of HA. 
There was no correlation between HAS and the arthroscopy score for active or 
contralateral joints. 
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2. OA cases 
Case No Age 
(years) 
Sex Breed Duration 
(months) 
Joint 
15 m TB-X 12 MCP 
2 12 m H 12 FP 
3 4 m ? 3 MCP 
4 7 m TB 3 MCP 
5 4 F TB 2 FP 
6 10 m H 5 DIP 
7 9 m TB 6 MCP 
8 7 m TB 2 MCP 
9 14 m H 7 TNff 
10 9 F H 4 TNT 
11 9 m TB 8 Tmr 
12 5 m TB 3 mc 
13 7 m LAT 6 Tmr 
14 ? F WBD 5 PIP 
15 12 m TB 3 MCP 
16 9 m WBD 8 TC 
19 12 F TBX 12 mc 
20 13 m ID 7 MCP 
21 17 m TBX 6 DIP 
25 13 m VvrBD 1 MCP 
26 5 F TB 5 Tmr 
29 8 m TB 19 MCP 
30 5 F Arab 8 PIP 
33 13 m WCob 3 DIT 
35 9 F TBX 4 ABC 
36 3 m IDTB 1.5 GH 
37 11 m IDX I TC 
39 16 m TB 3 DIP 
41 9 F Arab 9 CmC 
Table 8-4: Demographic variables of clinical OA cases 
Abbreviations: 
TB = thoroughbred, TBX = Thoroughbred Cross, ID = Irish Draught, H= hunter, 
WCob = Welsh Cob, WBD = warmblood, LAT = Latvian 
MCP = metacarpophalangeal joint, PEP = proximal interphalangeal joint, DIP = distal 
interphalangeal joint, TMT = tarsometatarsal joint, DIT = distal intertarsal joint, ABC 
antebrachiocarpal joint, MC = midcarpal joint, CMC = carpornetacarpal joint, TC 
tarsocrural joint, FP = femoropatellar joint, GH =glenohumeral joint. 
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From referred lameness cases 29 osteoaffluitic horses were diagnosed (Table 8-4). The 
mean age of this group was 9.5 years (range 3- 16 years) and the mean duration 
lameness was 5.7 months (range =1- 19 months). These horses were of mixed breeds, 
but 15/29 were Thoroughbred or Thoroughbred cross. Joints affected were also mixed, 
including 9/29 MCP, 5/29 TMT and 3/29 DIP joints. In most cases synovial fluid 
samples were only available from the clinically active OA joint. The results from these 
cases were combined with the baseline data from the CaPPS cohort for cross-sectional 
analysis. This combination resulted in a total number of 44 cases, of median age 9 years 
and median duration of lameness 4.5 months. 
The concentrations of HAS, and HASF, KS(5D4), GAG and BAP were measured. The 
median HAS in this group was 0.32 (0.10) gg/ml. The SF marker results are shown in 
Table 8-5. 
Marker AH joints MCP PIP 51P TNTF mc 
KS Median 18.43 15.38 28.82 26336 13.3 18.17 
llghnl SIQR (8.01) (3.62) (10.05) (9.17) (7.19) (4.25) 
n 41 10 5 9 8 3 
Range 1.14- 3.58- 4.52- 7.07- 1.14- 9.69. - 
69.23 25.11 69.23 49.28 34.71 26.71 
GAG Median 56.08 46.56 121.76 72.36 48.69 46.14 
gghrd SIQR (21.66) (16.78) (20.14) (26.74) (17.10) (15.81) 
n 40 10 5 9 8 3 
Range 3.32- 32.75- 9.34- 3.32- 7.34- 3.41- 
182.37 79.43 182.37 121.62 83.54 66.67 
BAP Median 8.53 5.51 -20.64 5.58 10.07 9.12 
Units SIQR (4.26) (2.54) (9.47) (2.88) (5.14) (2.13) 
n 32 5 5 9 7 3 
Range 0.65- 3.36- 3.87- 0.65 9.63- 4.83- 
28.46 14.77 26.87 13.97 28.46 13.35 
HA- SF Median 261.5 1040 179 141 40.77 1204 
gg/ml SIQR (407.47) (609.43) (87.49) (26.79) (40.14) (165.85) 
n 42 10 5 9 8 3 
Range 6.2- 272- 36- 74.3- 6.2- 701.6- 
1972 1972 1934 203 139.9 1365 
Table 8-5: Combined baseline SF marker concentrations from CaPPS and 
OA cases 
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Comparison of synovial fluid marker levels between OA cases and 
normals. 
Comparisons between OA and normal data for HA, KS, and GAG SF levels were made 
within joint types since it was already known (Chapter 7) that these normal marker levels 
varied between J oints. S ince there were no j oint differences in B AP levels, results for this 
marker from different joints were pooled for comparison. 
a) Hyaluronan 
The differences between HASF concentration in the MCP and PIP joints were not 
significant here, but the HASF concentration in the DIP joints was significantly lower 
than in the normal joints from this group of horses -p=0.0001 (Mann Whitney) (Figure 
8-6) 
The difference between these results and those from paired joints in the arthroscopy group 
might be because the population in the OA group was more variable. Despite the lack of 
significance the trend was similar. The low numbers of PIP joints affected in the OA 



















MCP PIP DIP 
Figure 8-6: Comparison of normal and OA HASF values in different joints 
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Figure 8-7: Cross-sectional comparison of KS(5D4) in different joints 
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Figure 8-9: Cross-sectional comparison of KS: GAG ratio in different 
joints 
Although the concentrations of KS and GAG tended to be lower in each OA joint when 
compared with normal controls (Figures 8-7,8-8.8-9), the differences were not always 
significant (Table 8-6). 
MCP PIP DIP 
Normal OA Normal OA Normal ýqA 
n 10 10 10 5 10 19 
HA 0.38 0.5 0.0001 
KS I NS 0.06 1 0.0002 GAG 1 -0.003 0.05 1 0.0002 
S. K. GAG 1 0.13 NS 1 0.08 
Table 8-6: Significance (Mann Whitney) of differences between OA (in OA 
group) and normal SF markers within different joints. 
p values of statistical significance are highlighted. NS = not significant 
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MCP DIP 










Figure 8-10: Cross-sectional comparison of BAP in OA and normal joints 
There was a significant increase between BAP in the SF nomial controls and OA joints 
p=0.002 (Mann Whitney). 
Cross sectional comparison of HA in serum 
The median HAS in the OA group was 0.32 gg/n-d compared to a median concentration of 
1.54 gg/n-d in the normal controls. 
This difference was very significant, p<0.000 1 (Mann Whitney). 
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Correlation between markers and background variables 
Marker concentrations in active OA joints and seruni were compared with background 
variables i. e. age and duration of OA. The only significant correlations were between 
baseline value of KS in SF and age, i. e. 
r. = 0.41 MCI = 0.1 - 0.64 p=0.009 
and between baseline HAS and age, i. e. 
r, = 0.45 95%CI = 0.048 - 0.73 p=0.026 
Difference between arthroscopy and OA populations 
Figure 8-11: Median BAP concentration in SF from different populations. 
Results indicated a difference between the arthroscopy and OA populations when 
compared to the normal controls (Fig 8-11). For this reason the overall levels of other 
markers measured were compared between these groups to see if a similar pattern was 














(MCP, PIP, DIP) 
joints 
Mean age 3.6 years 3.6 years 9 years 17 years 








Within groups p=0.01 P=0.005 
Between groups P=0.09 **p = NS 








Within groups P=0.002 P=0.002 











Within groups P=0.001 0.0001 
Between groups *p = 0.0002 **P = 0.0001 








Within groups p=NS 0.0001 













Within groups p=5.002 p=0.25 
Between groups 1 0.0001 1 **P = 0.25 
Table 8-7: Significance of differences between arthroscopy, OA, and 
normal populations for all markers (Mann Whitney). 
p values of statistical significance are highlighted . 
significance between active joints in different groups 
= significance of difference between normal controls in each group 
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From Table 8-7 it can be seen that there were significant differences between the 
arthroscopy and OA groups for levels of KS (5D4) as well as BAP concentrations in 
active and normal control joints. It is also interesting to note that when the results from the 
different joints are grouped together, the differences between the OA and normal controls 
are significant for every marker. 








0- 1 ff7i 1 Arthroscopy Arthroscopy OA group OA group group normal 
normal controls 
controls 
Figure 8-12: Cross-sectional comparison of HAS from normal, OA and 
arthroscopy cases 
There were significant differences between HAS in normal, artluoscopy and OA cases 
(Table 8-8) 
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Arthroscopy Normal controls OA group Normal 
group Arthroscopy n= 41 controls for 
n= 15 group OA group 
I n= 15 n= 10 
HAS gg/ml 0.18 (0.06) 0.35 (0.05) 0.32(0.10) 1.54(l. 41) 
Within groups p 0.001 p<0.0001 
Between groups p 0.0006 p<0.0001 
Table 8-8: Median values and significance (Mann Whitney - U) between 
normal, arthroscopy and OA serum HA. 
significance of difference between Arthroscopy and OA group 
= significance of difference between normal controls 
Discussion 
The clearly significant differences in HA, KS, KS: GAG ratio and BAP between active 
and contralateral joints in the arthroscopy samples indicate that these markers are useful in 
the cross-sectional assessment of OA in the horse. However the lack of significance 
between the OA and the normal controls in the OA group imply that without marker 
measurement in a paired inactive joint interpretation of results may be less clear. 
The lower concentrations of HA and KS and the increased levels of BAP in the SF of the 
OAjoint all agree with previously reported findings (Innes 1997; Todhunter et al. 1997; 
Tulamo et al. 1996) but the lack of significant difference in GAG levels does not (Alwan 
et al. 1991). Although differences between OA and normal joints were not always 
significant when compared within types of joint, the differences in marker levels in the 
OA joints followed the trends previously described. The lack of significance may have 
been caused by low numbers of some joints e. g. the PIP joint within the OA group, or by 
the differences in background variables between the OA joints and the normal control 
group used for comparison, in particular the median age for the OA and normal control 
group was unfortunately markedly different. 
HAS was significantly altered in both the arthroscopy and OA groups when compared to 
that from normal horses. However, unlike the situation in man where HAS is raised in 
OA (Campion et al. 1991) in this study HAS was lowered. The reason for this is not 
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understood. However the use of HAS as a reliable marker of OA in the horse must be 
approached with caution. No correlation between HASF and HAS could be found. The 
wide variation in normal values of HAS between horses has been reported (Chapter 7), 
and HAS been shown to be affected by exercise and by age (Tulamo, et al. 1996). In this 
study HAS was positively correlated with increasing age as was KS(5D4) in the SF. This 
has also been previously reported in human studies and is thought to be due to increased 
length and number of 5D4 epitopes on the KS chains. 
The correlation between arthroscopic score of cartilage damage and marker levels imparts 
further validity to the use of SF BAP and KS (5D4) in cross-sectional OA assessment. As 
noted in the introduction to this chapter, correlation between decreasing levels of KS 
(5D4) in the SF and increasing degrees of cartilage damage has previously been reported. 
However the positive correlation between SF BAP and articular cartilage degeneration is 
an unreported finding and demonstrates a link between changes in bone and articular 
cartilage in OA. 
Another interesting result from this study is the demonstration by marker measurement of 
clear differences between the arthroscopy and OA populations of horses. These two 
populations were chosen to provide cases of early and late stage OA , but no correlation 
between marker levels and duration of the disease was detected. Not only were there 
Significant differences between levels of BAP and KS in the arthroscopy and OA group 
active joints, but the levels of these markers in the arthroscopy contralateral joints and OA 
group normal control joints was also very significant. HAS levels were also lower in 
arthroscopy normal control horses when compared with the OA group normal controls. 
Correlation between SF KS and HAS and age of horses may be relevant here. The horses 
undergoing arthroscopic examination and their normal controls were all young (mean age 
3.6 years) while the OA group horses were older ( mean age 9 years) and their controls 
still older (mean age 17 years). This may account for the increase in HAS in the OA 
control group when compared with the younger arthroscopy population. It may also be 
the reason behind the higher level of KS(5D4) in the OA and OA controls when compared 
with the arthroscopy group. However the BAP concentrations were also significantly 
higher in both the arthroscopy active joints and the contralaterals than in the OA joints and 
normal control joints. No correlation could be found between BAP concentrations and 
age, duration of OA or type of joint. The joints included in the analysis of marker levels in 
the OA group were MCP, PIP, and DIP joints, while the majority of joints examined in 
the arthroscopy group were MC joints. Although no differences in normal BAP 
concentrations were found in different joints, investigations of normal variations did not 
include MC joints. 
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It should be remembered that the horses undergoing arthroscopic examination were in 
training and it is possible that differences in the use of the horses as well as the breeds 
involved may have been responsible for the reported marker differences. In one human 
study differences in serum KS between soccer players and runners was demonstrated 
(Roos et al. 1995) which was thought to be the effect of the different physical activity. It 
may also be that the articular cartilage pathology in the arthroscopy horses was different to 
that in the OA cases and may have been better classified as "traumatic arthritis" rather than 
early OA. In 1996 Tulamo reported (Tulamo et al. 1996) that HASF was higher in horses 
with acute traumatic arthritis than in those with OA, and although HASF showed no 
significant difference between the groups in this study, the alterations in the other markers 
could be because of a difference in the disease pathology. Synovial effusion was more 
common in the MC joints of the arthroscopy group than in the joints in OA group and this 
may have reduced concentrations of KS, but would have been unlikely to effect the 
KS: GAG ratio , or been the cause of the increase in the BAP concentration or alterations 
in the serum markers. This finding illustrates the point that as well as their potential as 
diagnostic aids in OA, biochemical markers provide information concerning the 
pathological events occurring within the joint in OA which helps in the understanding of 
the course of the disease. A panel of markers provides more useful information than one 
marker used in isolation, and an extension to this study should include the statistical 
analysis of the relationship between the markers studied here with allowance for the 
correlation with background variables. 
Summaa 
1. Concentrations of HASF, KS, KS: GAG, and BAP are all significantly different in OA 
compared to contralateral joints and are therefore useful as cross-sectional markers in OA. 
2. BAP, KS and the KS: GAG ratio show good correlation with articular cartilage 
pathology, which imparts criterion validity to these markers. 
3. HAS and KS (5D4) in SF are positively correlated with increasing age. 
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Chapter Nine 
Biochemical markers in osteoarthritis : 
Longitudinal studies and correlations 
Introduction 
The normal variations of synovial fluid (SF) and serum markers in osteoarthritis (OA) 
have been discussed in Chapters 7 and 8. In this chapter, temporal changes in the same 
markers will be described, in particular in relation to the use of these markers as measures 
of outcome as assessed in the Calcium pentosan polysulphate (CaPPS) trial. 
The common goals of the many scientists researching the use of biochemical markers 
include the ability to diagnose OA at an earlier stage in disease than by the traditionally 
accepted diagnostic imaging techniques, the differentiation of early and late stages of the 
disease, and the prediction of subsequent OA progression. Many cross-sectional studies 
investigating the use of these markers as diagnostic tools have been carried out, both in 
man and animals, and the results from these are promising. However the aim of finding 
markers capable of assessing longitudinal changes in OA and predicting progression of 
the disease requires prospective temporal studies, and very few have been reported in the 
literature. 
In 1994 Dahlberg and colleagues (Dahlberg et al. 1994) measured aggrecan, cartilage 
oligomeric matrix proýein (COMP), stromelysin, and TIMP-1 in SF samples obtained 
from human knee joints, directly following injury, and again 6 months and then 6 years 
later. The results were compared with those from samples from normal healthy 
volunteers. They showed that all markers increased significantly immediately following 
injury, but then fell to levels similar to reference controls. These results were in contrast 
to those reported by Lohmander el al, also in 1994 (Lohmander et al. 1994), which 
showed that levels of stromelysin, TRAP and proteoglycan in the knee SF rose 
significantly during the first day following injury, and then remained higher than controls. 
In canine studies of stifle OA (Innes 1997) the 5D4 epitope of keratan sulphate (KS(5D4)) 
dropped significantly 6 weeks following stifle surgery. No significant longitudinal 
changes were detected in hyaluronan (HA) or bone specific alkaline phosphatase (BAP). 
In one report of longitudinal SF marker measurements in the horse (Todhunter et al. 
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1993) KS(5D4) was measured in experimentally induced OA in ponies and was found to 
peak within 24 hours of surgery, but then fell. to, and remained at, normal reference 
values. 
The use of biocherrAcal markers has been explored as another potential method of 
outcome measurement in clinical trials, but as yet has not been validated for such use 
(Lequesne et al. 1994). Correlations between marker changes and other outcome 
measurements have frequently been made however in an attempt at validation. In 1996 
Fawthrop (Fawthrop et al. 1997) compared marker levels in two groups of patients 
classified as having progressive or non-progressive knee OA defted by radiological 
changes over a2 year time period. No significant differences were found between groups 
for levels of chondroitin sulphate (CS), KS, HA, or total glycosaminoglycans (GAG) in 
the SF. However in 1995, Sharif et al demonstrated the predictive value of both serum 
HA (HAS) (Sharif et al. 1995) and an increase in serum CONT (Sharif et al. 1995) in 
determining progressive OA of the knee, again classified by radiological change. HAS 
has also been found to correlate with knee radiography score and the general pattern of 
scintigraphic scan (Carnpion et al. 199 1). Serum COMP has been found to correlate with 
disease stage in OA (Lohmander et al. 1994) and more recently with scintigraphy scores 
(Petersson et al. 1998). In dogs, serum GAG was found to correlate with scintimetry 
indices and BAP correlated with radiographic osteophyte score (Innes 1997). However 
in a study by Belcher (Belcher et al. 1997) no correlations could be detected between 
radiographic scores and KS(5D4), GAG HA or 3B3 levels in the SF in knee OA. 
In order to validate a measure of outcome it should correlate with a known gold standard 
for the disease, which in the case of OA has traditionally been considered to be 
radiography. However in previous studies radiography has not proved to be a useful 
measure in chronic stages of OA and does not always correlate with other validated 
measures e. g. clinical changes (Dieppe et al. 1997). This may be because clinical and 
radiographic changes do not always occur in synchrony. In this study the clinical cohort 
were horses in various stages of chronic OA and the chosen gold standard measure of 
outcome was the global score of lameness improvement. Correlation of markers with this 
measure would therefore seem a more relevant method of validation. 
It is clear from the diversity of results reviewed that more longitudinal studies need to be 
undertaken before the temporal changes occurring in early through to late stage OA and 
their relevance to OA can be understood. It is likely that it will be the altering relationship 
between a panel of markers, rather than changes in one marker in isolation , that will 
ultimately be identified as useful in assessing OA progression. 
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Aims 
1. To investigate longitudinal changes in markers during the 9 month period of the trial. 
2. To assess validity of 
* 
markers by investigating correlations between marker changes 
and clinical outcome, scintigraphy, and radiography. 
I To investigate differences in outcome between the two treatment groups in the CaPPS 
trial. 
Methods 
The horses used for this study were those from the CaPPs trial. Only 14 horses had SF 
samples at sufficient time points for longitudinal analysis. For materials and methods see 
Chapter 4 for the trial design and Chapter 7 for marker assays. 
Statistical analysis. 
Horses were paired for analysis. Group comparisons of skewed data was by Wilcoxon 
matched pairs and of normally distributed data by Paired students t-test. Correlations were 
by Spearmans correlation coefficient where results were nonparametric i. e. SF samples 
and by the Pearsons correlation coefficient where results were parametric. Confidence 
intervals at 95% were stated and significance was accepted at 5%. For estimations of 
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For the demographic variables see Table 9- 1. 
Longitudinal SF samples were available from 14/19 horses on the CaPPS trial. These 
were matched for analysis as shown in Table 9- 1. Two horses in the low dose could not 
be matched (16 and 18), but data from these were included in baseline predictions and 
correlation analysis. There was no significant difference between the groups for age or 
duration of OA (Paired student t test). 
Synovial fluid markers 
a) Hyaluronan 
There was no significant difference between HA in SF between the high and low dose 
treatment groups at any sampling point (Wilcoxon signed rank) (Figures 9-1 a and b). 
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Figure 9-1a: Longitudinal variation in median HASF concentration in matched 
active and contralateral joints. 













Figure 9-1b: Longitudinal HASF concentration for all horses 


















Figure 9-2a : Longitudinal changes in median BAP concentrations. 
There was no significant difference between groups for BAP concentrations either at 
















Figure 9-2b: Longitudinal changes in BAP for all active joints. 
Median value = red line 
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Figure 9-5a : Longitudinal changes in median KS: GAG ratio in matched 
joints 
There were no significant differences between KS, GAG or KS: GAG ratio between the 














Figure 9-5b: Longitudinal changes in KS: GAG ratio for all horses, active OA, 
during trial. 
Median value = red line. 
There was no significant difference in KS: GAG ratio for any horse during the trial. 
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71-arKer C rrelation 
joints 
between clinically active and contralateral 
HA r=0.9 Cl = 0.83 - 0.95 p=<0.0001 
BAP r=0.72 CI = 0.26 - 0.91 p=0.005 
KS r=0.49 CI = 0.25 - 0.69 p=<0.0002 
GAG r=0.56 CI = 0.32 - 0.74 p=<0.0001 
KS: GAG r=0.37 CI = 0.12 - 0.59 p=<0.0046 
Table 9-2: Correlation of marker levels in paired joints (Spearmans 
correlation coefflcient). 
From Table 9-2 it can be seen that there was a significant correlation between clinically 
active and contralateral joints for each marker. Since this finding may imply a systemic 
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Figure 9-6: Correlation between HASF in clinically active and contralateral 
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Correlations between SF markers and clinical outcome. radiography and 
scintigraphy 
1. Clinical outcome 
There were no significant correlations between any SF markers and global score of 
lameness improvement. 
2. Radiography and scintigraphy 
Baseline HASF was significantly negatively correlated with both the scintigraphy global 
scan score and the radiography global score (Table 9-3). 
Increase in concentration of HA during the trial was also significantly correlated with 
decrease in activity index of the scintigraphic scans. Increase in the concentration of GAG 
in the SF during the trial was found to be correlated with increase in scintigraphic scan 
score but with decrease in the radiographic global score (Table 9-4). 
Serum marker studies 
Serum samples were available for analysis from all horses in the trial i. e. n=9 in the low 
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Figure 9-7: Longitudinal change in median HAS for high and low dose groups 
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1 
There was no significant difference in HAS between groups at any time point (Wilcoxon 
signed rank). 
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Figure 9-8: Longitudinal mean values of COMP 
The mean (SD) concentration of serum COMP in the low dose group was 1.47 (0.39) 
gg/ml at baseline and in the high dose group was 1.74 gg/ml at baseline. There was no 
significant difference between the high and low dose group for serum CONM 
concentration at any time point. 
Correlations of serum markers with backimound variables 
There was no correlation between serum CONIP and age or duration of OA. HAS 
however was positively correlated with age (see Chapter 8). 
There was no correlation between HAS and HASF in active joints. 
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Correlation serum marker data with clinical outcome. radiography and 
scintigraphy 
1- Clinical outcome, 
There was no significant correlation between baseline HAS levels and the global score of 
lameness improvement, nor was there any significant correlation between change in HAS 
or COMEP levels during the trial and global scores of lameness improvement. There was 
however a significant correlation between the baseline serum COMP concentration and the 
global score of outcome i. e. 
r, = -0.50 95%CI = -0.79 - -0.05, p=0.028 
Figure 9-9: Correlation between baseline serum COMP and global score of 
clinical improvement. 
Although the con-elation is not strong, it could indicate that baseline serum CONIP is 
predictive of clinical progression in OA. 
2. Radiougphy 
There was no significant correlation between HAS or CONIP levels and radiographic 
global scores, nor was there any significant correlation between change in these marker 
levels with change in radiography scores. 
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3. ScintigLaphy 
There was no significant correlation between HAS -or serum CONT, either atbaselineor 
in change during the trial, and scintigraphic global scores or scintimetry activity indices. 
Discussion 
No synovial fluid marker was found to correlate with clinical outcome which was the 
chosen "gold! ' standard measure of outcome in the trial although HASF was found to 
correlate with radiography and scintigraphy. 
No differences in outcome between the two treatment groups in the CaPPS trial were 
identified by the use of biochemical markers in this study. Although this may have been a 
true result, the potential for a Type H error, largely because of the low power of the 
study, has been discussed previously (Chapter 4). However there were also no significant 
temporal changes in any marker for all horses during the trial, indicating that in the stages 
of OA studied in this trial, none of the markers measured were able to identify any change 
in OA status. 
It was interesting to note that in this cohort of horses, unlike those in the arthroscopy 
group (Chapter 8) there were significant correlations between marker concentrations in the 
clinically active OA and the contralateral joints. This may have been because in many 
cases OA changes occurred bilaterally. It has been previously reported (Dahlberg et al. 
1994) that this finding may be because of increased weightbearing in the sound limb. It 
has also been suggested (Belcher et al. 1997) that this is because of a systemic effect. 
An important consequence of this is that caution should be employed when using a 
contralateral joint as a normal control . 
HASF at entry to the tdal was found to correlate, although weakly, with both the 
scintigraphy and the radiography global score. With the understanding that HASF is 
reduced in the OA joint compared to normal controls (Chapter 8), it is logical that a 
decrease in HASF concentration should indicate an increase in the global severity imaging 
scores. Change in the HASF during the trial coffelated more significantly, and negatively, 
with the change'in the scintimetry activity index. The correlation between an increase in 
activity in the subchondral bone and a decrease in HASF is an indication of a link 
between bone changes and turnover of HA within the joint. 
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No other SF markers measured at baseline were predictive of change as measured by 
other methods. Since the change in scintigraphic scan and radiographic scores were so 
small in these cases (Chapter 6), this is not surprising. The change in BAP and KS did 
not show any correlations with other measures but change in GAG concentration was 
positively correlated to scintigraphic but negatively correlated to radiographic scores. 
Correlation between serum GAG and scintimetry activity indices has previously been 
reported (Innes 1997) providing further evidence for a link between bone and cartilage 
turnover. However since scintigraphic and radiographic scores have been found to be 
correlated to each other (Chapter 6) it is difficult to understand why the correlation found 
here between GAG and radiographic score should be negative. In Chapter 8 cross- 
sectional differences between OA and normal joints for GAG were not significant and in 
Chapter 6 change in radiography score during the trial period was minimal. In view of 
these findings, interpretation of these correlations has to remain inconclusive. 
No SF marker was found to correlate with clinical outcome which was the chosen "gold" 
standard measure of outcome in the CaPPS trial. However, all the horses in the trial had 
OA of more than 3 months duration and it may be that in this chronic condition, none of 
the markers measured here could demonstrate significant change. 
HAS did not correlate with any other outcome measure, unlike in man where it has been 
found to be predictive of OA progression. Single sample measurement of this marker 
does not appear to be useful in the horse, since it has a wide normal variation and change 
throughout the day. It is also important to note that the serum levels of HA did not 
correlate with those in the SF of clinically active OA joints. However, serum CONT was 
found to correlate with the global score of lameness improvement indicating that a high 
serum COMP at baseline is predictive of clinical deterioration. 
In this study, none of the markers measured has been useful in the identification of 
longitudinal change in OA. HASF has shown interesting correlations with scintigraphy 
and radiography, and a single baseline measurement of serum CONT may be said to be 
predictive of clinical change in OA. This study has been limited by small numbers, and 
these preliminary results would merit ftu-ther investigation in a larger trial. 
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Summary 
1. No significant longitudinal changes were discovered in any marker measured during 
the 9 months of the trial. 
2. Single measurements of HASF correlated with radiography and scintigraphy scores 
and increase in HASF correlated with decrease in the scintimetry activity indices. Single 
baseline serum COMP measurement was predictive of clinical change. 
3. No difference in outcome between high and low dose treatment groups in the CaPPS 
trial was identified by the use of biochemical markers. 
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ChapterTen 
Are all -ioints 
the same? 
Variations between nonnal equine -ioints 
Introduction 
The purpose of this study was to investigate whether metabolic differences exist between 
normal equine joints. OA in the horse has traditionally been classified according to the type of 
disease occurring in joints of high or low range of motion (See Chapter 1 Table 1- 1). During 
the assessment of the CaPPS trial it seemed that (Chapter 5 Figure 5-6 and 5-7) horses with 
OA in low motion joints (TNIT, PIP, and DIP) were more likely to show clinical 
improvement than those with OA affecting high motion joints (MCP and MC) but the clinical 
data was too small to determine this accurately. Variations have been found in marker levels 
(Chapter 7) and ratios of glycosaminoglycans in the synovial fluid of normal equine 
metacarpophalangeal (MCP), proximal interphalangeal (PEP), and distal interphalangeal (DIP) 
joints (Fuller et al. 1996) but the reason for this difference is not known. It may relate to a 
difference in metabolism between the cartilage in these joints. This may provide evidence that 
cartilage physiology is specific to the function required by the particular joint. In human 
research, studies indicate that osteoarthritis (OA) of different joint sites may involve a 
different set of risk factors, which raise important issues about aetiopathogenesis (Kirwan et 
al. 1994). It seems that the localisation of OA within and between joints may be controlled by 
a balance of systemic and local factors, and therefore OA of one joint may have a different 
aetiology to that of another. It may also follow that efficient therapy in OA would differ 
according to the joint affected. 
In many clinical UWs performed in horses, cases of OA affecting a variety of different joints 
are included, and responses to treatment of these joints directly compared. The existence of 
joint differences would add another source of variability to trials thereby decreasing the 
accuracy of the assessment. Therefore, in this chapter, findings from studies investigating 
differences occurring between normal equine joints will be reported. 
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Variations in metabolism 
Differences in the metabolism of various joints were explored by illvestiga&Z 1he tesponse 
of cartilage from different equine joints to the same challenge by a cytokine. Interleukin -I 
UL- 1) is a protein secreted by the cells of the monocyte-macrophage line, although it has been 
found to be produced in smaller quantities by the chondrocytes themselves. It has been 
found to stimulate the proteolytic pathways of extracellular matrix breakdown while subduing 
the synthesis leading to new matrix fonnation (Pelletier et al. 1993). It stimulates the 
expression of proteases including stromelysin, collagenases, and plasminogen activating 
factor. This has been confirmed in vivo by intra-articular injection of the cytokine (Lotz et al. 
1995). This cytokine was chosen for use in this study since it has been found to occur in 
equine synovial fluid at a higher concentration in osteoarthritic (Alwan et al. 199 1) than in 
normal joints and it is thought therefore to be involved in the pathogenesis of the disease. 
Also, recently it has been shown in man that the joint and joint site from which cartilage is 
sampled may affect responses to EL-1 (Hauselmann et al. 1996; Hauselmann et al. 1993). A 
dose rate of lOng/ml was used since this has been shown in previous studies to elicit a 
response in cartilage from horses in the same age group i. e. mean age 12 years (MacDonald 
et al. 1992). In this study the recombinant human IL- Ia was used; however previous studies 
have shown that there is a considerable degree of homology between human and equine EL- 
Ia (Morris et al. 1990). 
Concentration of total sulphated glycosaminoglycans (GAG) in the supernatant can be 
measured to quantify the degree of degradation occurring in the cartilage explants as a result 
of the catabolic cytokine. During cartilage breakdown, as described in detail in Chapter 1, it is 
the upregulation of metalloproteinases by these cytokines, and then the subsequent activation 
of these enzymes by serine proteases that lead to the release of glycosaminoglycans from the 
cartilage matrix. One of the metalloproteinases involved in this process is MNT-2 or the 
72kDa gelatinase. This is produced by the chondrocytes and once activated, degrades Type 
IV and denatured Type H collagen. The measurement of metalloproteinase activity in cartilage 
explants will elucidate whether any potential differences in cartilage response are related to 
differences in enzyme production. 
Cartilage explant cultures have been found to be a good model for the analysis of matdx 
degeneration (Tyler et al. 1990). Cartilage culture has several advantages over that of isolated 
chondrocytes including the fact that the extracellular matrix is similar to that in vivo, and the 
chondrocytes are not exposed to exogenous proteolytic activity. 
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Structural variations 
Studies arising from the work on normal joint differences included those to determine 
differences in other parameters in normal MCP PEP and DIP joints which may have an effect 
on SF marker levels and cartilage responses, i. e. cartilage thickness and mass. 
A ims 
1. To investigate the hypothesis that cartilage from different normal equine joints responds 
differently to the same catabolic challenge. This investigation was carried out using in vitro 
cartilage explant culture techniques. Release of GAGs from the explants and activity of the 
metalloproteinase NIW-2 were measured to demonstrate the effects of IL- 1a stimulation. 
2. To establish whether basic structural differences occurring in joints may be related to 
marker variations previously reported. 
Materials 
48 well tissue culture plates 
Dulbecco's modified Eagle's Medium 
Human recombinant IIL-1(x 
Streptomycin 
96 well polystyrene assay plate 
Diinetllylmethylene blue dye 
Papain 
Na2HP04 
Bovine tracheal chondroitin sulphate A 
NaCl 
Glycine 
Automated plate mader 
Life Technology Ltd., Paisley, UK. 
Life Technology Ltd., Paisley, UK. 
Sigma Chemical Co., Poole Dorset, UK. 
Sigma Chemical Co. 
Nunc (ImmunoPlate Maxisorp), 
Life Technology Ltd., Paisley, UK. 
Serva, Heidelberg, FRG 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chernical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Labsystems, Multiskan, 
Life Sciences International. 
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Methods 
Variations in metabolism : 
Horse Type Approximate age 
(years) 
1 Pony 10 
2 Pony 10 
3 ThoroughbredX 15 
4 Pony 20 
5 ThoroughbredX 10 
6 ThoroughbredX 10 
Table 10-1: Distribution of types and ages of horses from which cartilage 
explants were harvested. 
Tissue culture 
Full thickness cartilage samples from normal equine joints were taken from both articular 
surfaces of each of the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and 
distal interphalangeal (DIP) joints from six horses destroyed for reasons unrelated to 
locornotor system disorders (Table 10-1). The mean age of the horses was 12 years (range 
10-15). The samples were harvested using aseptic techniques immediately following humane 
destruction. These were maintained in Dulbecco's modified Eagles medium (DNIEM ) to 
which antibiotic agents had been added. Under sterile conditions the cartilage samples were 
diced into uniform Irmn explants and randornised before placing in duplicate into a 36 well 
flat bottomed culture plate. Iml of DNEEM was added to each well and the explants were then 
cultured in a humidified incubator at 37"C, in'an atmosphere containing 5% Col. After 24 
hours the explant supernatant samples were removed and stored at -2011C. The medium was 
replaced in the control samples by fresh DMIEM , and in each paired stimulated sample by 
DNIEEM to which lOng/ml recombinant human IL-1 (Sigma) had been added. This procedure 
was repeated at the end of day 2 and 3. After this the medium was replaced daily in all 
samples by fresh DMEEM only. At the end of this seven day period the remaining explants 
were also removed from the culture plate and stored at -200C until ready for assay. 
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Glycosaminoglycan 
- assay The remaining cartilage explants were first digested overnight at 6511C with a papain buffer 
consisting of 2% papain (Sigma), 0.5M Cysteine-HCI, 0.05M EDTA, and OAM Na acetate. 
The supernatants and the digested cartilage explants were then analysed for total 
glycosaminoglycans (GAG) by a direct colorimetric method (Famdale et al. 1986). 
Gelatin zymography 
Samples of the supernatants were sent to Dr P. Clegg (Liverpool University) where gelatin 
zymography was performed to determine gelatinase activity as described in Clegg et al 
(Clegg et al. 1997) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) was performed using a vertical gel apparatus (Bio-Rad, Hemel Hempstead, UK) 
according to the method of Laenunli (1970), with the modification that gelatin was included 
in the resolving gel (Hibbs et al. 1985). Gelatin was co-polymerised into 0.75 mm thick, 
7.5% polyacrylamide gels at a final concentration of 2.5mg/ml. Cell culture supematants 
samples were diluted 4: 1 in a Tris/HCl sample buffer containing 1.5% SDS, 5% glycerol and 
0.005% Bromophenol blue, pH 6.8 and incubated at 37*C for one hour prior to 
electrophoresis. Each dilution (7.5=B51) was loaded in a well and samples electrophoresed at 
200V for approximately 45 minutes. The gels were washed for one hour at room temperature 
in 2.5% Triton X-100, rinsed in distilled water and incubated for 18 hours at 37*C in a 
reactivation buffer containing 50mMTris/HCl, 50m-- M CaC12, lonim NaCl, 0.05% Brij35, 
pH7.6. Following incubation, the gels were stained with 2% Coomassie brilliant blue R-200 
followed by destaining in a mixture of 7% (v/v) glacial acetic acid, 30% (v/v) methanol and 
63% (v/v) distilled water. The gels were dried in a cellophane sandwich. Molecular weight 
standard markers (Mark 12 wide range protein standards: Novex) were run on each gel which 
were stained prior to the gel being washed in Triton. 
Image analysis of gelatin z=ogms 
Computer assisted image analysis of the zymography gels was performed as described in 
Clegg et al (Clegg et al. 1997). For each gel, the activity value (AV) of each MAT-2 band 
was determined as the product of its area and mean intensity using an image analysis program 
(NIH image 1.44). The relative activity value was calculated by division of the AV of the 




Statistical analysis on the GAG samples was by repeated measures ANOVA. The numbers 
were too few to test normality but since the statistics were done on rates it could be assumed 
that these were normally distributed. Mann Whitney nonparametric tests were used to 
compare population of samples for the M2vW-2 results. 
Structural variations : 
a) Cartilage thickness 
Differences in cartilage thickness in the MCP, PIP, and DIP joints of normal horses was 
investigated. Each of these three joints from the same foreleg of six horses was sectioned in a 
frontal plane perpendicular to the weight bearing surface of the joint and the thickness of the 
cartilage of the proximal and distal joint surface was measured at three different points across 
the joint. In three of these horses the same measurements were also carried out on the same 
three joints from one hindleg, to ascertain whether any difference exists between fore and 
hind leg cartilage thickness. 
b) Cartilage Mass 
The cartilage from each entire joint surface of each of the MCP, PIP, and DIP joints from the 
same leg from six horses was dissected free with a scalpel, and then weighed. 
Statistical analysis was carried out by ANOVA. 
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Results 
Variations in metabolism: 
Glycosaminoglycans 
Results were expressed as percentage total GAG, i. e. GAG released into the supernatant as a 
% of the total GAG in the system. (See Tables 10-2 and 10-3). 
Horse 1 2 3 4 5 6 
MCP Control 9.75 13.13 9.62 6.13 17.24 14.96 
Stimulated 16.04 22.79 16.80 8.79 21.01 24.56 
Difference 6.29 9.67 7.18 2.66 3.77 9.59 
PIP Control 17.06 20.89 35.61 14.03 18.89 13.48 
Stimulated 21.41 53.09 51.71 20.42 38.60 29.57 
Difference 4.36 32.19 16.10 6.38 19.71 16.09 
DEP Control 21.23 39.59 36.23 21.13 34.31 34.61 
Stimulated 30.97 86.22 46.82 24.07 66.15 58.59 
Difference 9.73 46.64 10.58 2.93 31.84 23.97 
Table 10-2: Total % GAG release from control and stimulated cartilage 
explants, at Day 7, for all horses. 
MCP = metacarpophalangeal joint, PIP = proximal interphalangeal joint 
DIP = distal interphalangeal joint) 
Day 1 Day 7 
MCP Control 3.40 11.80 
Stimulated 3.17 18.33 
PIP Control 6.52 19.99 
Stimulated 6.45 35.80 
DIP Control 9.03 31.18 
Stimulated 9.83 52.14 
Table 10-3: Mean total % GAG release from control and stimulated cartilage 
explants at day 1 and day 7. 
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There was a significant difference between the rate of release of GAG from the unstimulated 
control samples from the different joints over the 7 day period (p=O. 0004) with the cartilage 
from the DIP joint releasing GAG at the higher rate than the PEP which in turn released GAG 
at a higher rate than the MCP joint ( See Figure 10-1 ). 









0 Seriesl , Series2 
MCP control MCP I 
0 Series3 A Series4 
PIP control PIP IL-1 
0 SeriesS Series6 
DIP Control DIP IL-1 
34 
Days 
Figure 10-1: Mean cumulative % GAG release from control and stimulated 
samples from the MCP, PIP, and DIP joints. 
(GAG = total glycosaminoglycans, MCP = metacarpophalangeal joint, PIP = proximal 
interphalangeal joint, DIP = distal interphalangeal joint, IIL- I= interleukin - 1) 
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All the cartilage explants responded to the IIL- 1 stimulus by releasing GAG at a higher rate 
than unstimulated explants. One explant sample responded at a lesser rate than the others, this 
sample was from the oldest horse in the group. The rate of release of GAG in specific 
response to EL- I stimulation was calculated as the difference between the rate of release of 
GAG in the control samples and that in the stimulated ones. There were significant 
differences between joints in relation to total GAG released, over the whole 7 day period of 










; u. - I 'I- 
MCP PIP DIP 
0.02 
Figure 10-2: Mean (+ SD) difference between total GAG release of stimulated 
and control samples in the MCP, PIP, and DIP joints. 
(For abbreviations see Figure 10- 1) 
The difference in response between samples in different joints over the 3 day period of 
stimulation of the cartilage was significant (p = 0.03), however the difference in recovery 
rates after withdrawal of the IL- I was not significant. 
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MMP-2 
Results for MAV-2 are expressed as a relative activity value (as compared with the foetal calf 
serum standard). MAT-2 production by cartilage explants from the MCP joint is shown in 
Figure 10-3 and Figure 10-4. Samples from horses 2 and 5 demonstrated significant 
increases in MNT-2 production (p<0.01) in IIL-la stimulated compared to unstimulated 
samples. 
NUAP-2 production by cartilage explants, from the PIP joint is shown in Figure 10-5 and 
Figure 10-6. Samples from horse 2 (p<0.01) and horse 4 (p<0.05) demonstrated significant 
increases in NUMP-2 production in EL-lcc. stimulated compared to unstimulated samples. 
NfMP-2 production by cartilage explants from the DIP joint is shown in Figure 10-7 and 
Figure 10-8. Samples from horse 2 (p<0.01) demonstrated significant increases in MNIP-2 
production in IIL- Ia stimulated compared to unstimulated samples. 
No statistical difference was noted between MMIP-2 production by cartilage explants, obtained 
AOM difieirent fofrifg, a( ally 6W gGiM, wAr&cr urze 2m. 22v)ated oT stimulated with 
IIL-la. 
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Figure 10-3: Relative activity values of MMP-2 in unstimulated control 
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Figure 10.4b: Relative activity values of MMP-2 in IL-1 stimulated cartilage 
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Figure 10-5: Relative activitY values of MMP-2 in unstimulated control 
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Figure 10-6a: Relative activity values of MMP-2 in all IL-1 stimulated 
cartilage explants from PIP joint 
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Figure 10.6b: Relative activity values of MMP-2 in IL-1 stimulated cartilage 
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Figure 10-7: Relative activity values of MMP-2 in unstimulated control 
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Figure 10-8: Relative activity values of AMP-2 in IL-1 stimulated cartilage 
explants from DIP joint 
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Structural variations 




MCP PIP(Fore) DIP(Fore) MTP PIP(Hin DIP(Hind) 
Frýoximal 1.11(0.11) 1.98(0.19) 0.88(0.08) . 03(0.12) -1.5(0.87) 
Di-s-0- I M. (6"07-) 1.24(0.12) 2.10(0.21) 0.87(0.11) .0 (l - 1) 
Table 10-4: Mean cartilage thickness (SD) in mm of proximal and distal 
cartilage surfaces of normal MCP/MTP, PIP, and DIP joints. 
MCP = metacarpophalangeal , NITP metatarsophalangeal, 
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Figure 10-9: Cartilage thickness in proximal surface of matched normal 
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Figure 10-10: Cartilage thickness of distal surface of matched normal MCP, 
PIP, and DIP joints 
Joint MCP/MTP PIP DIP 
Forelimb 3.34(0.43) 2.18(0.23) 4.46(0.32) 
Hindlimb 3.09(0.67) 1.54(0.4) 4.06(0.97) 
Table 10-5: Mean (SD) cartilage mass in grams of cartilage from fore and 
hindlimb normal joints. 
For abbreviations see Table 10-4 
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Figure 10-11: Mass of cartilage from both surfaces of matched normal MCP, 
PIP, and DIP joints. 
Results show a significant difference (p< 0.001) between the thickness of cartilage in the 
MCP, PIP, and DEP joints. There is a similar significant difference (p< 0.00 1) between the 
cartilage thickness of the hindlimb MTP, PIP and DEP joints. There is no significant 
difference between the cartilage thickness in joints from the forelimb as compared with the 
equivalent hindlimb joint. 
There is a significant difference, p< 0.00 1, between the cartilage mass of the MCP , PIP, and 
DIP of the forelimb, and p< 0.02 between the hindlimb MrP , PEP and DIP joints - 
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Discussion 
Variation in metabolism 
The data reported here clearly indicate a significant difference in the rate of release of GAG 
from the matrix of normal cartilage from these three different joints, as well as an increased 
rate of response of cartilage from different joints to the same challenge by interleukin - 1. This 
implies an intrinsic difference in the cartilage from the MCP, PIP, and DIP joints, since 
without any stimulation from external cytokines, the turnover of GAG in vitro is greater in 
the DIP joint than the PIP, which in turn is still greater than that of the MCP. What causes 
this difference is not understood. 
The cartilage explants used in this study were all from the same age group of horses, 5 out of 
the 6 horses were estimated to be 10 -15 years old. Interestingly, the cartilage from horse 4 
which was 20 years old was the least responsive to the effect of 11L-l. This age effect has 
previously (MacDonald et al. 1992) been reported where explants obtained from older horses 
were considerably less responsive to EL- 1 at a similar dose rate of I Ong/ml, both in respect of 
synthesis and release of proteoglycan. 
The extracellular matrix of cartilage is produced by the chondrocytes which also control 
matrix synthesis and degradation and therefore turnover. Chondrocyte metabolism is 
controlled by both genetic factors and environmental circumstances, such as changes in the 
composition of the extracellular matrix and physical stimuli. Diffusion of substances within 
the matrix depends on molecular size, shape and charge as well as concentration of 
proteogglycans in the cartilage. Proteoglycan concentration increases with depth of cartilage 
(MLow et al. 1992) probably in order to resist compressive strain. The thickness and possibly 
also shock absorbence of the cartilage increases from MCP, to PIP, and further to DEP in the 
same order as the rate of release of GAG from normal cartilage explants in vitro increase. It is 
possible, although maybe simplistic to think that a higher normal rate of GAG release is 
simply related to a higher concentration of proteoglycan in the cartilage. However the results 
of this study show that the rate of release of GAG also varies between these joints in 
response to addition of EL- I to the explant system. 
It could be that the altered environmental conditions caused by removal of cartilage from the 
in vivo to the in vitro state may cause upregulation of the cytokines mediating normal 
turnover of proteoglycan. However, all the explants in this study were prepared in the same 
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way and exposed to the same conditions, so these factors do not provide an explanation for 
the differences reported here. Alterations in the matrix composition e. g. a higher 
concentration of proteoglycan could affect the diffusion rate of IL-1, although at l7kDa it is a 
relatively small molecule. 
I 
The normal turnover of proteoglycan depends on a balance between proteinases and 
proteinase inhibitors. This normal equilibrium is thought to be upset in the pathogenesis of 
OA. It is well reported elsewhere (Pelletier et al. 1993) that EL-1 causes an increase in 
cartilage degradation and a decrease in proteoglycan synthesis by the upregulation of 
metalloproteinases. The effects of IL-1 on chondrocytes are mediated by a single high affinity 
receptor (Lotz et al. 1995). It is possible that the numbers or sensitivity of IIL- I receptors 
may differ between joints. Chondrocytes also produce the EL- I receptor antagonist, which 
competitively inhibits EL-1 binding to its receptor and this too may be produced in different 
amounts by different joints. It has recently been shown that chondrocytes from human knee 
and ankle joints differ in response to EL-1 and EL-1 receptor antagonist (Hauselmann et al. 
1993), and this seems to be the most likely explanation for the differences reported in this 
study. The response of cartilage to ]IL-1 may also be mediated by the presence of other 
extracellular regulators that can enhance or inhibit its effect (Lotz et al. 1995). 
This work has not demonstrated a difference in NIMEP-2 release from cartilage obtained from 
different joints of the distal limb of the horse, no matter whether stimulated with IL- 1a or 
not. It would appear unlikely that, in this model of cartilage degradation, MNT-2 is affecting 
all of the aggrecan breakdown and thus GAG release. Further work is now required using 
monoclonal antibodies to neoepitopes of aggrecan to identify at which site aggrecan is being 
cleaved to help identify which types of enzymes are causing the release of GAGs in the horse 
(Fosang et al. 1996). Another approach which could be used to identify the enzyme which is 
involved in the GAG release from cartilage of different joints is the addition of specific NINT 
inhibitors to the culture media (Kozaci et al. 1997). 
An interesting finding from this work is the variation in response of cartilage from different 
horses to the effect of IIL-la stimulation. Cartilage obtained from horse 2 always 
demonstrated an extremely high N4M[P-2 release with EL-W stimulation, which was always 
statistically significant, no matter from which joint this was obtained. In addition, in horse 2 
samples, a lot of active MMP-2 was also produced from stimulated cartilage explants, in 
addition to MNIP-2 zymogen (results not shown). Cartilage from the PIP joint from horse 
number 4 and from the DIP joint in horse number 5 also demonstrated statistically significant 
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increase in Wa-2 production upon IL- I cc stimulation in comparison to the unstimulated 
cartilage. Cartilage from all the other horses and sites tested demonstrated no statistically 
significant alteration in MNIP-2 production with-EL-la stimulation. The reason for the 
difference in response with different cartilage samples to IIL-la stimulation is unclear, 
especially why all the samples from horse 2 appeared to have such a large response. We can 
hypothesise that the response to IL-lcc stimulation requires having both IL-1 receptors 
available on the cells, an 
*da relative 
lack of 11L-l receptor antagonists (Pelletier et al. 1993). 
It is of interest that the cartilage from horse 2 should demonstrate similar responses, no matter 
from what site it was obtained, tending to indicate that the causal factors to the reaction in this 
case are systemic rather than local to an individual joint. 
Interestingly, GAG release from the explants obtained from horse 2 demonstrated an 
extremely high response to EL-lcc stimulation (Table 10-2). Thus it would appear that the 
explants obtained from horse 2 were particularly sensitive to IIL-lcc stimulation, and this 
stimulation did cause a large up-regulation of MNT-2 (zymogen and active) production as 
well. It is impossible from this data to form a link between the increase in enzyme 
production, and the release of GAGs from the explants. 
Whatever the reason for the alteration in response between these three joints , it clearly 
indicates that there are differences in cartilage metabolism. This may be the result of 
adaptation to different environmental influences existing within these joints, but the increased 
sensitivity to the action of EL- I (x also suggests a possible reduction in resistance of cartilage 
to the degradative influence of this cytokine, and maybe therefore an increased susceptibility 
to disease. Further studies need to be carried out into the rate of synthesis of GAG in the 
MCP, PIP, and DIP joints in order to assess the rate of GAG turnover more thoroughly, as 
well as investigations into the number and sensitivity of IL-I receptors existing in these 
joints. An epidemiological survey to establish the prevalence of osteouthritis in these three 
joints in the horse would also be valuable. 
Structural variation 
The results from the study on normal levels of keratan sulphate in SF (Chapter 7) show an 
increase in ratio of this marker to total glycosaminoglycans from MCP to PEP and further to 
the DIP joint. It has been reported that there is an increased concentration of keratan sulphate 
in the deeper levels of thicker cartilage. The increase in cartilage thickness from MCP to PIP 
and then to DIP joint reported here may therefore be relevant to the ratio changes. 
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The mass of cartilage is least in the PIP joint, and increases in the MCP and further in the DEP 
joint. This finding therefore does not support one view that the difference in markers reported 
in Chapter 7 is simply related to a difference in mass of cartilage between these joints. 
Despite the fact that further work must be done to investigate the differences in joint 
metabolism and structure reported here and the reasons for this variation , it is apparent 
from 
this study that joints are not biologically the same, and this must be taken into account when 
designing clinical trials and assessing therapies. 
Summaa 
1. An explant system was set up for 7 days to investigate the hypothesis that cartilage from 
different equine j oints may respond differently to challenge with interleukin- 1 (EL- I cc). The 
% GAG released and the response to challenge from the cartilage of the PIP and DEP joints 
was significantly higher (p<0.02 ANOVA) than that of the MCP joint. These findings 
indicate that cartilage from the MCP joint may be less reactive than that from the PIP or DEP 
joints to the same EL-1 challenge. No significant differences were found in the activity of 
MMP-2 between the three joints. 
2. Structural differences in cartilage thickness and mass do exist between the equine MCP, 
PIP, and DEP joints. Changes in cartilage thickness may explain the differences in marker 
ratios reported in Chapter 7 but there is no direct relationship between the markers measured 
and the cartilage mass. 
3. Differences between joints must be taken into account when designing clinical trials. 
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Chapter Eleven 
General conclusions and future studies 
Were the aims achieved? 
Aims: 
1. To carry out a controlled, blinded, pilot clinical trial in order to assess the 
validity and reliability of the present commonly used measures of outcome in 
the horse, i. e. functional outcome and radiography, and the more recent 
scintigraphic and molecular marker techniques, as methods of measuring 
changes in OA occurring in horses in clinical trials, and to evaluate a 
potential disease modifying drug in osteoarthritis . 
A prospective, controlled, randomised and double blinded pilot study with clear inclusion 
criteria, was conducted. This allowed for the assessment of the validity and reliability of the 
chosen measures of outcome, and for the identification of some areas of difficulty . 
a) Functional outcome 
The scoring of lameness was found to be a valid and reliable measurement tool, both intra- 
and inter-observer. This subjective measurement, is the most common method of assessing 
the degree of limb pain in the horse and is used regularly in clinical trials and yet assessment 
of its validity has not previously been reported in the equine literature. Having established 
that lameness scoring is a valid method of measuring functional outcome it would be 
interesting to compare this method with an objective form of gait analysis, e. g. force plate 
studies. 
The use of owner questionnaires, employing Likert scales, was also found to be a reliable 
and valid method of measurement of change within the trial. Physician and owner global 
scores of outcome correlated well. No previous reports of owner assessment of disability in 
equine osteoarthritis (OA) could be found in the literature. It would be beneficial to develop 
these questionnaires to provide more information on outcome in future clinical trials. 
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b) Imaging 
Scoring of joint space narrowing, osteophytes, and global scoring of osteoarthritic change on 
radiographs was found to be reproducible cross-sectionally but was not useful in identifying 
change during this trial. Despite this, the radiography scoring system would seem to be the 
present method of choice for measurement of structural outcome. 
Qualitative scoring of scintigraphic scans was only reliable intra-observer. Although 
scintigraphy was useful as an additional diagnostic technique in some cases, it was not 
helpful in measuring change during the trial and could not replace radiography. The use of the 
quantitative method of scintimetry in assessing the scintigraphy results was reliable but did 
not offer any essential additional information. 
The lack of significant correlations between imaging measurements, i. e. scintigraphy or 
radiography, and the clinical changes measured by global scores of lameness improvement, 
has been reported many times in previous studies and was not unexpected. 
More study is necessary in the interpretation of scintigraphic bone scans and the effect of 
variables such as limb positioning and blood flow. Improvement in interpretation could be 
made by a study of normal scintigraphic differences in the joints of clinically sound horses. 
With improvement in the available software packages for the interpretation of scans, 
adjustments for variables could be made more easily. 
Calcium pentosan polysulphate (CaPPS) was not found to be an effective disease modifying 
drug in osteoarthritis (DMOAD) in this study. Having carried out this pilot study it will now 
be acceptable to assess the drug further by continuing the trial over a longer time period, 
both in order to recruit a larger number of cases to provide a sample size to give the trial 
adequate power and also to allow for more meaningful changes in the imaging measures of 
outcome. It should be noted that the majority of cases recruited were in stages of chronic OA 
which was less than ideal, since it did not allow for the comparison of the effectiveness of 
measurement techniques in the early diagnosis of OA. 
c) Molecular markers in serum and synovialfluid 
Molecular markers were not found to be useful in the measurement of change in joint status 
during the trial period, however, the trial did allow for the discovery of some interesting 
cross-sectional differences and correlations with other measurement parameters (see point 3). 
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Overall, in the trial carried out in this study, lameness scoring was considered to be the most 
useful measure of change. Radiography, scintigraphy, and molecular markers were useful in 
diagnosis of OA but not in measuring change over time. 
2. To establish normal parameters of molecular markers in equine serum and 
in synovial fluid from different joints. 
A range of normal values of molecular markers in serum and in different equine joints has 
been established. There does not appear to be a diumal rhythm of serum hyaluronan (HAS) 
in the horse. However, the wide variation in normal values of HAS that does exist both 
within and between horses, and the effect of variables such as age and exercise on this 
marker make it unlikely to be useful as a serum marker of OA in the horse. 
We have found that there is a change in the ratio of keratan sulphate (KS-5D4) to total 
glycosaminoglycans (GAG) in the SF of normal equine joints, increasing from the 
metacarpophalangeal (MCP), to the proximal interphalangeal (PIP), and further to the distal 
interphalangeal (DIP) joints. The normal concentrations of hyaluronan (HA) and cartilage 
oligomeric matrix protein (COMP) within the MCP, PEP, and DIP joints also varies. While it 
is vital that these normal differences are taken into account when interpreting marker changes 
in OA, it is possible that these variations relate to a difference in metabolism between the 
cartilage in these joints, a finding which highlights the potential use of markers as tools to 
measure the natural history of OA. 
3. To investigate the use of molecular marker technology to assess changes 
in joint status and disease process both cross-sectionally and in longitudinal 
change in OA. 
Markers measured in this study were found to be valuable in identifying cross-sectional 
differences between normal and OA joints. Measurement of HA, KS, GAG, KS: GAG ratio, 
and bone specific alkaline phosphatase (BAP) in synovial fluid were all significantly different 
in clinically active OA joints when compared to contralaterals. Concentrations of BAP, KS, 
and the KS: GAG ratio also demonstrated significant correlations with articular cardla( ,,, e 
pathology, an important finding which adds validity to their use as markers of joint pathology 
and in the case of BAP, demonstrates a link between subchondral bone and articular cartilage 
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disease status. This is the first study to report the use of synovial fluid BAP measurements in 
the horse. 
Differences in concentrations of these markers in contralateral control joints also identified 
differences between populations of horses, which may have been related to training, breed, 
or age. 
HA concentration in synovial fluid was found to corTelate with radiography and scintigraphy 
scores, but temporal changes in markers were not useful measurements of OA change in the 
trial, and did not correlate with changes in any other parameter. However, concentration of 
COUP in serum at the beginning of the trial was found to correlate with the global score of 
lameness improvement and could therefore be said to be predictive of OA change. 
4. To investigate whether there is variation in the metabolism of different 
normal equine joints, by the examination of response to challenge by the 
articular cartilage . 
In vitro cartilage studies demonstrated that there is a significant difference in the rate of 
release of GAG from the matrix of normal cartilage from the MCP, PIP, and DIP joints, as 
well as a difference in susceptibility of cartilage from these different joints to the same 
challenge by interleukin -1. This implies an intrinsic difference in the cartilage from the 
MCP, PIP, and DIP joints. These findings may provide evidence that cartilage physiology is 
specific to the function required by the particular joint. No difference was found between the 
three joints in the activity of the gelatinase MNP-2. 
To establish whether there are differences in GAG synthesis as well as in degradation, 
cartilage from these three joints could be used in in vitro culture systems to examine the 
relative synthesis of GAG by 35 sulphate labelling in vitro. This would increase the 
understanding of potential differences in the overall turnover of GAG. 
A further project relating to the investigation of metabolic joint differences could involve the 
assessment of the relative prevalence and risk factors of osteoarthritis in the MCP, PIP, and 
DEP joints both in a population of riding horses and in racehorses. This could be conducted 
by questionnaire, using the Likert scale, and would include our definition of osteoarthritis, 
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and detailed questions to establish the methods used in accurate diagnosis of the disease, the 
joints affected and in which type of horse. 
Summary 
ini This study has served to highlight the correct methodology for cl cal trials and has identified 
some of the problem areas when dealing with equine cases. Functional outcome measured by 
lameness scoring, and radiography scoring cross-sectionally, have been proved to be reliable, 
but improvements need to be made in interpretation of scintigraphic data. Biochemical 
markers were not effective in the longitudinal assessment of osteoarthritic change, but were 
very useful in gaining insight into joint status and identifying cross-sectional differences. 
Work done on establishing normal ranges of markers, the correlation between markers and 
articular cartilage pathology, and the changes in marker levels occurring in the OA joint has 
formed a basis for the validation of these markers as measures of outcome in clinical trials. 
The study has provided evidence that joints are biologically different, by both the 
investigation of synovial fluid rnarker levels, and the response of the articular cartilage to 
challenge. 
There is a requirement in equine research for basic epidemiological studies into the incidence 
and prevalence of equine OA and for well planned clinical trials using previously validated 
measures of outcome. This study has established that these trials should be joint specific, has 
validated the use of lameness scoring, and confirmed that radiography scoring is reliable. It is 
hoped that this information will assist in improving the standard of equine clinical trials, 
which may lead to progress in the search for a more effective therapy for OA in the horse. 
"In research the horizon recedes as we advance, and is no nearer at sixty than it was at 
twenty. As the power of endurance weakens with age, the urgency of the pursuit grows more 
intense ..... And research is always incomplete. " 
Mark Panison 1813 - 1884 
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